<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=us-ascii">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>Revatio II-86-PI-en-clean</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Courier;
	panose-1:2 7 4 9 2 2 5 2 4 4;}
@font-face
	{font-family:"Tms Rmn";
	panose-1:2 2 6 3 4 5 5 2 3 4;}
@font-face
	{font-family:Helv;
	panose-1:2 11 6 4 2 2 2 3 2 4;}
@font-face
	{font-family:"New York";
	panose-1:2 4 5 3 6 5 6 2 3 4;}
@font-face
	{font-family:System;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:Batang;
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:PMingLiU;
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:Dotum;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimHei;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:MingLiU;
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:Mincho;
	panose-1:2 2 6 9 4 3 5 8 3 5;}
@font-face
	{font-family:Gulim;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:Century;
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:"Angsana New";
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"Cordia New";
	panose-1:2 11 3 4 2 2 2 2 2 4;}
@font-face
	{font-family:Mangal;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Latha;
	panose-1:2 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sylfaen;
	panose-1:1 10 5 2 5 3 6 3 3 3;}
@font-face
	{font-family:Vrinda;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Raavi;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Shruti;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sendnya;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Gautami;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tunga;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Estrangelo Edessa";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:DengXian;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Palatino Linotype";
	panose-1:2 4 5 2 5 5 5 3 3 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Segoe UI Emoji";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Segoe UI Symbol";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:BISansCond;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Black";
	panose-1:2 11 10 4 2 1 2 2 2 4;}
@font-face
	{font-family:"Bahnschrift Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Bahnschrift;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight SemiConde";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold SemiConden";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Candara;
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Candara Light";
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Comic Sans MS";
	panose-1:3 15 7 2 3 3 2 2 2 4;}
@font-face
	{font-family:Consolas;
	panose-1:2 11 6 9 2 2 4 3 2 4;}
@font-face
	{font-family:Constantia;
	panose-1:2 3 6 2 5 3 6 3 3 3;}
@font-face
	{font-family:Corbel;
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"Corbel Light";
	panose-1:2 11 3 3 2 2 4 2 2 4;}
@font-face
	{font-family:Ebrima;
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Franklin Gothic Medium";
	panose-1:2 11 6 3 2 1 2 2 2 4;}
@font-face
	{font-family:Gabriola;
	panose-1:4 4 6 5 5 16 2 2 13 2;}
@font-face
	{font-family:Gadugi;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Georgia;
	panose-1:2 4 5 2 5 4 5 2 3 3;}
@font-face
	{font-family:Impact;
	panose-1:2 11 8 6 3 9 2 5 2 4;}
@font-face
	{font-family:"Ink Free";
	panose-1:3 8 4 2 0 5 0 0 0 0;}
@font-face
	{font-family:"Javanese Text";
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Leelawadee UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Leelawadee UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Lucida Console";
	panose-1:2 11 6 9 4 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Unicode";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Malgun Gothic";
	panose-1:2 11 5 3 2 0 0 2 0 4;}
@font-face
	{font-family:"\@Malgun Gothic";}
@font-face
	{font-family:"Malgun Gothic Semilight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Malgun Gothic Semilight";}
@font-face
	{font-family:"Microsoft Himalaya";
	panose-1:1 1 1 0 1 1 1 1 1 1;}
@font-face
	{font-family:"Microsoft JhengHei";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei";}
@font-face
	{font-family:"Microsoft JhengHei UI";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI";}
@font-face
	{font-family:"Microsoft JhengHei Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei Light";}
@font-face
	{font-family:"Microsoft JhengHei UI Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI Light";}
@font-face
	{font-family:"Microsoft New Tai Lue";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft PhagsPa";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft Sans Serif";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Microsoft Tai Le";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft YaHei";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei";}
@font-face
	{font-family:"Microsoft YaHei UI";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei UI";}
@font-face
	{font-family:"Microsoft YaHei Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei Light";}
@font-face
	{font-family:"Microsoft YaHei UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei UI Light";}
@font-face
	{font-family:"Microsoft Yi Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:MingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU-ExtB";}
@font-face
	{font-family:PMingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@PMingLiU-ExtB";}
@font-face
	{font-family:MingLiU_HKSCS-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU_HKSCS-ExtB";}
@font-face
	{font-family:"Mongolian Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:"MS UI Gothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS UI Gothic";}
@font-face
	{font-family:"MS PGothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS PGothic";}
@font-face
	{font-family:"MV Boli";
	panose-1:2 0 5 0 3 2 0 9 0 0;}
@font-face
	{font-family:"Myanmar Text";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Segoe Print";
	panose-1:2 0 6 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Segoe Script";
	panose-1:3 11 5 4 2 0 0 0 0 3;}
@font-face
	{font-family:"Segoe UI Black";
	panose-1:2 11 10 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Historic";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semibold";
	panose-1:2 11 7 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:NSimSun;
	panose-1:2 1 6 9 3 1 1 1 1 1;}
@font-face
	{font-family:"\@NSimSun";}
@font-face
	{font-family:SimSun-ExtB;
	panose-1:2 1 6 9 6 1 1 1 1 1;}
@font-face
	{font-family:"\@SimSun-ExtB";}
@font-face
	{font-family:"Sitka Small";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Text";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Subheading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Heading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Display";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Banner";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Trebuchet MS";
	panose-1:2 11 6 3 2 2 2 2 2 4;}
@font-face
	{font-family:Webdings;
	panose-1:5 3 1 2 1 5 9 6 7 3;}
@font-face
	{font-family:"\@Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Yu Gothic UI";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI";}
@font-face
	{font-family:"Yu Gothic UI Semibold";
	panose-1:2 11 7 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semibold";}
@font-face
	{font-family:"Yu Gothic Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Light";}
@font-face
	{font-family:"Yu Gothic UI Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Light";}
@font-face
	{font-family:"Yu Gothic Medium";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Medium";}
@font-face
	{font-family:"Yu Gothic UI Semilight";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semilight";}
@font-face
	{font-family:"HoloLens MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Agency FB";
	panose-1:2 11 5 3 2 2 2 2 2 4;}
@font-face
	{font-family:Algerian;
	panose-1:4 2 7 5 4 10 2 6 7 2;}
@font-face
	{font-family:"Book Antiqua";
	panose-1:2 4 6 2 5 3 5 3 3 4;}
@font-face
	{font-family:"Arial Narrow";
	panose-1:2 11 6 6 2 2 2 3 2 4;}
@font-face
	{font-family:"Arial Rounded MT Bold";
	panose-1:2 15 7 4 3 5 4 3 2 4;}
@font-face
	{font-family:"Baskerville Old Face";
	panose-1:2 2 6 2 8 5 5 2 3 3;}
@font-face
	{font-family:"Bauhaus 93";
	panose-1:4 3 9 5 2 11 2 2 12 2;}
@font-face
	{font-family:"Bell MT";
	panose-1:2 2 5 3 6 3 5 2 3 3;}
@font-face
	{font-family:"Bernard MT Condensed";
	panose-1:2 5 8 6 6 9 5 2 4 4;}
@font-face
	{font-family:"Bodoni MT";
	panose-1:2 7 6 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Black";
	panose-1:2 7 10 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Condensed";
	panose-1:2 7 6 6 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Poster Compressed";
	panose-1:2 7 7 6 8 6 1 5 2 4;}
@font-face
	{font-family:"Bookman Old Style";
	panose-1:2 5 6 4 5 5 5 2 2 4;}
@font-face
	{font-family:"Bradley Hand ITC";
	panose-1:3 7 4 2 5 3 2 3 2 3;}
@font-face
	{font-family:"Britannic Bold";
	panose-1:2 11 9 3 6 7 3 2 2 4;}
@font-face
	{font-family:"Berlin Sans FB";
	panose-1:2 14 6 2 2 5 2 2 3 6;}
@font-face
	{font-family:"Berlin Sans FB Demi";
	panose-1:2 14 8 2 2 5 2 2 3 6;}
@font-face
	{font-family:Broadway;
	panose-1:4 4 9 5 8 11 2 2 5 2;}
@font-face
	{font-family:"Brush Script MT";
	panose-1:3 6 8 2 4 4 6 7 3 4;}
@font-face
	{font-family:"Bookshelf Symbol 7";
	panose-1:5 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Californian FB";
	panose-1:2 7 4 3 6 8 11 3 2 4;}
@font-face
	{font-family:"Calisto MT";
	panose-1:2 4 6 3 5 5 5 3 3 4;}
@font-face
	{font-family:Castellar;
	panose-1:2 10 4 2 6 4 6 1 3 1;}
@font-face
	{font-family:"Century Schoolbook";
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:Centaur;
	panose-1:2 3 5 4 5 2 5 2 3 4;}
@font-face
	{font-family:Chiller;
	panose-1:4 2 4 4 3 16 7 2 6 2;}
@font-face
	{font-family:"Colonna MT";
	panose-1:4 2 8 5 6 2 2 3 2 3;}
@font-face
	{font-family:"Cooper Black";
	panose-1:2 8 9 4 4 3 11 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Bold";
	panose-1:2 14 7 5 2 2 6 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Light";
	panose-1:2 14 5 7 2 2 6 2 4 4;}
@font-face
	{font-family:"Curlz MT";
	panose-1:4 4 4 4 5 7 2 2 2 2;}
@font-face
	{font-family:Dubai;
	panose-1:2 11 5 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Light";
	panose-1:2 11 3 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Medium";
	panose-1:2 11 6 3 3 4 3 3 2 4;}
@font-face
	{font-family:Elephant;
	panose-1:2 2 9 4 9 5 5 2 3 3;}
@font-face
	{font-family:"Engravers MT";
	panose-1:2 9 7 7 8 5 5 2 3 4;}
@font-face
	{font-family:"Eras Bold ITC";
	panose-1:2 11 9 7 3 5 4 2 2 4;}
@font-face
	{font-family:"Eras Demi ITC";
	panose-1:2 11 8 5 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Light ITC";
	panose-1:2 11 4 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Medium ITC";
	panose-1:2 11 6 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Felix Titling";
	panose-1:4 6 5 5 6 2 2 2 10 4;}
@font-face
	{font-family:Forte;
	panose-1:3 6 9 2 4 5 2 7 2 3;}
@font-face
	{font-family:"Franklin Gothic Book";
	panose-1:2 11 5 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi";
	panose-1:2 11 7 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi Cond";
	panose-1:2 11 7 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Heavy";
	panose-1:2 11 9 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Medium Cond";
	panose-1:2 11 6 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Freestyle Script";
	panose-1:3 8 4 2 3 2 5 11 4 4;}
@font-face
	{font-family:"French Script MT";
	panose-1:3 2 4 2 4 6 7 4 6 5;}
@font-face
	{font-family:"Footlight MT Light";
	panose-1:2 4 6 2 6 3 10 2 3 4;}
@font-face
	{font-family:Garamond;
	panose-1:2 2 4 4 3 3 1 1 8 3;}
@font-face
	{font-family:Gigi;
	panose-1:4 4 5 4 6 16 7 2 13 2;}
@font-face
	{font-family:"Gill Sans MT";
	panose-1:2 11 5 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans MT Condensed";
	panose-1:2 11 5 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold Condensed";
	panose-1:2 11 10 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold";
	panose-1:2 11 10 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gloucester MT Extra Condensed";
	panose-1:2 3 8 8 2 6 1 1 1 1;}
@font-face
	{font-family:"Gill Sans MT Ext Condensed Bold";
	panose-1:2 11 9 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Century Gothic";
	panose-1:2 11 5 2 2 2 2 2 2 4;}
@font-face
	{font-family:"Goudy Old Style";
	panose-1:2 2 5 2 5 3 5 2 3 3;}
@font-face
	{font-family:"Goudy Stout";
	panose-1:2 2 9 4 7 3 11 2 4 1;}
@font-face
	{font-family:"Harlow Solid Italic";
	panose-1:4 3 6 4 2 15 2 2 13 2;}
@font-face
	{font-family:Harrington;
	panose-1:4 4 5 5 5 10 2 2 7 2;}
@font-face
	{font-family:Haettenschweiler;
	panose-1:2 11 7 6 4 9 2 6 2 4;}
@font-face
	{font-family:"High Tower Text";
	panose-1:2 4 5 2 5 5 6 3 3 3;}
@font-face
	{font-family:"Imprint MT Shadow";
	panose-1:4 2 6 5 6 3 3 3 2 2;}
@font-face
	{font-family:"Informal Roman";
	panose-1:3 6 4 2 3 4 6 11 2 4;}
@font-face
	{font-family:"Blackadder ITC";
	panose-1:4 2 5 5 5 16 7 2 13 2;}
@font-face
	{font-family:"Edwardian Script ITC";
	panose-1:3 3 3 2 4 7 7 13 8 4;}
@font-face
	{font-family:"Kristen ITC";
	panose-1:3 5 5 2 4 2 2 3 2 2;}
@font-face
	{font-family:Jokerman;
	panose-1:4 9 6 5 6 13 6 2 7 2;}
@font-face
	{font-family:"Juice ITC";
	panose-1:4 4 4 3 4 10 2 2 2 2;}
@font-face
	{font-family:"Kunstler Script";
	panose-1:3 3 4 2 2 6 7 13 13 6;}
@font-face
	{font-family:"Wide Latin";
	panose-1:2 10 10 7 5 5 5 2 4 4;}
@font-face
	{font-family:"Lucida Bright";
	panose-1:2 4 6 2 5 5 5 2 3 4;}
@font-face
	{font-family:"Lucida Calligraphy";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Fax";
	panose-1:2 6 6 2 5 5 5 2 2 4;}
@font-face
	{font-family:"Lucida Handwriting";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Sans";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Typewriter";
	panose-1:2 11 5 9 3 5 4 3 2 4;}
@font-face
	{font-family:Magneto;
	panose-1:4 3 8 5 5 8 2 2 13 2;}
@font-face
	{font-family:"Maiandra GD";
	panose-1:2 14 5 2 3 3 8 2 2 4;}
@font-face
	{font-family:"Matura MT Script Capitals";
	panose-1:3 2 8 2 6 6 2 7 2 2;}
@font-face
	{font-family:Mistral;
	panose-1:3 9 7 2 3 4 7 2 4 3;}
@font-face
	{font-family:"Modern No\. 20";
	panose-1:2 7 7 4 7 5 5 2 3 3;}
@font-face
	{font-family:"Monotype Corsiva";
	panose-1:3 1 1 1 1 2 1 1 1 1;}
@font-face
	{font-family:"Niagara Engraved";
	panose-1:4 2 5 2 7 7 3 3 2 2;}
@font-face
	{font-family:"Niagara Solid";
	panose-1:4 2 5 2 7 7 2 2 2 2;}
@font-face
	{font-family:"OCR A Extended";
	panose-1:2 1 5 9 2 1 2 1 3 3;}
@font-face
	{font-family:"Old English Text MT";
	panose-1:3 4 9 2 4 5 8 3 8 6;}
@font-face
	{font-family:Onyx;
	panose-1:4 5 6 2 8 7 2 2 2 3;}
@font-face
	{font-family:"MS Outlook";
	panose-1:5 1 1 0 1 0 0 0 0 0;}
@font-face
	{font-family:"Palace Script MT";
	panose-1:3 3 3 2 2 6 7 12 11 5;}
@font-face
	{font-family:Papyrus;
	panose-1:3 7 5 2 6 5 2 3 2 5;}
@font-face
	{font-family:Parchment;
	panose-1:3 4 6 2 4 7 8 4 8 4;}
@font-face
	{font-family:Perpetua;
	panose-1:2 2 5 2 6 4 1 2 3 3;}
@font-face
	{font-family:"Perpetua Titling MT";
	panose-1:2 2 5 2 6 5 5 2 8 4;}
@font-face
	{font-family:Playbill;
	panose-1:4 5 6 3 10 6 2 2 2 2;}
@font-face
	{font-family:"Poor Richard";
	panose-1:2 8 5 2 5 5 5 2 7 2;}
@font-face
	{font-family:Pristina;
	panose-1:3 6 4 2 4 4 6 8 2 4;}
@font-face
	{font-family:"Rage Italic";
	panose-1:3 7 5 2 4 5 7 7 3 4;}
@font-face
	{font-family:Ravie;
	panose-1:4 4 8 5 5 8 9 2 6 2;}
@font-face
	{font-family:"MS Reference Sans Serif";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"MS Reference Specialty";
	panose-1:5 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Rockwell Condensed";
	panose-1:2 6 6 3 5 4 5 2 1 4;}
@font-face
	{font-family:Rockwell;
	panose-1:2 6 6 3 2 2 5 2 4 3;}
@font-face
	{font-family:"Rockwell Extra Bold";
	panose-1:2 6 9 3 4 5 5 2 4 3;}
@font-face
	{font-family:"Script MT Bold";
	panose-1:3 4 6 2 4 6 7 8 9 4;}
@font-face
	{font-family:"Showcard Gothic";
	panose-1:4 2 9 4 2 1 2 2 6 4;}
@font-face
	{font-family:"Snap ITC";
	panose-1:4 4 10 7 6 10 2 2 2 2;}
@font-face
	{font-family:Stencil;
	panose-1:4 4 9 5 13 8 2 2 4 4;}
@font-face
	{font-family:"Tw Cen MT";
	panose-1:2 11 6 2 2 1 4 2 6 3;}
@font-face
	{font-family:"Tw Cen MT Condensed";
	panose-1:2 11 6 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Tw Cen MT Condensed Extra Bold";
	panose-1:2 11 8 3 2 2 2 2 2 4;}
@font-face
	{font-family:"Tempus Sans ITC";
	panose-1:4 2 4 4 3 13 7 2 2 2;}
@font-face
	{font-family:"Viner Hand ITC";
	panose-1:3 7 5 2 3 5 2 2 2 3;}
@font-face
	{font-family:Vivaldi;
	panose-1:3 2 6 2 5 5 6 9 8 4;}
@font-face
	{font-family:"Vladimir Script";
	panose-1:3 5 4 2 4 4 7 7 3 5;}
@font-face
	{font-family:"Wingdings 2";
	panose-1:5 2 1 2 1 5 7 7 7 7;}
@font-face
	{font-family:"Wingdings 3";
	panose-1:5 4 1 2 1 8 7 7 7 7;}
@font-face
	{font-family:AngsanaUPC;}
@font-face
	{font-family:CordiaUPC;}
@font-face
	{font-family:Abadi;}
@font-face
	{font-family:"Abadi Extra Light";}
@font-face
	{font-family:Aharoni;}
@font-face
	{font-family:Aldhabi;}
@font-face
	{font-family:Aparajita;}
@font-face
	{font-family:"Arabic Typesetting";}
@font-face
	{font-family:"Arial Nova";}
@font-face
	{font-family:"Arial Nova Cond";}
@font-face
	{font-family:"Arial Nova Cond Light";}
@font-face
	{font-family:"Arial Nova Light";}
@font-face
	{font-family:"Avenir Next LT Pro";}
@font-face
	{font-family:"Avenir Next LT Pro Light";}
@font-face
	{font-family:BatangChe;}
@font-face
	{font-family:Bembo;}
@font-face
	{font-family:Biome;}
@font-face
	{font-family:"Biome Light";}
@font-face
	{font-family:"Browallia New";}
@font-face
	{font-family:BrowalliaUPC;}
@font-face
	{font-family:Cavolini;}
@font-face
	{font-family:Dante;}
@font-face
	{font-family:DaunPenh;}
@font-face
	{font-family:David;}
@font-face
	{font-family:Daytona;}
@font-face
	{font-family:"Daytona Condensed";}
@font-face
	{font-family:"Daytona Condensed Light";}
@font-face
	{font-family:"Daytona Light";}
@font-face
	{font-family:"DengXian Light";}
@font-face
	{font-family:DilleniaUPC;}
@font-face
	{font-family:DokChampa;}
@font-face
	{font-family:DotumChe;}
@font-face
	{font-family:"Elephant Pro";}
@font-face
	{font-family:EucrosiaUPC;}
@font-face
	{font-family:Euphemia;}
@font-face
	{font-family:FangSong;}
@font-face
	{font-family:FrankRuehl;}
@font-face
	{font-family:FreesiaUPC;}
@font-face
	{font-family:"Georgia Pro";}
@font-face
	{font-family:"Georgia Pro Black";}
@font-face
	{font-family:"Georgia Pro Cond";}
@font-face
	{font-family:"Georgia Pro Cond Black";}
@font-face
	{font-family:"Georgia Pro Cond Light";}
@font-face
	{font-family:"Georgia Pro Cond Semibold";}
@font-face
	{font-family:"Georgia Pro Light";}
@font-face
	{font-family:"Georgia Pro Semibold";}
@font-face
	{font-family:"Gill Sans Nova";}
@font-face
	{font-family:"Gill Sans Nova Cond";}
@font-face
	{font-family:"Gill Sans Nova Cond Lt";}
@font-face
	{font-family:"Gill Sans Nova Cond Ultra Bold";}
@font-face
	{font-family:"Gill Sans Nova Cond XBd";}
@font-face
	{font-family:"Gill Sans Nova Light";}
@font-face
	{font-family:"Gill Sans Nova Ultra Bold";}
@font-face
	{font-family:Gisha;}
@font-face
	{font-family:Grotesque;}
@font-face
	{font-family:"Grotesque Light";}
@font-face
	{font-family:GulimChe;}
@font-face
	{font-family:Gungsuh;}
@font-face
	{font-family:GungsuhChe;}
@font-face
	{font-family:"Hadassah Friedlaender";}
@font-face
	{font-family:HGGothicE;}
@font-face
	{font-family:HGMaruGothicMPRO;}
@font-face
	{font-family:HGMinchoE;}
@font-face
	{font-family:HGPGothicE;}
@font-face
	{font-family:HGPMinchoE;}
@font-face
	{font-family:HGPSoeiKakugothicUB;}
@font-face
	{font-family:HGSGothicE;}
@font-face
	{font-family:HGSMinchoE;}
@font-face
	{font-family:HGSoeiKakugothicUB;}
@font-face
	{font-family:HGSSoeiKakugothicUB;}
@font-face
	{font-family:IrisUPC;}
@font-face
	{font-family:"Iskoola Pota";}
@font-face
	{font-family:JasmineUPC;}
@font-face
	{font-family:KaiTi;}
@font-face
	{font-family:Kalinga;}
@font-face
	{font-family:Kartika;}
@font-face
	{font-family:"Khmer UI";}
@font-face
	{font-family:Kigelia;}
@font-face
	{font-family:"Kigelia Arabic";}
@font-face
	{font-family:"Kigelia Arabic Light";}
@font-face
	{font-family:"Kigelia Light";}
@font-face
	{font-family:KodchiangUPC;}
@font-face
	{font-family:Kokila;}
@font-face
	{font-family:"Lao UI";}
@font-face
	{font-family:Leelawadee;}
@font-face
	{font-family:"Levenim MT";}
@font-face
	{font-family:LilyUPC;}
@font-face
	{font-family:"Mangal Pro";}
@font-face
	{font-family:Meiryo;}
@font-face
	{font-family:"Meiryo UI";}
@font-face
	{font-family:"Microsoft GothicNeo";}
@font-face
	{font-family:"Microsoft GothicNeo Light";}
@font-face
	{font-family:"Microsoft Uighur";}
@font-face
	{font-family:MingLiU_HKSCS;}
@font-face
	{font-family:Miriam;}
@font-face
	{font-family:"Miriam Fixed";}
@font-face
	{font-family:"Modern Love";}
@font-face
	{font-family:"Modern Love Caps";}
@font-face
	{font-family:"Modern Love Grunge";}
@font-face
	{font-family:MoolBoran;}
@font-face
	{font-family:"MS PMincho";}
@font-face
	{font-family:"MT Extra";}
@font-face
	{font-family:Narkisim;}
@font-face
	{font-family:"Neue Haas Grotesk Text Pro";}
@font-face
	{font-family:"News Gothic MT";}
@font-face
	{font-family:Nyala;}
@font-face
	{font-family:OCRB;}
@font-face
	{font-family:"Plantagenet Cherokee";}
@font-face
	{font-family:Posterama;}
@font-face
	{font-family:"Quire Sans";}
@font-face
	{font-family:"Quire Sans Light";}
@font-face
	{font-family:"Quire Sans Pro Light";}
@font-face
	{font-family:"Rockwell Light";}
@font-face
	{font-family:"Rockwell Nova";}
@font-face
	{font-family:"Rockwell Nova Cond";}
@font-face
	{font-family:"Rockwell Nova Cond Light";}
@font-face
	{font-family:"Rockwell Nova Extra Bold";}
@font-face
	{font-family:"Rockwell Nova Light";}
@font-face
	{font-family:Rod;}
@font-face
	{font-family:"Sabon Next LT";}
@font-face
	{font-family:"Sagona Book";}
@font-face
	{font-family:"Sagona ExtraLight";}
@font-face
	{font-family:"Sakkal Majalla";}
@font-face
	{font-family:"Sanskrit Text";}
@font-face
	{font-family:Selawik;}
@font-face
	{font-family:"Selawik Light";}
@font-face
	{font-family:"Selawik Semibold";}
@font-face
	{font-family:"Shonar Bangla";}
@font-face
	{font-family:"Simplified Arabic";}
@font-face
	{font-family:"Simplified Arabic Fixed";}
@font-face
	{font-family:"Sitka Banner Semibold";}
@font-face
	{font-family:"Sitka Display Semibold";}
@font-face
	{font-family:"Sitka Heading Semibold";}
@font-face
	{font-family:"Sitka Small Semibold";}
@font-face
	{font-family:"Sitka Subheading Semibold";}
@font-face
	{font-family:"Sitka Text Semibold";}
@font-face
	{font-family:"Source Sans Pro";}
@font-face
	{font-family:"Source Sans Pro Black";}
@font-face
	{font-family:"Source Sans Pro ExtraLight";}
@font-face
	{font-family:"Source Sans Pro Light";}
@font-face
	{font-family:"Source Sans Pro SemiBold";}
@font-face
	{font-family:"Speak Pro";}
@font-face
	{font-family:"Speak Pro Light";}
@font-face
	{font-family:STCaiyun;}
@font-face
	{font-family:STFangsong;}
@font-face
	{font-family:STHupo;}
@font-face
	{font-family:STKaiti;}
@font-face
	{font-family:STXihei;}
@font-face
	{font-family:STXingkai;}
@font-face
	{font-family:STXinwei;}
@font-face
	{font-family:STZhongsong;}
@font-face
	{font-family:"TH SarabunPSK";}
@font-face
	{font-family:"The Hand";}
@font-face
	{font-family:"The Hand Black";}
@font-face
	{font-family:"The Hand Extrablack";}
@font-face
	{font-family:"The Hand Light";}
@font-face
	{font-family:"The Serif Hand";}
@font-face
	{font-family:"The Serif Hand Black";}
@font-face
	{font-family:"The Serif Hand Extrablack";}
@font-face
	{font-family:"The Serif Hand Light";}
@font-face
	{font-family:"Tisa Offc Serif Pro";}
@font-face
	{font-family:"Tisa Offc Serif Pro Thin";}
@font-face
	{font-family:"Trade Gothic Next";}
@font-face
	{font-family:"Trade Gothic Next Cond";}
@font-face
	{font-family:"Trade Gothic Next Cond Hv";}
@font-face
	{font-family:"Trade Gothic Next Heavy";}
@font-face
	{font-family:"Trade Gothic Next Light";}
@font-face
	{font-family:"Traditional Arabic";}
@font-face
	{font-family:"UD Digi Kyokasho N-B";}
@font-face
	{font-family:"UD Digi Kyokasho N-R";}
@font-face
	{font-family:"UD Digi Kyokasho NK-B";}
@font-face
	{font-family:"UD Digi Kyokasho NK-R";}
@font-face
	{font-family:"UD Digi Kyokasho NP-B";}
@font-face
	{font-family:"UD Digi Kyokasho NP-R";}
@font-face
	{font-family:Univers;}
@font-face
	{font-family:"Univers Condensed";}
@font-face
	{font-family:"Univers Condensed Light";}
@font-face
	{font-family:"Univers Light";}
@font-face
	{font-family:"Urdu Typesetting";}
@font-face
	{font-family:Utsaah;}
@font-face
	{font-family:Vani;}
@font-face
	{font-family:"Verdana Pro";}
@font-face
	{font-family:"Verdana Pro Black";}
@font-face
	{font-family:"Verdana Pro Cond";}
@font-face
	{font-family:"Verdana Pro Cond Black";}
@font-face
	{font-family:"Verdana Pro Cond Light";}
@font-face
	{font-family:"Verdana Pro Cond SemiBold";}
@font-face
	{font-family:"Verdana Pro Light";}
@font-face
	{font-family:"Verdana Pro SemiBold";}
@font-face
	{font-family:Vijaya;}
@font-face
	{font-family:"Walbaum Display";}
@font-face
	{font-family:"Walbaum Display Heavy";}
@font-face
	{font-family:"Walbaum Display Light";}
@font-face
	{font-family:"Walbaum Display SemiBold";}
@font-face
	{font-family:"Walbaum Heading";}
@font-face
	{font-family:"Walbaum Text";}
@font-face
	{font-family:"Yu Mincho";}
@font-face
	{font-family:"Yu Mincho Demibold";}
@font-face
	{font-family:"Yu Mincho Light";}
@font-face
	{font-family:"TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPSMT;}
@font-face
	{font-family:"Times New Roman Bold";
	panose-1:2 2 8 3 7 5 5 2 3 4;}
@font-face
	{font-family:PraxisCom-Regular;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EUAlbertina;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"\@TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:"\@Batang";
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@BatangChe";}
@font-face
	{font-family:"\@Gungsuh";}
@font-face
	{font-family:"\@GungsuhChe";}
@font-face
	{font-family:"\@DengXian Light";}
@font-face
	{font-family:"\@Gulim";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@GulimChe";}
@font-face
	{font-family:"\@Dotum";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@DotumChe";}
@font-face
	{font-family:"\@Meiryo";}
@font-face
	{font-family:"\@Meiryo UI";}
@font-face
	{font-family:"\@MingLiU";
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:"\@PMingLiU";
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"\@MingLiU_HKSCS";}
@font-face
	{font-family:"\@MS PMincho";}
@font-face
	{font-family:"\@STXingkai";}
@font-face
	{font-family:"\@STZhongsong";}
@font-face
	{font-family:"\@Yu Mincho";}
@font-face
	{font-family:"\@Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Times-Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:CourierNewPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"SAS Monospace";}
@font-face
	{font-family:"Bookshelf Symbol 3";}
@font-face
	{font-family:Goudy;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Garamond-Italic;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:DIN-Bold;}
@font-face
	{font-family:"CG Times \(W1\)";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"HelveticaNeue Condensed";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@HGMaruGothicMPRO";}
@font-face
	{font-family:CourierStd;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EFPPNA+TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@TimesNewRoman";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRomanPSMT\,Times New Rom";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRoman\,Times New Roman";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRoman\,Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"CG Times";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Minion;}
@font-face
	{font-family:CourierNew;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Noto Sans Symbols";}
@font-face
	{font-family:LZLLQG+TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPS;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:HelveticaNeueLTStd-Cn;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings-Regular;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@HelveticaNeueLTStd-Cn";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Wingdings-Regular";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Geneva;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRoman\,BoldItalic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:ArialMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h1
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:17.85pt;
	text-indent:-17.85pt;
	line-height:13.0pt;
	font-size:13.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
h2
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Helvetica",sans-serif;
	font-weight:bold;
	font-style:italic;}
h3
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h4
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h5
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;}
h6
	{margin:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;
	font-style:italic;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-align:justify;
	text-indent:-28.35pt;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-link:"Comment Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	font-size:10.0pt;
	font-family:"Helvetica",sans-serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	font-size:8.0pt;
	font-family:"Helvetica",sans-serif;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{mso-style-link:"Endnote Text Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{mso-style-name:"Body Text\,Body Text Char Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-decoration:underline;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:113.4pt;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;
	color:blue;}
p.MsoDate, li.MsoDate, div.MsoDate
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	text-decoration:underline;}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.9pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBlockText, li.MsoBlockText, div.MsoBlockText
	{margin-top:0in;
	margin-right:.75in;
	margin-bottom:0in;
	margin-left:.5in;
	text-align:justify;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{mso-style-link:"Document Map Char";
	margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
	{mso-style-link:"Plain Text Char";
	margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p
	{margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Arial Unicode MS",serif;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.SmPCsubheading
	{mso-style-name:"SmPC subheading";
	font-family:"Times New Roman",serif;
	font-weight:bold;
	vertical-align:baseline;}
p.RegNote, li.RegNote, div.RegNote
	{mso-style-name:RegNote;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:15.0pt;
	margin-left:0in;
	line-height:125%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:red;}
p.RRNormal, li.RRNormal, div.RRNormal
	{mso-style-name:"RR Normal";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:15.0pt;
	margin-left:0in;
	line-height:125%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.NormalBold, li.NormalBold, div.NormalBold
	{mso-style-name:"Normal Bold";
	margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.Paragraph, li.Paragraph, div.Paragraph
	{mso-style-name:Paragraph;
	mso-style-link:"Paragraph Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.paragraph0, li.paragraph0, div.paragraph0
	{mso-style-name:paragraph;
	margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.konourinai
	{mso-style-name:konourina_i;
	font-family:"Arial",sans-serif;
	color:navy;}
span.PlainTextChar
	{mso-style-name:"Plain Text Char";
	mso-style-link:"Plain Text";
	font-family:"Calibri",sans-serif;
	color:black;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.NormalAgency, li.NormalAgency, div.NormalAgency
	{mso-style-name:"Normal \(Agency\)";
	mso-style-link:"Normal \(Agency\) Char";
	margin:0in;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.TabletextrowsAgency, li.TabletextrowsAgency, div.TabletextrowsAgency
	{mso-style-name:"Table text rows \(Agency\)";
	margin:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.NormalAgencyChar
	{mso-style-name:"Normal \(Agency\) Char";
	mso-style-link:"Normal \(Agency\)";
	font-family:"Verdana",sans-serif;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char";
	mso-style-link:"Comment Text";}
span.EndnoteTextChar
	{mso-style-name:"Endnote Text Char";
	mso-style-link:"Endnote Text";}
span.ParagraphChar
	{mso-style-name:"Paragraph Char";
	mso-style-link:Paragraph;}
span.DocumentMapChar
	{mso-style-name:"Document Map Char";
	mso-style-link:"Document Map";
	font-family:"Tahoma",sans-serif;}
span.msoIns
	{mso-style-name:"";
	text-decoration:underline;
	color:teal;}
span.msoDel
	{mso-style-name:"";
	text-decoration:line-through;
	color:red;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink=purple style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=NormalBold align=center style='text-align:center'><span
style='font-size:11.0pt'>ANNEX I</span></p>

<p class=NormalBold align=center style='text-align:center'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<h1 align=center style='margin:0in;text-align:center;text-indent:0in;
line-height:normal'><span style='font-size:11.0pt'>SUMMARY OF PRODUCT
CHARACTERISTICS</span></h1>

<p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF THE
MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Revatio
20&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; QUALITATIVE
AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each film-coated
tablet contains 20&nbsp;mg of sildenafil (as citrate). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Excipient(s)
with known effect</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each tablet also
contains 0.7&nbsp;mg of lactose.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For the full
list of excipients, see section 6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
<span style='text-transform:uppercase'>form</span></span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Film-coated
tablet.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>White, round,
biconvex film-coated tablets marked &#8220;PFIZER&#8221; on one side and
&#8220;RVT 20&#8221;on the other.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB style='text-transform:uppercase'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clinical
particulars</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.1&nbsp;&nbsp;&nbsp;&nbsp; Therapeutic indications</span></b></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Adults</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Treatment of adult patients with pulmonary
arterial hypertension classified as WHO functional class II and III, to improve
exercise capacity. Efficacy has been shown in primary pulmonary hypertension
and pulmonary hypertension associated with connective tissue disease.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><u><span lang=EN-GB>Paediatric population</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Treatment of paediatric patients aged 1&nbsp;year
to 17&nbsp;years old with pulmonary arterial hypertension. Efficacy in terms of
improvement of exercise capacity or pulmonary haemodynamics has been shown in
primary pulmonary hypertension and pulmonary hypertension associated with
congenital heart disease (see section 5.1).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.5pt;text-indent:-28.5pt;line-height:
normal'><b><span lang=EN-GB>4.2<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>Posology and method of administration</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Treatment should
only be initiated and monitored by a physician experienced in the treatment of
pulmonary arterial hypertension. In case of clinical deterioration in spite of
Revatio treatment, alternative therapies should be considered.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span class=SmPCsubheading><i><u><span
lang=EN-GB style='font-weight:normal'>Adults</span></u></i></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The recommended
dose is 20&nbsp;mg three times a day (TID). Physicians should advise patients
who forget to take Revatio to take a dose as soon as possible and then continue
with the normal dose. Patients should not take a double dose to compensate for
the missed dose.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Paediatric
population (1 year to 17 years)</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB>For paediatric patients aged 1&nbsp;year to
17&nbsp;years old, the recommended dose in patients &#8804;&nbsp;20&nbsp;kg is
10&nbsp;mg three times a day and for patients &gt;&nbsp;20&nbsp;kg is
20&nbsp;mg three times a day. </span><span lang=EN-GB>Higher than recommended
doses should not be used in paediatric patients with PAH (see also sections 4.4
and 5.1). The 20&nbsp;mg tablet should not be used in cases where 10&nbsp;mg TID
should be administered in younger patients. Other pharmaceutical forms are
available for administration to patients </span><span lang=EN-GB>&#8804;&nbsp;20&nbsp;kg
and other younger patients </span><span lang=EN-GB>who are not able to swallow
tablets.</span></p>

<p class=MsoNormal style='line-height:normal'><span class=SmPCsubheading><span
lang=EN-GB>&nbsp;</span></span></p>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'><i><u><span
lang=EN-GB>Patients using other medicinal products</span></u></i></p>

<p class=MsoNormal style='line-height:normal'>In general, any dose adjustment
should be administered only after a careful benefit-risk assessment. A downward
dose adjustment to 20&nbsp;mg twice daily should be considered when sildenafil
is co&#8209;administered to patients already receiving CYP3A4 inhibitors like
erythromycin or saquinavir. A downward dose adjustment to 20&nbsp;mg once daily
is recommended in case of co&#8209;administration with more potent CYP3A4
inhibitors <span lang=EN-GB>clarithromycin, telithromycin and nefazodone</span>.
<span lang=EN-GB>For the use of sildenafil with the most potent CYP3A4
inhibitors, see section 4.3. </span>Dose adjustments for sildenafil may be
required when co-administered with CYP3A4 inducers (see section 4.5).</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
class=SmPCsubheading><u><span lang=EN-GB style='font-weight:normal'>Special
populations</span></u></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span class=SmPCsubheading><i><u><span
lang=EN-GB style='font-weight:normal'>Elderly (&#8805; 65&nbsp;years)</span></u></i></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Dose adjustments
are not required in elderly patients. Clinical efficacy as measured by 6-minute
walk distance could be less in elderly patients.</span></p>

<p class=MsoNormal style='line-height:normal'><b>&nbsp;</b></p>

<p class=MsoNormal style='line-height:normal'><span class=SmPCsubheading><i><u><span
lang=EN-GB style='font-weight:normal'>Renal impairment</span></u></i></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Initial dose
adjustments are not required in patients with renal impairment, including
severe renal impairment (creatinine clearance &lt;&nbsp;30&nbsp;ml/min<i>).</i>
A downward dose adjustment to 20&nbsp;mg twice daily should be considered after
a careful benefit-risk assessment only if therapy is not well-tolerated.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span class=SmPCsubheading><i><u><span
lang=EN-GB style='font-weight:normal'>Hepatic impairment</span></u></i></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Initial dose
adjustments are not required in patients with hepatic impairment (Child-Pugh
class A and B). A downward dose adjustment to 20&nbsp;mg twice daily should be
considered after a careful benefit&#8209;risk assessment only if therapy is not
well-tolerated.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Revatio is
contraindicated in patients with severe hepatic impairment (Child-Pugh class C)
(see section 4.3).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span class=SmPCsubheading><i><u><span
lang=EN-GB style='font-weight:normal'>Paediatric population (children less than
1 year and neonates)</span></u></i></span></p>

<p class=MsoNormal style='line-height:normal'><a name="_Hlk30429470"><span
lang=EN-GB>Outside its authorised indications, sildenafil should not be used in
neonates with persistent pulmonary hypertension of the newborn as risks
outweigh the benefits (see section 5.1).</span></a><span lang=EN-GB> The safety
and efficacy of Revatio in other conditions in children below 1&nbsp;year of
age has not been established. No data are available.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Discontinuation
of treatment</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Limited data
suggest that the abrupt discontinuation of Revatio is not associated with
rebound worsening of pulmonary arterial hypertension. However to avoid the
possible occurrence of sudden clinical deterioration during withdrawal, a
gradual dose reduction should be considered. Intensified monitoring is
recommended during the discontinuation period.</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal><u><span lang=EN-GB>Method of administration</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Revatio is for oral use only. Tablets
should be taken approximately 6 to 8&nbsp;hours apart with or without food.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.3&nbsp;&nbsp;&nbsp;&nbsp; Contraindications</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Hypersensitivity to the active substance or to any of the excipients
listed in section 6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Co-administration
with nitric oxide donors (such as amyl nitrite) or nitrates in any form due to
the hypotensive effects of nitrates (see section 5.1).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:6.0pt;line-height:normal'><span
lang=EN-GB>The co-administration of PDE5 inhibitors, including sildenafil, with
guanylate cyclase stimulators, such as riociguat, is contraindicated as it may
potentially lead to symptomatic hypotension (see section 4.5).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Combination with
the most potent of the CYP3A4 inhibitors (eg, ketoconazole, itraconazole,
ritonavir) (see section 4.5).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>Patients who have loss of vision in one eye because of <span
lang=EN-GB>non-arteritic anterior ischaemic optic neuropathy (NAION),</span>
regardless of whether this episode was in connection or not with previous PDE5
inhibitor exposure (see section 4.4).</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>The safety of sildenafil has not
been studied in the following sub-groups of patients and its use is therefore
contraindicated:</p>

<p class=MsoNormal style='line-height:normal'>Severe hepatic impairment,</p>

<p class=MsoNormal style='line-height:normal'>Recent history of stroke or
myocardial infarction,</p>

<p class=MsoNormal style='line-height:normal'>Severe hypotension (blood pressure
&lt;&nbsp;90/50&nbsp;mmHg) at initiation.</p>

<p class=MsoDate><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.5pt;text-indent:-28.5pt;line-height:
normal'><b><span lang=EN-GB>4.4<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>Special warnings and precautions for use</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The efficacy of
Revatio has not been established in patients with severe pulmonary arterial
hypertension (functional class IV). If the clinical situation deteriorates,
therapies that are recommended at the severe stage of the disease (eg,
epoprostenol) should be considered (see section 4.2). The benefit-risk balance
of sildenafil has not been established in patients assessed to be at WHO functional
class I pulmonary arterial hypertension.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Studies with
sildenafil have been performed in forms of pulmonary arterial hypertension
related to primary (idiopathic), connective tissue disease associated or
congenital heart disease associated forms of PAH (see section 5.1). The use of
sildenafil in other forms of PAH is not recommended.</span></p>

<p class=MsoPlainText><span lang=X-NONE style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoPlainText><span lang=X-NONE style='font-size:11.0pt'>In the long
term paediatric extension study, an increase in deaths was observed in patients
administered doses higher than the recommended dose. Therefore, doses higher
than the recommended doses should not be used in paediatric patients with PAH (see
also sections 4.2 and 5.1).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Retinitis
pigmentosa</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The safety of
sildenafil has not been studied in patients with known hereditary degenerative
retinal disorders such as <i>retinitis pigmentosa</i> (a minority of these patients
have genetic disorders of retinal phosphodiesterases) and therefore its use is
not recommended.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Vasodilatory
action</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>When prescribing
sildenafil</span><span lang=EN-GB>, physicians should carefully consider
whether patients with certain underlying conditions could be adversely affected
by sildenafil&#8217;s mild to moderate vasodilatory effects, for example
patients with hypotension, patients with fluid depletion, severe left
ventricular outflow obstruction or autonomic dysfunction (see section 4.4).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Cardiovascular
risk factors</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In
post-marketing experience with sildenafil for male erectile dysfunction,
serious cardiovascular events, including myocardial infarction, unstable
angina, sudden cardiac death, ventricular arrhythmia, cerebrovascular
haemorrhage, transient ischaemic attack, hypertension and hypotension have been
reported in temporal association with the use of sildenafil. Most, but not all,
of these patients had pre-existing cardiovascular risk factors. Many events
were reported to occur during or shortly after sexual intercourse and a few
were reported to occur shortly after the use of sildenafil without sexual
activity. It is not possible to determine whether these events are related
directly to these factors or to other factors.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-AU
style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-AU
style='layout-grid-mode:line'>Priapism</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sildenafil
should be used with caution in patients with anatomical deformation of the
penis (such as angulation, cavernosal fibrosis or Peyronie&#8217;s disease), or
in patients who have conditions which may predispose them to priapism (such as
sickle cell anaemia, multiple myeloma or leukaemia).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Prolonged
erections and priapism have been reported with sildenafil in post-marketing
experience. In the event of an erection that persists longer than 4&nbsp;hours,
the patient should seek immediate medical assistance. If priapism is not
treated immediately, penile tissue damage and permanent loss of potency could
result (see section 4.8).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-AU
style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Vaso-occlusive
crises in patients with s</span></u><u><span lang=EN-AU style='layout-grid-mode:
line'>ickle cell anaemia</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-AU
style='layout-grid-mode:line'>Sildenafil should not be used in patients with
pulmonary hypertension secondary to sickle cell anaemia. In a clinical study
events of vaso-occlusive crises requiring hospitalisation were reported more
commonly by patients receiving Revatio than those receiving placebo leading to
the premature termination of this study.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-AU
style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-AU
style='layout-grid-mode:line'>Visual events</span></u></p>

<p class=MsoNormal style='line-height:normal'><em><span lang=EN-GB
style='font-style:normal'>Cases of visual defects have been reported spontaneously
in connection with the intake of&nbsp;sildenafil and other PDE5 inhibitors. Cases
of non&#8209;arteritic anterior ischaemic optic neuropathy, a rare condition,
have been reported spontaneously and in an observational study in connection with
the intake of&nbsp;sildenafil and other PDE5 inhibitors (see section 4.8). In
the event of any sudden visual defect, the treatment should be stopped
immediately and alternative treatment should be considered (see section 4.3).</span></em></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-AU
style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-AU style='layout-grid-mode:line'>Alpha-blockers</span></u></p>

<p class=MsoBodyText2 style='line-height:normal'><span lang=EN-AU
style='color:windowtext;layout-grid-mode:line'>Caution is advised when
sildenafil is administered </span><span style='color:windowtext'>to patients
taking an alpha-blocker as the co&#8209;administration may lead to symptomatic
hypotension in susceptible individuals (see section 4.5). </span><span
lang=EN-GB style='color:windowtext'>In order to minimise the potential for
developing postural hypotension, patients should be haemodynamically stable on
alpha-blocker therapy prior to initiating sildenafil treatment. Physicians
should advise patients what to do in the event of postural hypotensive
symptoms.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Bleeding
disorders</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Studies with
human platelets indicate that sildenafil potentiates the antiaggregatory effect
of sodium nitroprusside <i>in vitro</i>. There is no safety information on the
administration of sildenafil to patients with bleeding disorders or active
peptic ulceration. Therefore sildenafil should be administered to these
patients only after careful benefit-risk assessment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Vitamin K
antagonists</span></u></p>

<p class=MsoNormal style='line-height:normal'>In pulmonary arterial
hypertension patients, there may be a potential for increased risk of bleeding
when sildenafil is initiated in patients already using a Vitamin K antagonist,
particularly in patients with pulmonary arterial hypertension secondary to
connective tissue disease.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Veno-occlusive
disease</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No data are
available with sildenafil in patients with pulmonary hypertension associated
with pulmonary veno-occlusive disease. However, cases of life threatening
pulmonary oedema have been reported with vasodilators (mainly prostacyclin)
when used in those patients. Consequently, should signs of pulmonary oedema
occur when sildenafil is administered in patients with pulmonary hypertension,
the possibility of associated veno-occlusive disease should be considered.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Galactose intolerance</span></u></p>

<p class=MsoNormal style='line-height:normal'>Lactose monohydrate is present in
the tablet film coat. <span lang=EN-GB>Patients with rare hereditary problems
of galactose intolerance, the Lapp lactase deficiency or glucose-galactose
malabsorption should not take this medicine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Use of
sildenafil with bosentan</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The efficacy of
sildenafil in patients already on bosentan therapy has not been conclusively
demonstrated (see sections 4.5 and 5.1).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoCommentText style='page-break-after:avoid'><u><span lang=X-NONE
style='font-size:11.0pt'>Concomitant use with other PDE5 inhibitors</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The safety and efficacy of sildenafil when co-administered with
other PDE5 inhibitor products, including Viagra, has not been studied in PAH
patients and</span><span lang=EN-GB> such concomitant use is not recommended
(see section 4.5).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=NormalBold style='page-break-after:avoid'><span style='font-size:11.0pt'>4.5&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt'>Interaction with other medicinal products and other
forms of interaction</span></p>

<p class=NormalBold style='page-break-after:avoid'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span class=SmPCsubheading><u><span
lang=EN-GB style='font-weight:normal'>Effects of other medicinal products on
sildenafil</span></u></span></p>

<p class=MsoNormal style='page-break-after:avoid'><span class=SmPCsubheading><i><u><span
lang=EN-GB style='font-weight:normal'><span style='text-decoration:none'>&nbsp;</span></span></u></i></span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=IT>In vitro
studies</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sildenafil
metabolism is principally mediated by the cytochrome P450 (CYP) isoforms 3A4
(major route) and 2C9 (minor route). Therefore, inhibitors of these isoenzymes
may reduce sildenafil clearance and inducers of these isoenzymes may increase
sildenafil clearance. For dose recommendations, see sections 4.2 and 4.3.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=NL>In vivo
studies<b> </b></span></u></i></p>

<p class=MsoNormal><span lang=EN-GB>Co-administration of oral sildenafil and
intravenous epoprostenol has been evaluated (see sections 4.8 and 5.1).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The efficacy and safety of sildenafil
co-administered with other treatments for pulmonary arterial hypertension (eg, ambrisentan,
iloprost) has not been studied in controlled clinical trials. Therefore,
caution is recommended in case of co-administration.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>The safety and efficacy of sildenafil when co-administered
with other PDE5 inhibitors has not been studied in pulmonary arterial
hypertension patients (see section 4.4).</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Population
pharmacokinetic analysis of pulmonary arterial hypertension clinical trial data
indicated a reduction in sildenafil clearance and/or an increase of oral
bioavailability when co-administered with CYP3A4 substrates and the combination
of CYP3A4 substrates and beta-blockers. These were the only factors with a
statistically significant impact on sildenafil pharmacokinetics in patients
with pulmonary arterial hypertension. The exposure to sildenafil in patients on
CYP3A4 substrates and CYP3A4 substrates plus beta-blockers was 43&nbsp;% and 66&nbsp;%
higher, respectively, compared to patients not receiving these classes of
medicines. Sildenafil exposure was 5-fold higher at a dose of 80&nbsp;mg three
times a day compared to the exposure at a dose of 20&nbsp;mg three times a day.
This concentration range covers the increase in sildenafil exposure observed in
specifically designed drug interaction studies with CYP3A4 inhibitors (except with
the most potent of the CYP3A4 inhibitors eg, ketoconazole, itraconazole,
ritonavir).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>CYP3A4 inducers
seemed to have a substantial impact on the pharmacokinetics of sildenafil in
pulmonary arterial hypertension patients, which was confirmed in the in-vivo
interaction study with CYP3A4 inducer bosentan.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Co-administration
of bosentan (a moderate inducer of CYP3A4, CYP2C9 and possibly of CYP2C19)
125&nbsp;mg twice daily with sildenafil 80&nbsp;mg three times a day (at steady
state) concomitantly administered during 6&nbsp;days in healthy volunteers
resulted in a 63&nbsp;% decrease of sildenafil AUC. </span><span lang=EN-GB>A
population pharmacokinetic analysis of sildenafil data from adult PAH patients
in clinical trials including a 12 week study to assess the efficacy and safety
of oral sildenafil 20 mg three times a day when added to a stable dose of
bosentan (62.5 mg &#8211; 125 mg twice a day) indicated a decrease in
sildenafil exposure with bosentan co-administration, similar to that observed
in healthy volunteers (see sections 4.4 and 5.1).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Efficacy of
sildenafil should be closely monitored in patients using concomitant potent
CYP3A4 inducers, such as carbamazepine, phenytoin, phenobarbital, St
John&#8217;s wort and rifampicine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Co-administration
of the HIV protease inhibitor ritonavir, which is a highly potent P450
inhibitor, at steady state (500&nbsp;mg twice daily) with sildenafil
(100&nbsp;mg single dose) resulted in a 300&nbsp;% (4-fold) increase in
sildenafil C<sub>max</sub> and a 1,000&nbsp;% (11-fold) increase in sildenafil
plasma AUC. At 24&nbsp;hours, the plasma levels of sildenafil were still
approximately 200&nbsp;ng/ml, compared to approximately 5&nbsp;ng/ml when
sildenafil was administered alone. This is consistent with ritonavir&#8217;s
marked effects on a broad range of P450 substrates. Based on these
pharmacokinetic results co-administration of sildenafil with ritonavir is
contraindicated in pulmonary arterial hypertension patients (see section 4.3).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Co-administration
of the HIV protease inhibitor saquinavir, a CYP3A4 inhibitor, at steady state
(1200&nbsp;mg three times a day) with sildenafil (100&nbsp;mg single dose)
resulted in a 140&nbsp;% increase in sildenafil C<sub>max</sub> and a 210&nbsp;%
increase in sildenafil AUC. Sildenafil had no effect on saquinavir
pharmacokinetics. For dose recommendations, see section 4.2.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>When a single
100&nbsp;mg dose of sildenafil was administered with erythromycin, a moderate
CYP3A4 inhibitor, at steady state (500&nbsp;mg twice daily for 5&nbsp;days),
there was a 182&nbsp;% increase in sildenafil systemic exposure (AUC). For dose
recommendations, see section 4.2. In healthy male volunteers, there was no
evidence of an effect of azithromycin (500&nbsp;mg daily for 3&nbsp;days) on
the AUC, C<sub>max</sub>, T<sub>max</sub>, elimination rate constant, or
subsequent half-life of sildenafil or its principal circulating metabolite. No
dose adjustment is required. Cimetidine (800&nbsp;mg), a cytochrome P450
inhibitor and a non-specific CYP3A4 inhibitor, caused a 56&nbsp;% increase in
plasma sildenafil concentrations when co&#8209;administered with sildenafil
(50&nbsp;mg) to healthy volunteers. No dose adjustment is required.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>The most potent of the CYP3A4
inhibitors such as ketoconazole and itraconazole would be expected to have
effects similar to ritonavir (see section 4.3). CYP3A4 inhibitors like<span
lang=EN-GB> clarithromycin, telithromycin and nefazodone are expected to have
an effect in between that of ritonavir and CYP3A4 inhibitors like saquinavir or
erythromycin, a seven-fold increase in exposure is assumed. Therefore dose
adjustments are recommended when using CYP3A4 inhibitors (see section 4.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The population
pharmacokinetic analysis in pulmonary arterial hypertension patients suggested
that co-administration of beta-blockers in combination with CYP3A4 substrates might
result in an additional increase in sildenafil exposure compared with
administration of CYP3A4 substrates alone.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Grapefruit juice
is a weak inhibitor of CYP3A4 gut wall metabolism and may give rise to modest
increases in plasma levels of sildenafil. No dose adjustment is required but
the concomitant use of sildenafil and grapefruit juice is not recommended.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Single doses of
antacid (magnesium hydroxide/aluminium hydroxide) did not affect the
bioavailability of sildenafil.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Co-administration
of oral contraceptives (ethinyloestradiol 30&nbsp;</span><span lang=EN-GB
style='font-family:Symbol'>m</span><span lang=EN-GB>g and levonorgestrel
150&nbsp;</span><span lang=EN-GB style='font-family:Symbol'>m</span><span
lang=EN-GB>g) did not affect the pharmacokinetics of sildenafil.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Nicorandil is a
hybrid of potassium channel activator and nitrate. Due to the nitrate component
it has the potential to have serious interaction with sildenafil (see section
4.3).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span class=SmPCsubheading><u><span
lang=EN-GB style='font-weight:normal'>Effects of sildenafil on other medicinal
products</span></u></span></p>

<p class=MsoNormal style='page-break-after:avoid'><span class=SmPCsubheading><u><span
lang=EN-GB style='font-weight:normal'><span style='text-decoration:none'>&nbsp;</span></span></u></span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=IT>In vitro
studies</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sildenafil is a
weak inhibitor of the cytochrome P450 isoforms 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4
(IC<sub>50</sub>&nbsp;&gt;&nbsp;150&nbsp;</span><span lang=EN-GB
style='font-family:Symbol'>m</span><span lang=EN-GB>M).&nbsp; </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>There are no data on the interaction
of sildenafil and non-specific phosphodiesterase inhibitors such as
theophylline or dipyridamole.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=NL>In vivo
studies</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No significant
interactions were shown when sildenafil (50&nbsp;mg) was co-administered with
tolbutamide (250&nbsp;mg) or warfarin (40&nbsp;mg), both of which are
metabolised by CYP2C9.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sildenafil had
no significant effect on atorvastatin exposure (AUC increased 11&nbsp;%),
suggesting that sildenafil does not have a clinically relevant effect on
CYP3A4.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No interactions
were observed between sildenafil (100&nbsp;mg single dose) and acenocoumarol.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sildenafil
(50&nbsp;mg) did not potentiate the increase in bleeding time caused by acetyl
salicylic acid (150&nbsp;mg).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sildenafil
(50&nbsp;mg) did not potentiate the hypotensive effects of alcohol in healthy
volunteers with mean maximum blood alcohol levels of 80&nbsp;mg/dl.</span></p>

<p class=MsoNormal style='line-height:normal'><s><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></s></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In a study of
healthy volunteers sildenafil at steady state (80&nbsp;mg three times a day)
resulted in a 50&nbsp;% increase in bosentan AUC (125&nbsp;mg twice daily). </span><span
lang=EN-GB>A population pharmacokinetic analysis of data from a study of adult PAH
patients on background bosentan therapy (62.5 mg - 125&nbsp;mg twice a day)
indicated an increase (20% (95% CI: 9.8 - 30.8)) of bosentan AUC with
co-administration of steady-state sildenafil (20&nbsp;mg three times a day) of
a smaller magnitude than seen in healthy volunteers when co-administered with
80 mg sildenafil three times a day (see sections 4.4 and 5.1).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In a specific
interaction study, where sildenafil (100&nbsp;mg) was co-administered with
amlodipine in hypertensive patients, there was an additional reduction on
supine systolic blood pressure of 8&nbsp;mmHg. The corresponding additional
reduction in supine diastolic blood pressure was 7&nbsp;mmHg. These additional
blood pressure reductions were of a similar magnitude to those seen when
sildenafil was administered alone to healthy volunteers.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>In three
specific drug&#8209;drug interaction studies, the alpha-blocker doxazosin
(4&nbsp;mg and 8&nbsp;mg) and sildenafil (25&nbsp;mg, 50&nbsp;mg, or
100&nbsp;mg) were administered simultaneously to patients with benign prostatic
hyperplasia (BPH) stabilized on doxazosin therapy. In these study populations,
mean additional reductions of supine systolic and diastolic blood pressure of
7/7&nbsp;mmHg, 9/5&nbsp;mmHg, and 8/4&nbsp;mmHg, respectively, and mean
additional reductions of standing blood pressure of 6/6&nbsp;mmHg, 11/4&nbsp;mmHg,
and 4/5&nbsp;mmHg, respectively were observed. When sildenafil and doxazosin
were administered simultaneously to patients stabilized on doxazosin therapy,
there were infrequent reports of patients who experienced symptomatic postural
hypotension. These reports included dizziness and lightheadedness, but not
syncope. Concomitant administration of sildenafil to patients taking alpha&#8209;blocker
therapy may lead to symptomatic hypotension in susceptible individuals (see
section 4.4).</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sildenafil
(100&nbsp;mg single dose) did not affect the steady state pharmacokinetics of
the HIV protease inhibitor saquinavir, which is a CYP3A4 substrate/inhibitor.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Consistent with
its known effects on the nitric oxide/cGMP pathway (see section 5.1),
sildenafil was shown to potentiate the hypotensive effects of nitrates, and its
co-administration with nitric oxide donors or nitrates in any form is therefore
contraindicated (see section 4.3).</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Riociguat: Preclinical studies showed additive systemic blood
pressure lowering effect when PDE5 inhibitors were combined with riociguat. In
clinical studies, riociguat has been shown to augment the hypotensive effects
of PDE5 inhibitors. There was no evidence of favourable clinical effect of the
combination in the population studied. Concomitant use of riociguat with PDE5
inhibitors, including sildenafil, is contraindicated (see section 4.3).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Sildenafil had no clinically significant
impact on the plasma levels of oral contraceptives (ethinyloestradiol 30&nbsp;</span><span
lang=EN-GB style='font-family:Symbol'>m</span><span lang=EN-GB>g and
levonorgestrel 150&nbsp;</span><span lang=EN-GB style='font-family:Symbol'>m</span><span
lang=EN-GB>g).</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'><u><span
lang=EN-GB>Paediatric population</span></u></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>Interaction
studies have only been performed in adults.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.6&nbsp;&nbsp;&nbsp;&nbsp; Fertility,
pregnancy and lactation</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='text-align:justify'><u><span lang=EN-GB>Women of
childbearing potential and contraception in males and females</span></u></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>Due to lack of
data on effects of Revatio in pregnant women, Revatio is not recommended for
women of childbearing potential unless also using appropriate contraceptive
measures.</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>There are no data from the use of sildenafil in pregnant women.
Animal studies do not indicate direct or indirect harmful effects with respect
to pregnancy and embryonal/foetal development. Studies in animals have shown
toxicity with respect to postnatal development (see section 5.3).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Due to lack of
data, Revatio should not be used in pregnant women unless strictly necessary.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Breast-feeding</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>There are no adequate and well controlled studies in
lactating women. Data from one lactating woman indicate that sildenafil and its
active metabolite N-desmethylsildenafil are excreted into breast milk at very
low levels. No clinical data are available regarding adverse events in
breast-fed infants, but amounts ingested would not be expected to cause any
adverse effects. Prescribers should carefully assess the mother&#8217;s
clinical need for sildenafil and any potential adverse effects on the breast&#8209;fed
child.</span></p>

<p class=MsoNormal style='text-align:justify'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='text-align:justify'><u><span lang=EN-GB>Fertility</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Non-clinical data revealed no special
hazard for humans based on conventional studies of fertility (see section 5.3).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.7&nbsp;&nbsp;&nbsp;&nbsp; Effects on ability to
drive and use machines</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Revatio has moderate influence on the
ability to drive and use machines.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>As dizziness
and altered vision were reported in clinical trials with sildenafil, patients
should be aware of how they might be affected by Revatio, before driving or using
machines.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.8&nbsp;&nbsp;&nbsp;&nbsp; Undesirable
effects</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u>Summary of the safety profile</u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>In the
pivotal placebo-controlled study of Revatio in pulmonary arterial hypertension,
a total of 207&nbsp;patients were randomized to and treated with 20&nbsp;mg, 40&nbsp;mg,
or 80&nbsp;mg TID doses of Revatio and 70&nbsp;patients were randomized to
placebo. The duration of treatment was 12&nbsp;weeks. <span lang=EN-GB>The
overall frequency of discontinuation in sildenafil treated patients at doses of
20&nbsp;mg, 40&nbsp;mg and 80&nbsp;mg TID was 2.9&nbsp;%, 3.0&nbsp;% and 8.5&nbsp;%
respectively, compared to 2.9&nbsp;% with placebo. Of the</span><span
lang=EN-GB> </span>277&nbsp;subjects treated in the pivotal study, 259 entered
a long-term extension study. Doses up to 80&nbsp;mg three times a day
(4&nbsp;times the recommended dose of 20&nbsp;mg <span lang=EN-GB>three times a
day</span>) were administered and after <span lang=EN-GB>3 years 87&nbsp;% of
183&nbsp;patients on study treatment were receiving Revatio 80&nbsp;mg TID.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=Paragraph style='margin-bottom:0in'><span style='font-size:11.0pt'>In
a placebo-controlled study of </span><span lang=EN-GB style='font-size:11.0pt'>Revatio
</span><span style='font-size:11.0pt'>as an adjunct to intravenous epoprostenol
in pulmonary arterial hypertension</span><span lang=EN-GB style='font-size:
11.0pt'>, a total of 134&nbsp;patients were treated with Revatio (</span><span
style='font-size:11.0pt'>in a fixed titration starting from 20&nbsp;mg, to
40&nbsp;mg and then 80&nbsp;mg, three times a day, as tolerated) and
epoprostenol, and 131&nbsp;patients were treated with placebo and epoprostenol.
The duration of treatment was 16&nbsp;weeks. The overall frequency of
discontinuations in sildenafil/epoprostenol treated patients due to adverse
events was 5.2&nbsp;% compared to 10.7&nbsp;% in the placebo/epoprostenol
treated patients. Newly reported adverse reactions, which occurred more
frequently in the sildenafil/ epoprostenol group, were ocular hyperaemia, vision
blurred, nasal congestion, night sweats, back pain and dry mouth. The known
adverse reactions headache, flushing, pain in extremity and oedema were noted
in a higher frequency in sildenafil/epoprostenol treated patients compared to
placebo/epoprostenol treated patients. Of the subjects who completed the
initial study, 242 entered a long-term extension study. Doses up to 80&nbsp;mg
TID were administered and after 3 years 68&nbsp;% of 133&nbsp;patients on study
treatment were receiving Revatio 80&nbsp;mg TID.</span></p>

<p class=Paragraph style='margin-bottom:0in'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>I<span
lang=EN-GB>n the twoplacebo-controlled studies adverse events were generally
mild to moderate in severity. The most commonly reported adverse reactions that
occurred (greater or equal to 10&nbsp;%) on </span>Revatio<span lang=EN-GB>
compared to placebo were headache, flushing, dyspepsia, diarrhoea and pain in
extremity.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Tabulated list of adverse reactions</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'>Adverse reactions which
occurred in &gt;&nbsp;1&nbsp;% of Revatio-treated patients and were more
frequent (&gt;&nbsp;1&nbsp;% difference) on Revatio in the pivotal study or in
the Revatio combined data set of both the placebo&#8209;controlled studies in
pulmonary arterial hypertension, at doses of 20, 40 or 80&nbsp;mg <span
lang=EN-GB>TID</span> are listed in the table below by class and frequency
grouping (very common (<span style='font-family:Symbol'>&sup3;</span>&nbsp;1/10),
common (<span style='font-family:Symbol'>&sup3;</span>&nbsp;1/100 to
&lt;&nbsp;1/10), <span lang=EN-GB>uncommon (</span><span lang=EN-GB
style='font-family:Symbol'>&sup3;</span><span lang=EN-GB>&nbsp;1/1000 to <u>&lt;&nbsp;</u>1/100)
and not known (cannot be estimated from the available data). </span>Within each
frequency grouping, adverse reactions are presented in order of decreasing
seriousness.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'>Reports from post-marketing experience are included in italics.</p>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:solid windowtext 1.0pt;
  border-right:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>MedDRA system organ class (V.14.0)</b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b>Adverse reaction</b></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>Infections and infestations</b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Common</p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>cellulitis,
  influenza, bronchitis, sinusitis, rhinitis, gastroenteritis</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>Blood and lymphatic system disorders</b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Common</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=ES>anaemia</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>Metabolism and nutrition disorders</b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Common</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>fluid
  retention</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>Psychiatric disorders</b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Common</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>insomnia,
  anxiety</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>Nervous system disorders</b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Very common</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>headache </span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Common</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>migraine,
  tremor, paraesthesia, burning sensation, hypoaesthesia</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>Eye disorders</b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Common</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>retinal haemorrhage,
  visual impairment, vision blurred, photophobia, chromatopsia, cyanopsia, eye
  irritation, ocular hyperaemia</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Uncommon</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>visual
  acuity reduced, diplopia, abnormal sensation in eye</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Not known</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Non-arteritic
  anterior ischaemic optic neuropathy (NAION)*, Retinal vascular occlusion*,
  Visual field defect*</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>Ear and labyrinth disorders</b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Common</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>vertigo</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Not known</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>sudden hearing
  loss</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>Vascular disorders</b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Very common</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>flushing</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Not Known</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>hypotension</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>Respiratory, thoracic and mediastinal disorders</b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Common</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=FR>epistaxis,
  cough, nasal congestion </span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b>Gastrointestinal
  disorders</b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Very common</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>diarrhoea,
  dyspepsia </span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Common</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>gastritis,
  gastrooesophageal reflux disease, haemorrhoids, abdominal distension, dry
  mouth</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>Skin and subcutaneous tissue disorders</b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Common</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  lang=EN-GB>alopecia, erythema, night sweats</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Not known</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><i><span
  lang=EN-GB>rash</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>Musculoskeletal and connective tissue disorders</b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Very common</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'>pain in
  extremity</p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Common</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'>myalgia,
  back pain </p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b>Renal and urinary
  disorders</b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>haematuria</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>Reproductive system and breast disorders </b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Uncommon</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>penile haemorrhage, haematospermia, </span>gynaecomastia</p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Not known</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><i>priapism,
  erection increased</i></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b>General disorders and
  administration site conditions</b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Common</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'>pyrexia</p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span style='font-size:8.0pt'>*These
adverse events/reactions have been reported in patients taking sildenafil for the
treatment of male erectile dysfunction (MED). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'><u><span
lang=EN-GB>Paediatric population</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>In the placebo-controlled study of Revatio in patients 1 to 17&nbsp;years
of age with pulmonary arterial hypertension, a total of 174&nbsp;patients were
treated three times a day with either<i> </i>low (10&nbsp;mg in patients &gt;&nbsp;20&nbsp;kg;
no patients &#8804;&nbsp;20&nbsp;kg received the low dose), medium (10&nbsp;mg
in patients&nbsp;&#8805;&nbsp;8-20&nbsp;kg;&nbsp;20&nbsp;mg in patients&nbsp;&#8805;&nbsp;20-45&nbsp;kg;
40&nbsp;mg in patients&nbsp;&gt;&nbsp;45&nbsp;kg) or high dose (20&nbsp;mg in
patients&nbsp;&#8805;&nbsp;8-20&nbsp;kg; 40&nbsp;mg in patients&nbsp;&#8805;&nbsp;20-45&nbsp;kg;
80&nbsp;mg in patients&nbsp;&gt;&nbsp;45&nbsp;kg) regimens of Revatio and 60
were treated with placebo.<i>&nbsp; </i></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The adverse
reactions profile seen in this paediatric study was generally consistent with
that in adults (see table above). The most common adverse reactions that
occurred (with a frequency &#8805;&nbsp;1&nbsp;%) in Revatio patients (combined
doses) and with a frequency&nbsp;&gt; 1&nbsp;%&nbsp;over placebo patients were </span><span
lang=EN-GB>pyrexia, upper respiratory tract infection (each 11.5%), vomiting
(10.9%), erection increased (including spontaneous penile erections in male
subjects) (9.0%), nausea, bronchitis (each 4.6%), pharyngitis (4.0%),
rhinorrhoea (3.4%), and pneumonia, rhinitis (each 2.9%).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Of the 234
paediatric subjects treated in the short-term, placebo-controlled study, 220
subjects entered the long-term extension study. Subjects on active sildenafil
therapy continued on the same treatment regimen, while those in the placebo
group in the short-term study were randomly reassigned to sildenafil treatment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The most common
adverse reactions reported across the duration of the short-term and long-term
studies were generally similar to those observed in the short-term study.
Adverse reactions reported in &gt;10% of 229 subjects treated with sildenafil
(combined dose group, including 9 patients that did not continue into the
long-term study) were upper respiratory infection (31%), headache (26%),
vomiting (22%), bronchitis (20%), pharyngitis (18%), pyrexia (17%), diarrhoea
(15%), and influenza, epistaxis (12% each). Most of these adverse reactions
were considered mild to moderate in severity.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>Serious adverse events were
reported in 94 (41%) of the 229 subjects receiving sildenafil. Of the 94 subjects
reporting a serious adverse event, 14/55 (25.5%) subjects were in the low dose
group, 35/74 (47.3%) in the medium dose group, and 45/100 (45%) in the high
dose group.&nbsp;The most common serious adverse events that occurred with a
frequency &#8805;&nbsp;1&nbsp;% in sildenafil patients (combined doses) were
pneumonia (7.4%), cardiac failure, pulmonary hypertension (each 5.2%), upper
respiratory tract infection (3.1%), right ventricular failure, gastroenteritis
(each 2.6%), syncope, bronchitis, bronchopneumonia, pulmonary arterial
hypertension (each 2.2%), chest pain, dental caries (each 1.7%), and cardiogenic
shock, gastroenteritis viral, urinary tract infection (each 1.3%).</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The following
serious adverse events were considered to be treatment related, enterocolitis,
convulsion, hypersensitivity, stridor, hypoxia, neurosensory deafness and
ventricular arrhythmia.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB>Reporting of suspected adverse reactions</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Reporting
suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the
medicinal product. Healthcare professionals are asked to report any suspected
adverse reactions via <span style='background:silver'>the national reporting
system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix
V</a></span>.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.9&nbsp;&nbsp;&nbsp;&nbsp; Overdose</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>In single dose volunteer studies of doses up to 800&nbsp;mg, adverse
reactions were similar to those seen at lower doses, but the incidence rates
and severities were increased. At single doses of 200&nbsp;mg the incidence of
adverse reactions (headache, flushing, dizziness, dyspepsia, nasal congestion,
and altered vision) was increased.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In cases of
overdose, standard supportive measures should be adopted as required. Renal
dialysis is not expected to accelerate clearance as sildenafil is highly bound
to plasma proteins and not eliminated in the urine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACOLOGICAL
PROPERTIES</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.1 &nbsp;&nbsp;&nbsp; Pharmacodynamic properties</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pharmacotherapeutic
group: Urologicals, Drugs used in erectile dysfunction, ATC code: G04BE03</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Mechanism of
action</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sildenafil is a
potent and selective inhibitor of cyclic guanosine monophosphate (cGMP)
specific phosphodiesterase type 5 (PDE5), the enzyme that is responsible for
degradation of cGMP. Apart from the presence of this enzyme in the corpus
cavernosum of the penis, PDE5 is also present in the pulmonary vasculature<i>. </i>Sildenafil,
therefore, increases cGMP within pulmonary vascular smooth muscle cells
resulting in relaxation. In patients with pulmonary arterial hypertension this
can lead to vasodilation of the pulmonary vascular bed and, to a lesser degree,
vasodilatation in the systemic circulation.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Pharmacodynamic
effects</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Studies <i>in
vitro</i> have shown that sildenafil is selective for PDE5. Its effect is more
potent on PDE5 than on other known phosphodiesterases. There is a 10-fold
selectivity over PDE6 which is involved in the phototransduction pathway in the
retina. There is an 80&#8209;fold selectivity over PDE1, and over 700&#8209;fold
over PDE 2, 3, 4, 7, 8, 9, 10 and 11. In particular, sildenafil has greater
than 4,000&#8209;fold selectivity for PDE5 over PDE3, the cAMP-specific phosphodiesterase
isoform involved in the control of cardiac contractility.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sildenafil
causes mild and transient decreases in systemic blood pressure which, in the
majority of cases, do not translate into clinical effects. After chronic dosing
of 80&nbsp;mg three times a day to patients with systemic hypertension the mean
change from baseline in systolic and diastolic blood pressure was a decrease of
9.4&nbsp;mmHg and 9.1&nbsp;mm Hg respectively. After chronic dosing of
80&nbsp;mg three times a day to patients with pulmonary arterial hypertension
lesser effects in blood pressure reduction were observed (a reduction in both
systolic and diastolic pressure of 2&nbsp;mmHg). </span>At the recommended dose
of 20&nbsp;mg three times a day no reductions in systolic or diastolic pressure
were seen.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Single oral
doses of sildenafil up to 100&nbsp;mg in healthy volunteers produced no
clinically relevant effects on ECG. After chronic dosing of 80&nbsp;mg three
times a day to patients with pulmonary arterial hypertension no clinically
relevant effects on the ECG were reported.</span></p>

<p class=MsoBodyTextIndent style='margin-left:0in'><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In a study of
the hemodynamic effects of a single oral 100&nbsp;mg dose of sildenafil in 14
patients with severe coronary artery disease (CAD) (&gt;&nbsp;70&nbsp;%
stenosis of at least one coronary artery), the mean resting systolic and
diastolic blood pressures decreased by 7&nbsp;% and 6&nbsp;% respectively
compared to baseline. Mean pulmonary systolic blood pressure decreased by 9&nbsp;%.
Sildenafil showed no effect on cardiac output, and did not impair blood flow
through the stenosed coronary arteries.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Mild and
transient differences in colour discrimination (blue/green) were detected in
some subjects using the Farnsworth-Munsell 100 hue test at 1&nbsp;hour
following a 100&nbsp;mg dose, with no effects evident after 2&nbsp;hours
post-dose. The postulated mechanism for this change in colour discrimination is
related to inhibition of PDE6, which is involved in the phototransduction
cascade of the retina. Sildenafil has no effect on visual acuity or contrast
sensitivity. In a small size placebo-controlled study of patients with
documented early age-related macular degeneration (n&nbsp;=&nbsp;9), sildenafil
(single dose, 100&nbsp;mg) demonstrated no significant changes in visual tests
conducted (visual acuity, Amsler grid, colour discrimination simulated traffic
light, Humphrey perimeter and photostress).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Clinical efficacy and safety</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Efficacy in adult patients with pulmonary arterial hypertension
(PAH)</span></u></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>A randomised,
double&#8209;blind, placebo&#8209;controlled study was conducted in 278&nbsp;patients
with primary pulmonary hypertension, PAH associated with connective tissue
disease, and PAH following surgical repair of congenital heart lesions.
Patients were randomised to one of four treatment groups: placebo, sildenafil
20&nbsp;mg, sildenafil 40&nbsp;mg or sildenafil 80&nbsp;mg, three times a day.
Of the 278&nbsp;patients randomised, 277&nbsp;patients received at least 1 dose
of study drug. The study population consisted of 68&nbsp;(25&nbsp;%) men and
209&nbsp;(75&nbsp;%) women with a mean age of 49&nbsp;years (range: 18-81&nbsp;years)
and baseline 6&#8209;minute walk test distance between 100 and 450&nbsp;metres
inclusive (mean: 344&nbsp;metres). </span>175&nbsp;patients (63&nbsp;%)
included were diagnosed with primary pulmonary hypertension, 84 (30&nbsp;%)
were diagnosed with <span lang=EN-GB>PAH </span>associated with connective
tissue disease and 18 (7&nbsp;%) of the patients were diagnosed with <span
lang=EN-GB>PAH </span>following surgical repair of congenital heart lesions.
Most patients were WHO Functional Class II (107/277, 39&nbsp;%) or III
(160/277, 58&nbsp;%) with a mean baseline 6 minute walking distance of 378&nbsp;meters
and 326&nbsp;meters respectively; fewer patients were Class I (1/277, 0.4&nbsp;%)
or IV (9/277, 3&nbsp;%) at baseline.<span lang=EN-GB> Patients with left
ventricular ejection fraction &lt;&nbsp;45&nbsp;% or left ventricular
shortening fraction &lt;&nbsp;0.2 were not studied.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sildenafil (or
placebo) was added to patients&#8217; background therapy which could have
included a combination of anticoagulation, digoxin, calcium channel blockers,
diuretics or oxygen. The use of prostacyclin, prostacyclin analogues and
endothelin receptor antagonists was not permitted as add-on therapy, and
neither was arginine supplementation. Patients who previously failed bosentan
therapy were excluded from the study.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The primary
efficacy endpoint was the change from baseline at week 12 in 6-minute walk
distance </span><span lang=EN-GB>(6MWD)</span><span lang=EN-GB>. A
statistically significant increase in </span><span lang=EN-GB>6MWD</span><span
lang=EN-GB> was observed in all 3&nbsp;sildenafil dose groups compared to those
on placebo. Placebo corrected increases in </span><span lang=EN-GB>6MWD</span><span
lang=EN-GB> were 45&nbsp;metres (p&nbsp;&lt;&nbsp;0.0001), 46&nbsp;metres
(p&nbsp;&lt;&nbsp;0.0001) and 50&nbsp;metres (p&nbsp;&lt;&nbsp;0.0001) for
sildenafil 20&nbsp;mg, 40&nbsp;mg and 80&nbsp;mg TID respectively. There was no
significant difference in effect between sildenafil doses. </span><span
lang=EN-GB>For patients with a baseline 6MWD &lt;&nbsp;325&nbsp;m improved
efficacy was observed with higher doses (</span><span lang=EN-GB>placebo-corrected
improvements of 58&nbsp;metres, 65&nbsp;metres and 87&nbsp;metres for 20&nbsp;mg,
40&nbsp;mg and 80&nbsp;mg doses TID, respectively).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>When analysed by
WHO functional class, a statistically </span><span lang=EN-GB>significant
increase in 6MWD was observed in the 20&nbsp;mg dose group. For class II and
class III, placebo corrected increases of 49&nbsp;metres (p&nbsp;=&nbsp;0.0007)
and 45&nbsp;metres (p&nbsp;=&nbsp;0.0031) were observed respectively.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The improvement
in </span><span lang=EN-GB>6MWD</span><span lang=EN-GB> was apparent after 4&nbsp;weeks
of treatment and this effect was maintained at weeks 8 and 12. </span><span
lang=EN-GB>Results were generally consistent in subgroups according to
aetiology (primary and connective tissue disease-associated PAH), WHO
functional class, gender, race, location, mean PAP and PVRI.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Patients on all sildenafil doses achieved a statistically
significant reduction in mean pulmonary arterial pressure (mPAP) </span><span
lang=EN-GB>and pulmonary vascular resistance (PVR) </span><span lang=EN-GB>compared
to those on placebo. Placebo-corrected treatment effects </span><span
lang=EN-GB>with mPAP were</span><span lang=EN-GB>&nbsp;&#8211;2.7&nbsp;mmHg
(p&nbsp;=&nbsp;0.04), </span><span lang=EN-GB>&#8209;3.0&nbsp;mm Hg
(p&nbsp;=&nbsp;0.01) and &#8209;5.1&nbsp;mm Hg (p&nbsp;&lt;&nbsp;0.0001) </span><span
lang=EN-GB>for sildenafil 20&nbsp;mg, </span><span lang=EN-GB>40&nbsp;mg and
80&nbsp;mg</span><span lang=EN-GB> TID respectively. </span><span lang=EN-GB>Placebo&#8209;corrected
treatment effects with PVR were &#8209;178&nbsp;dyne.sec/cm<sup>5</sup>
(p=0.0051), &#8209;195&nbsp;dyne.sec/cm<sup>5</sup> (p=0.0017) and &#8209;320&nbsp;dyne.sec/cm<sup>5&nbsp;</sup>(p<a
name="OLE_LINK1">&lt;0.0001</a>) for sildenafil 20&nbsp;mg, 40&nbsp;mg and
80&nbsp;mg TID, respectively.</span><span lang=EN-GB> The percent reduction at 12&nbsp;weeks
for sildenafil 20&nbsp;mg, 40&nbsp;mg and 80&nbsp;mg TID in PVR (11.2&nbsp;%,
12.9&nbsp;%, 23.3&nbsp;%) was proportionally greater than the reduction in
systemic vascular resistance (SVR) (7.2&nbsp;%, 5.9&nbsp;%, 14.4&nbsp;%). </span><span
lang=EN-GB>The effect of sildenafil on mortality is unknown.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>A greater percentage of patients on each of the sildenafil doses
(i.e. 28&nbsp;%, 36&nbsp;% and 42&nbsp;% of subjects who received sildenafil
20&nbsp;mg, 40&nbsp;mg and 80&nbsp;mg TID doses, respectively) showed an improvement
by at least one WHO functional class at week 12 compared to placebo (7&nbsp;%).
The respective odds ratios were 2.92&nbsp;(p=0.0087), 4.32&nbsp;</span><span
lang=EN-GB>(p=0.0004) and 5.75&nbsp;(p&lt;0.0001)</span><span
class=MsoCommentReference><span lang=EN-GB style='font-size:8.0pt'>.</span></span></p>

<p class=MsoNormal><i><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB>Long-term
survival data in naive population</span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Patients
enrolled into the pivotal study were eligible to enter a long term open label
extension study. </span><span lang=EN-GB>At 3&nbsp;years 87&nbsp;% of the
patients were receiving a dose of 80&nbsp;mg TID. </span><span lang=EN-GB>A
total of 207&nbsp;patients were</span><span lang=EN-GB> treated with Revatio in
the pivotal study, and their long term survival status was assessed for a minimum
of 3&nbsp;years. In this population, Kaplan-Meier estimates of 1, 2 and 3&nbsp;year
survival were 96&nbsp;%, 91&nbsp;% and 82&nbsp;%, respectively. Survival in
patients of WHO functional class II at baseline at 1,&nbsp;2&nbsp;and 3&nbsp;years
was 99&nbsp;%, 91&nbsp;%, and 84&nbsp;% respectively, and for patients of</span>
WHO functional class III at baseline was <span lang=EN-GB>94&nbsp;%, 90&nbsp;%,
and 81&nbsp;%, respectively.</span></p>

<p class=MsoNormal><i><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal><i><u><span lang=EN-GB>Efficacy in adult patients with PAH
(when used in combination with epoprostenol)</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB>A randomised, double-blind, placebo
controlled study was conducted in 267&nbsp;patients with PAH who were
stabilised on intravenous epoprostenol. The PAH patients included those with
Primary Pulmonary Arterial Hypertension (212/267, 79&nbsp;%) and PAH associated
with connective tissue disease (55/267, 21&nbsp;%).<b> </b>Most patients were
WHO Functional Class II (68/267, 26&nbsp;%) or III (175/267, 66&nbsp;%); fewer
patients were Class I (3/267, 1&nbsp;%) or IV (16/267, 6&nbsp;%) at baseline;
for a few patients (5/267, 2&nbsp;%), the WHO Functional Class was unknown.
Patients were randomised to placebo or sildenafil (in a fixed titration
starting from 20&nbsp;mg, to 40&nbsp;mg and then 80&nbsp;mg, three times a day
as tolerated) when used in combination with intravenous epoprostenol.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in'><span style='font-size:11.0pt'>The
primary efficacy endpoint was the change from baseline at week 16 in 6-minute
walk distance. There was a statistically significant benefit of sildenafil
compared to placebo in 6-minute walk distance. A mean placebo corrected
increase in walk distance of 26&nbsp;metres was observed in favour of
sildenafil (95&nbsp;% CI: 10.8, 41.2) (p&nbsp;=&nbsp;0.0009). </span><span
lang=EN-GB style='font-size:11.0pt'>For patients with a baseline walking
distance &#8805;&nbsp;325&nbsp;metres, the treatment effect was 38.4&nbsp;metres
in favour of sildenafil; for patients with a baseline walking distance
&lt;&nbsp;325&nbsp;metres, the treatment effect was 2.3&nbsp;metres in favour
of placebo. For patients with primary PAH, the treatment effect was 31.1&nbsp;metres
compared to 7.7&nbsp;metres for patients with PAH associated with</span><span
style='font-size:11.0pt'> connective tissue disease</span><span lang=EN-GB
style='font-size:11.0pt'>. The difference in results between these
randomisation subgroups may have arisen by chance in view of their limited
sample size.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Patients on sildenafil achieved a
statistically significant reduction in mean Pulmonary Arterial Pressure (mPAP)
compared to those on placebo. A mean placebo-corrected treatment effect of &#8209;3.9&nbsp;mmHg
was observed in favour of sildenafil (95&nbsp;% CI: &#8209;5.7, &#8209;2.1)
(p&nbsp;=&nbsp;0.00003). <strong><span style='font-weight:normal'>Time to
clinical worsening was a secondary endpoint as defined as the time from
randomisation to the first occurrence of a clinical worsening event (death,
lung transplantation, initiation of bosentan therapy, or clinical deterioration
requiring a change in epoprostenol therapy). Treatment with sildenafil
significantly delayed the time to clinical worsening of PAH compared to placebo
(p&nbsp;=&nbsp;0.0074). 23&nbsp;subjects experienced clinical worsening events
in the placebo group (17.6&nbsp;%) compared with 8&nbsp;subjects in the sildenafil
group (6.0&nbsp;%).</span></strong></span></p>

<p class=MsoNormal><strong><span lang=EN-GB style='font-weight:normal'>&nbsp;</span></strong></p>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'><u><span
lang=EN-GB>Long-term Survival Data in the background epoprostenol study</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Patients
enrolled into the epoprostenol add-on therapy study were eligible to enter a
long term open label extension study. </span><span lang=EN-GB>At 3&nbsp;years
68&nbsp;% of the patients were receiving a dose of 80&nbsp;mg TID.</span><span
lang=EN-GB> A total of 134&nbsp;patients were</span><span lang=EN-GB> treated
with Revatio in the initial study, and their long term survival status was
assessed for a minimum of 3&nbsp;years. In this population, Kaplan-Meier
estimates of 1, 2 and 3&nbsp;year survival were 92&nbsp;%, 81&nbsp;% and 74&nbsp;%,
respectively.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Efficacy and safety in adult patients
with PAH (when used in combination with bosentan)</span></u></p>

<p class=MsoNormal><span lang=EN-GB>A randomized, double-blind, placebo
controlled study was conducted in 103 clinically stable subjects with PAH (WHO
FC II and III) who were on bosentan therapy for a minimum of three months. The
PAH patients included those with primary PAH, and PAH associated with</span><span
lang=EN-GB> connective tissue disease</span><span lang=EN-GB>. Patients were
randomized to placebo or sildenafil (20 mg</span> three times a day<span
lang=EN-GB>) in combination with bosentan (62.5&#8209;125&nbsp;mg</span> twice
a day<span lang=EN-GB>). The primary efficacy endpoint was the change from
baseline at Week 12 in 6</span>MWD<span lang=EN-GB>. The results indicate that
there is no significant difference in mean change from baseline on 6MWD
observed between sildenafil (20 mg three times a day) and placebo (</span>13.62&nbsp;m
(95% CI: -3.89 to 31.12) and 14.08&nbsp;m (95% CI: -1.78 to 29.95),
respectively<span lang=EN-GB>).</span></p>

<p class=MsoNormal><span style='background:yellow'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Differences in 6MWD were observed between
patients with primary PAH and PAH associated with </span><span lang=EN-GB>connective
tissue disease</span><span lang=EN-GB>. For subjects with primary PAH (67 subjects),
mean changes from baseline were 26.39 m (95% CI: 10.70 to 42.08) and 11.84 m (95%
CI: -8.83 to 32.52) for the sildenafil and placebo groups, respectively.
However, for subjects with PAH associated with </span><span lang=EN-GB>connective
tissue disease</span><span lang=EN-GB> (36 subjects) mean changes from baseline
were -18.32 m (95% CI: -65.66 to 29.02) and 17.50&nbsp;m (95% CI: -9.41 to
44.41) for the sildenafil and placebo groups, respectively.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Overall, the
adverse events were generally similar between the two treatment groups
(sildenafil plus bosentan vs. bosentan alone), and consistent with the known
safety profile of sildenafil when used as monotherapy (see sections 4.4 and
4.5).</span></p>

<p class=MsoNormal><strong><span lang=EN-GB style='font-weight:normal'>&nbsp;</span></strong></p>

<p class=MsoNormal style='text-align:justify'><u><span lang=EN-GB>Paediatric population</span></u></p>

<p class=MsoNormal style='text-align:justify'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='text-align:justify'><i><span lang=EN-GB>Pulmonary
arterial hypertension</span></i></p>

<p class=MsoNormal style='text-align:justify'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>A total of 234&nbsp;subjects aged 1&nbsp;to
17&nbsp;years were treated in a randomized, double-blind, multi-centre, placebo
controlled parallel group, dose ranging study. Subjects (38&nbsp;% male and 62&nbsp;%
female) had a body weight </span><span lang=EN-GB style='font-family:Symbol'>&sup3;</span><span
lang=EN-GB>&nbsp;8&nbsp;kg, and had primary pulmonary hypertension (PPH) [33&nbsp;%],
or PAH secondary to congenital heart disease [systemic&#8209;to&#8209;pulmonary
shunt 37&nbsp;%, surgical repair 30&nbsp;%]. In this trial, 63</span><span
lang=EN-GB> of 234 (27&nbsp;%) patients were &lt; 7&nbsp;years old (sildenafil
low dose = 2; medium dose = 17; high dose = 28; placebo = 16) and 171 of 234 (73&nbsp;%)
patients were 7&nbsp;years or older (sildenafil low dose = 40; medium dose =
38; and high dose = 49; placebo = 44). </span>Most<span lang=EN-GB> subjects
were WHO Functional Class I (</span>75/234,&nbsp;32&nbsp;<span lang=EN-GB>%) or
II (120/234, 51&nbsp;%) at baseline; fewer patients were Class III (35/234, 15&nbsp;%)
or IV (1/234, 0.4&nbsp;%); for a few patients (3/234, 1.3&nbsp;%), the WHO
Functional Class was unknown.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Patients were na&iuml;ve for specific PAH
therapy and the use of prostacyclin, prostacyclin analogues and endothelin
receptor antagonists was not permitted in the study, and neither was arginine
supplementation, nitrates, alpha-blockers and potent CYP450 3A4 inhibitors.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The primary objective of the study was to
assess the efficacy of 16&nbsp;weeks of chronic treatment with oral sildenafil
in paediatric subjects to improve exercise capacity as measured by the
Cardiopulmonary Exercise Test (CPET) in subjects who were developmentally able
to perform the test, n&nbsp;=&nbsp;115). Secondary endpoints included
haemodynamic monitoring, symptom assessment, WHO functional class, change in
background treatment, and quality of life measurements.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Subjects were allocated to one of three
sildenafil treatment groups, </span><span lang=EN-GB>low (10&nbsp;mg), medium
(10-40&nbsp;mg) or high dose (20-80&nbsp;mg) regimens of Revatio given three
times a day, </span><span lang=EN-GB>or placebo. Actual doses administered within
a group were dependent on body weight (see Section 4.8). </span><span
lang=EN-GB style='color:black'>The proportion of subjects receiving supportive medicinal
products at baseline (</span><span lang=EN-GB>anticoagulants, digoxin, calcium
channel blockers, diuretics and/or oxygen) <span style='color:black'>was
similar in the combined sildenafil treatment group (47.7&nbsp;%) and the
placebo treatment group (41.7&nbsp;%).</span></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The primary endpoint was the
placebo-corrected percentage change in peak VO<sub>2</sub> from baseline to
week 16 assessed by CPET testing in the combined dose groups (Table 2). A total
of 106 out of 234 (45&nbsp;%) subjects were evaluable for CPET, which comprised
those children &#8805;&nbsp;7&nbsp;years old and developmentally able to
perform the test. Children &lt;&nbsp;7&nbsp;years (sildenafil combined dose =
47; placebo = 16) were evaluable only for the secondary endpoints. Mean
baseline peak volume of oxygen consumed (VO<sub>2</sub>) values were comparable
across the sildenafil treatment groups (17.37&nbsp;to 18.03&nbsp;ml/kg/min),
and slightly higher for the placebo treatment group (20.02&nbsp;ml/kg/min). The
results of the main analysis (combined dose groups versus placebo) were not
statistically significant (p&nbsp;=&nbsp;0.056) (see Table 2). The estimated
difference between the medium sildenafil dose and placebo was 11.33&nbsp;% (95&nbsp;%
CI: 1.72 to 20.94) (see Table 2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Table 2:
Placebo Corrected % Change from Baseline in Peak VO<sub>2</sub> by Active
Treatment Group</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:8.5pt;border-collapse:collapse'>
 <tr>
  <td width=177 valign=top style='width:132.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Treatment group</span></b></p>
  </td>
  <td width=150 valign=top style='width:112.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><b><span lang=EN-GB>Estimated difference</span></b></p>
  </td>
  <td width=184 valign=top style='width:138.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><b><span lang=EN-GB>95% confidence interval</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=177 valign=top style='width:132.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Low dose</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>(n=24)</span></b></p>
  </td>
  <td width=150 valign=top style='width:112.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>3.81</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=184 valign=top style='width:138.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>-6.11, 13.73</span></p>
  </td>
 </tr>
 <tr>
  <td width=177 valign=top style='width:132.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Medium dose</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>(n=26)</span></b></p>
  </td>
  <td width=150 valign=top style='width:112.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>11.33</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=184 valign=top style='width:138.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>1.72, 20.94</span></p>
  </td>
 </tr>
 <tr>
  <td width=177 valign=top style='width:132.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>High dose</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>(n=27)</span></b></p>
  </td>
  <td width=150 valign=top style='width:112.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>7.98</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=184 valign=top style='width:138.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>-1.64, 17.60</span></p>
  </td>
 </tr>
 <tr>
  <td width=177 valign=top style='width:132.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Combined dose
  groups (n=77)</span></b></p>
  </td>
  <td width=150 valign=top style='width:112.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>7.71</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>(p = 0.056)</span></p>
  </td>
  <td width=184 valign=top style='width:138.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>-0.19, 15.60</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><i><span lang=EN-GB>n=29 for placebo group</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>Estimates based on ANCOVA with
adjustments for the covariates baseline peak VO<sub>2</sub>, etiology and
weight group</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Dose related improvements were observed
with pulmonary vascular resistance index (PVRI) and mean pulmonary arterial
pressure (mPAP). </span><span lang=EN-GB>The sildenafil medium and high dose
groups both showed PVRI reductions compared to placebo, of 18&nbsp;% (95&nbsp;%
CI: 2&nbsp;% to<span style='color:black;background:white'> 32&nbsp;%) and 27&nbsp;%
(95&nbsp;% CI: 14&nbsp;% to 39&nbsp;%), respectively; whilst the low dose group
showed </span>no significant difference from placebo (difference of 2&nbsp;%).
The sildenafil medium and high dose groups displayed mPAP changes from baseline
compared to placebo, of &#8209;3.5&nbsp;mmHg (95&nbsp;% CI: &#8209;8.9, 1.9)
and &#8209;7.3&nbsp;mmHg (95&nbsp;%&nbsp;CI:&nbsp;&#8209;12.4,&nbsp;&#8209;2.1),
respectively; whilst the low dose group showed little difference from placebo
(difference of 1.6&nbsp;mmHg). Improvements were observed with cardiac index
with all three sildenafil groups over placebo, 10&nbsp;%, 4&nbsp;% and 15&nbsp;%
for the low, medium and high dose groups respectively.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Significant improvements
in functional class were demonstrated only in subjects on sildenafil high dose compared
to placebo. Odds ratios for the sildenafil low, medium and high dose groups
compared to placebo were 0.6 (95&nbsp;% CI: 0.18, 2.01), 2.25 (95&nbsp;% CI:
0.75, 6.69) and 4.52 (95&nbsp;% CI: 1.56, 13.10), respectively.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB>Long term extension data</span></u></p>

<p class=MsoPlainText style='page-break-after:avoid'><span lang=X-NONE
style='font-size:11.0pt'>Of the 234 paediatric subjects treated in the
short-term, placebo-controlled study, 220 subjects entered the long-term
extension study. Subjects who had been in the placebo group in the short-term
study were randomly reassigned to sildenafil treatment; subjects weighing </span><span
lang=X-NONE style='font-size:11.0pt'>&#8804; 20&nbsp;kg entered the medium or
high dose groups (1:1), while subjects weighing &gt; 20&nbsp;kg entered the
low, medium or high dose groups (1:1:1). Of the total 229 subjects who received
sildenafil, there were 55, 74, and 100 subjects in the low, medium and high
dose groups, respectively. </span><span lang=X-NONE style='font-size:11.0pt'>Across
the short-term and long-term studies, the overall duration of treatment from
start of double-blind for individual subjects ranged from 3</span><span
style='font-size:11.0pt'>&nbsp;</span><span lang=X-NONE style='font-size:11.0pt'>to</span><span
style='font-size:11.0pt'>&nbsp;</span><span lang=X-NONE style='font-size:11.0pt'>3129</span><span
style='font-size:11.0pt'>&nbsp;</span><span lang=X-NONE style='font-size:11.0pt'>days.
By sildenafil treatment group, median duration of sildenafil treatment was 1696
days (excluding the 5 subjects who received placebo in double-blind and were
not treated in the long-term extension study).</span></p>

<p class=MsoPlainText><span lang=X-NONE>&nbsp;</span></p>

<p class=MsoPlainText><span lang=X-NONE style='font-size:11.0pt'>Kaplan-Meier
estimates of survival at 3&nbsp;years in patients &gt; 20&nbsp;kg in weight at
baseline were 94&nbsp;%, 93&nbsp;% and 85&nbsp;% in the low, medium and high
dose groups, respectively; for patients &#8804; 20&nbsp;kg in weight at
baseline, the survival estimates were 94&nbsp;% and 93&nbsp;% for subjects in
the medium and high dose groups respectively (see sections 4.4 and 4.8).</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>During the
conduct of the study, there were a total of 42 deaths reported, whether on
treatment or reported as part of the survival follow-up. 37 deaths occurred
prior to a decision taken by the Data Monitoring Committee to down titrate
subjects to a lower dosage, based on an observed mortality imbalance with
increasing sildenafil doses.</span><span lang=EN-GB> Among these 37 deaths, </span><span
lang=EN-GB>the number (%) of deaths was 5/55 (9.1%), 10/74 (13.5%), and 22/100
(22%) in the sildenafil low, medium, and high dose groups, respectively. An
additional 5 deaths were reported subsequently.The causes of deaths were
related to PAH. </span><span lang=EN-GB>Higher than recommended doses should
not be used in paediatric patients with PAH (see sections 4.2 and 4.4).</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Peak VO<sub>2</sub> was assessed 1 year after the start of
the placebo-controlled study. Of those sildenafil treated subjects developmentally
able to perform the CPET 59/114 subjects (52&nbsp;%) had not shown any
deterioration in Peak VO<sub>2</sub> from start of sildenafil. Similarly 191 of
229 subjects (83&nbsp;%) <span lang=EN-GB style='color:black;background:white'>who
had received</span><span lang=EN-GB> <span style='color:black;background:white'>sildenafil
</span></span>had either maintained or improved their WHO Functional Class at 1
year assessment.</p>

<p class=MsoNormal style='text-autospace:none'><i><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal><i><span lang=EN-GB>Persistent pulmonary hypertension of the
newborn</span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>A randomized, double-blind, two-arm,
parallel-group, placebo-controlled study was conducted in 59&nbsp;neonates with
persistent pulmonary hypertension of the newborn (PPHN), or hypoxic respiratory
failure (HRF) and at risk for PPHN with oxygenation index (OI) &gt;15 and
&lt;60. The primary objective was to evaluate the efficacy and safety of IV
sildenafil when added to inhaled nitric oxide (iNO) compared with iNO alone.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The co-primary endpoints were treatment
failure rate, defined as need for additional treatment targeting PPHN, need for
</span><span lang=EN-GB>extracorporeal membrane oxygenation (</span><span
lang=EN-GB>ECMO), or death during the study; and time on iNO treatment after
initiation of IV study drug for patients without treatment failure. The
difference in </span><span lang=EN-GB>treatment failure rates was not
statistically significant between the two treatment groups (27.6% and 20.0% in
the iNO + IV sildenafil group and iNO + placebo group, respectively). For
patients without treatment failure, the mean time on iNO treatment </span><span
lang=EN-GB>after initiation of IV study drug </span><span lang=EN-GB>was the
same, approximately 4.1&nbsp;days, for the two&nbsp;treatment groups.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Treatment-emergent adverse events and
serious adverse events were reported in 22&nbsp;(75.9%) and 7&nbsp;(24.1%)
subjects in the iNO + IV sildenafil treatment group, respectively, and in 19
(63.3%) and 2&nbsp;(6.7%) subjects in the iNO + placebo group, respectively.
The most commonly reported treatment&#8209;emergent adverse events were
hypotension (8 [27.6%] subjects), hypokalaemia (7 [24.1%] subjects), anaemia
and drug withdrawal syndrome (4 [13.8%] subjects each) and bradycardia (3&nbsp;[10.3%]
subjects) in the iNO + IV sildenafil treatment group and pneumothorax (4
[13.3%] subjects), anaemia, oedema, hyperbilirubinaemia, C-reactive protein
increased, and hypotension (3&nbsp;[10.0%] subjects each) in the iNO + placebo
treatment group (see section 4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=NormalBold><span style='font-size:11.0pt'>5.2&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt'>Pharmacokinetic properties</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span class=SmPCsubheading><u><span
lang=EN-GB style='font-weight:normal'>Absorption</span></u></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sildenafil is
rapidly absorbed. Maximum observed plasma concentrations are reached within 30
to 120&nbsp;minutes (median 60&nbsp;minutes) of oral dosing in the fasted
state. The mean absolute oral bioavailability is 41&nbsp;% (range 25&#8209;63&nbsp;%).
After oral three times a day dosing of sildenafil, AUC and C<sub>max</sub>
increase in proportion with dose over the dose range of 20-40&nbsp;mg. After
oral doses of 80&nbsp;mg three times a day a more than dose proportional
increase in sildenafil plasma levels has been observed. In pulmonary arterial
hypertension patients, the oral bioavailability of sildenafil after 80&nbsp;mg
three times a day was on average 43&nbsp;% (90&nbsp;% CI: 27&nbsp;% - 60&nbsp;%)
higher compared to the lower doses. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>When sildenafil
is taken with food, the rate of absorption is reduced with a mean delay in T<sub>max</sub>
of 60&nbsp;minutes and a mean reduction in C<sub>max </sub>of 29&nbsp;% however,
the extent of absorption was not significantly affected (AUC decreased by 11&nbsp;%).</span></p>

<p class=MsoNormal style='line-height:normal'><span class=SmPCsubheading><span
lang=EN-GB>&nbsp;</span></span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
class=SmPCsubheading><u><span lang=EN-GB style='font-weight:normal'>Distribution</span></u></span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The mean steady state volume of distribution (Vss) for sildenafil is
105&nbsp;l, indicating distribution into the tissues. After oral doses of
20&nbsp;mg three times a day, the mean maximum total plasma concentration of
sildenafil at steady state is approximately 113&nbsp;ng/ml. Sildenafil and its
major circulating N-desmethyl metabolite are approximately 96&nbsp;% bound to
plasma proteins. Protein binding is independent of total drug concentrations.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
class=SmPCsubheading><u><span lang=EN-GB style='font-weight:normal'>Biotransformation</span></u></span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Sildenafil is cleared predominantly by the CYP3A4 (major route) and
CYP2C9 (minor route) hepatic microsomal isoenzymes. The major circulating
metabolite results from N-demethylation of sildenafil. This metabolite has a
phosphodiesterase selectivity profile similar to sildenafil and an <i>in vitro</i>
potency for PDE5 approximately 50&nbsp;% that of the parent drug. The
N-desmethyl metabolite is further metabolised, with a terminal half-life of
approximately 4&nbsp;h. </span>In patients with pulmonary arterial
hypertension, plasma concentrations of <span lang=EN-GB>N-desmethyl metabolite</span>
are approximately 72&nbsp;% those of sildenafil after 20&nbsp;mg three times a
day dosing (translating into a 36&nbsp;% contribution to sildenafil&#8217;s
pharmacological effects). The subsequent effect on efficacy is unknown.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
class=SmPCsubheading><u><span lang=EN-GB style='font-weight:normal'>Elimination</span></u></span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The total body clearance of sildenafil is 41&nbsp;l/h with a
resultant terminal phase half-life of 3-5&nbsp;h. After either oral or
intravenous administration, sildenafil is excreted as metabolites predominantly
in the faeces (approximately 80&nbsp;% of administered oral dose) and to a
lesser extent in the urine (approximately 13&nbsp;% of administered oral dose).</span></p>

<p class=MsoNormal style='line-height:normal'><span class=SmPCsubheading><span
lang=EN-GB>&nbsp;</span></span></p>

<p class=MsoNormal style='page-break-after:avoid'><span class=SmPCsubheading><u><span
lang=EN-GB style='font-weight:normal'>Pharmacokinetics in special patient
groups</span></u></span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Elderly</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Healthy elderly
volunteers (65&nbsp;years or over) had a reduced clearance of sildenafil,
resulting in approximately 90&nbsp;% higher plasma concentrations of sildenafil
and the active N-desmethyl metabolite compared to those seen in healthy younger
volunteers (18-45&nbsp;years). Due to age-differences in plasma protein
binding, the corresponding increase in free sildenafil plasma concentration was
approximately 40&nbsp;%.</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Renal
insufficiency</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In volunteers
with mild to moderate renal impairment (creatinine clearance
=&nbsp;30-80&nbsp;ml/min), the pharmacokinetics of sildenafil were not altered
after receiving a 50&nbsp;mg single oral dose. In volunteers with severe renal
impairment (creatinine clearance &lt;&nbsp;30&nbsp;ml/min), sildenafil
clearance was reduced, resulting in mean increases in AUC and C<sub>max</sub>
of 100&nbsp;% and 88&nbsp;% respectively compared to age&#8209;matched
volunteers with no renal impairment. In addition, N-desmethyl metabolite AUC
and C<sub>max</sub> values were significantly increased by 200&nbsp;% and 79&nbsp;%
respectively in subjects with severe renal impairment compared to subjects with
normal renal function.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Hepatic
insufficiency</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In volunteers
with mild to moderate hepatic cirrhosis (Child-Pugh class A and B) sildenafil
clearance was reduced, resulting in increases in AUC (85&nbsp;%) and C<sub>max</sub>
(47&nbsp;%) compared to age-matched volunteers with no hepatic impairment. In
addition, N-desmethyl metabolite AUC and C<sub>max</sub> values were
significantly increased by 154&nbsp;% and 87&nbsp;%, respectively in cirrhotic
subjects compared to subjects with normal hepatic function. The
pharmacokinetics of sildenafil in patients with severely impaired hepatic
function have not been studied.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Population
pharmacokinetics</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In patients with
pulmonary arterial hypertension, the average steady state concentrations were
20&#8209;50&nbsp;% higher over the investigated dose range of
20&#8211;80&nbsp;mg three times a day compared to healthy volunteers. There was
a doubling of the C<sub>min</sub> compared to healthy volunteers. Both findings
suggest a lower clearance and/or a higher oral bioavailability of sildenafil in
patients with pulmonary arterial hypertension compared to healthy volunteers.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB>Paediatric
population</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>From the
analysis of the pharmacokinetic profile of sildenafil in patients involved in
the paediatric clinical trials, body weight was shown to be a good predictor of
drug exposure in children. Sildenafil plasma concentration half-life values
were estimated to range from 4.2 to 4.4&nbsp;hours for a range of 10&nbsp;to
70&nbsp;kg of body weight and did not show any differences that would appear as
clinically relevant. C<sub>max</sub> after a single 20&nbsp;mg sildenafil dose
administered PO was estimated at 49, 104 and 165&nbsp;ng/ml for 70, 20 and
10&nbsp;kg patients, respectively. C<sub>max</sub> after a single 10&nbsp;mg
sildenafil dose administered PO was estimated at 24, 53 and 85&nbsp;ng/ml for
70, 20 and 10&nbsp;kg patients, respectively. T<sub>max</sub> was estimated at
approximately 1&nbsp;hour and was almost independent from body weight.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.3&nbsp;&nbsp;&nbsp;&nbsp; Preclinical
safety data</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>Non-clinical data revealed no special hazard for humans
based on conventional studies of safety pharmacology, repeated dose toxicity,
genotoxicity and carcinogenic potential, toxicity to reproduction and
development.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In pups of rats which were pre- and postnatally treated with
60&nbsp;mg/kg sildenafil, a decreased litter size, a lower pup weight on day 1
and a decreased 4-day survival were seen at exposures which were approximately
fifty times the expected human exposure at 20&nbsp;mg three times a day. Effects
in non&#8209;clinical studies were observed at exposures considered
sufficiently in excess of the maximum human exposure indicating little
relevance to clinical use.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-autospace:none'><span
lang=EN-GB>There were no adverse reactions, with possible relevance to clinical
use, seen in animals at clinically relevant exposure levels which were not also
observed in clinical studies.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.5pt;text-indent:-28.5pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.1<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>List of excipients</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Tablet core:</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=FR>Microcrystalline cellulose</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>Calcium hydrogen
phosphate (anhydrous)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Croscarmellose
sodium</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Magnesium
stearate</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Film coat:</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hypromellose</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Titanium dioxide
(E171)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lactose
monohydrate</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Glycerol
triacetate</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.2&nbsp;&nbsp;&nbsp;&nbsp; Incompatibilities</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not applicable.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.3&nbsp;&nbsp;&nbsp;&nbsp; Shelf
life</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>5&nbsp;years.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>6.4&nbsp;&nbsp;&nbsp; Special precautions for storage</span></b></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not store
above 30&deg;C. Store in the original package in order to protect from
moisture.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.5&nbsp;&nbsp;&nbsp;&nbsp; Nature and contents of
container</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>PVC/Aluminium
blisters of 90&nbsp;tablets.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pack size of 90&nbsp;tablets
in a carton.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>90 x 1 tablets
in PVC/Aluminium perforated unit dose blisters.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>PVC/Aluminium
blisters of 300&nbsp;tablets.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pack size of
300&nbsp;tablets in a carton.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>Not all pack sizes may be
marketed.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.6&nbsp;&nbsp;&nbsp; 
Special precautions for disposal and other handling</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>No special requirements for disposal.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pfizer Europe MA
EEIG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Boulevard de la
Plaine 17</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1050 Bruxelles</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Belgium</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S) </span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>EU/1/05/318/001</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>EU/1/05/318/004</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>EU/1/05/318/005</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DATE
OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Date of first authorisation: 28 October 2005</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Date of latest renewal: 23 September 2010</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp; DATE
OF REVISION OF THE TEXT</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Detailed
information on this medicinal product is available on the website of the
European Medicines Agency <a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a>
</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Revatio
0.8&nbsp;mg/ml solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; QUALITATIVE
AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each ml of
solution contains 0.8&nbsp;mg of sildenafil (as citrate). Each 20&nbsp;ml vial
contains 12.5&nbsp;ml of solution (10&nbsp;mg of sildenafil, as citrate).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For the full
list of excipients, see section 6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
<span style='text-transform:uppercase'>form</span></span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Solution for injection.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Clear,
colourless solution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB style='text-transform:uppercase'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clinical
particulars</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.1&nbsp;&nbsp;&nbsp;&nbsp; Therapeutic indications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>Revatio solution for injection is
for the&nbsp;treatment of adult patients (&#8805; 18 years) with pulmonary
arterial hypertension who are currently prescribed oral Revatio and who are
temporarily unable to take oral therapy, but are otherwise clinically and
haemodynamically stable.</p>

<p class=MsoNormal style='line-height:normal'><b>&nbsp;</b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Revatio (oral)
is indicated for treatment of adult patients with pulmonary arterial
hypertension classified as WHO functional class II and III, to improve exercise
capacity. Efficacy has been shown in primary pulmonary hypertension and
pulmonary hypertension associated with connective tissue disease.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>4.2&nbsp;&nbsp;&nbsp; Posology
and method of administration</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Treatment should
only be initiated and monitored by a physician experienced in the treatment of
pulmonary arterial hypertension. In case of clinical deterioration in spite of
Revatio treatment, alternative therapies should be considered.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Revatio solution for injection should be administered to patients
already prescribed oral Revatio as a replacement for oral administration under
conditions where they are temporarily unable to take oral Revatio therapy.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Safety and effectiveness of doses higher than 12.5&nbsp;ml
(10&nbsp;mg) TID have not been established.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span class=SmPCsubheading><i><u><span
lang=EN-GB style='font-weight:normal'>Adults</span></u></i></span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The recommended dose is </span><span lang=EN-GB>10</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>mg (corresponding to 12.5&nbsp;ml)
three times a day administered as an intravenous bolus injection (see section
6.6).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>A 10&nbsp;mg dose of Revatio solution for injection is predicted to
provide exposure of sildenafil and its N&#8209;desmethyl metabolite and
pharmacological effects comparable to those of a 20&nbsp;mg oral dose.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Patients
using other medicinal products</span></u></i></p>

<p class=MsoNormal style='line-height:normal'>In general, any dose adjustment
should be administered only after a careful benefit-risk assessment. A downward
dose adjustment to 10&nbsp;mg twice daily should be considered when sildenafil
is co&#8209;administered to patients already receiving CYP3A4 inhibitors like
erythromycin or saquinavir. A downward dose adjustment to 10&nbsp;mg once daily
is recommended in case of co&#8209;administration with more potent CYP3A4
inhibitors like<span lang=EN-GB> clarithromycin, telithromycin and nefazodone</span>.
<span lang=EN-GB>For the use of sildenafil with the most potent CYP3A4
inhibitors, see section 4.3. </span>Dose adjustments for sildenafil may be
required when co-administered with CYP3A4 inducers (see section 4.5).</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
class=SmPCsubheading><u><span lang=EN-GB style='font-weight:normal'>Special
populations</span></u></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span class=SmPCsubheading><i><u><span
lang=EN-GB style='font-weight:normal'>Elderly (&#8805;&nbsp;65&nbsp;years)</span></u></i></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Dose adjustments
are not required in elderly patients. Clinical efficacy as measured by 6-minute
walk distance could be less in elderly patients.</span></p>

<p class=MsoNormal style='line-height:normal'><b>&nbsp;</b></p>

<p class=MsoNormal style='line-height:normal'><span class=SmPCsubheading><i><u><span
lang=EN-GB style='font-weight:normal'>Renal impairment</span></u></i></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Initial dose
adjustments are not required in patients with renal impairment, including
severe renal impairment (creatinine clearance &lt;&nbsp;30&nbsp;ml/min<i>).</i>
A downward dose adjustment to 10&nbsp;mg twice daily should be considered after
a careful benefit-risk assessment only if therapy is not well-tolerated.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span class=SmPCsubheading><i><u><span
lang=EN-GB style='font-weight:normal'>Hepatic impairment</span></u></i></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Initial dose
adjustments are not required in patients with hepatic impairment (Child-Pugh
class A and&nbsp;B). A downward dose adjustment to 10&nbsp;mg twice daily
should be considered after a careful benefit&#8209;risk assessment only if
therapy is not well-tolerated.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Revatio is
contraindicated in patients with severe hepatic impairment (Child-Pugh class C)
(see section 4.3).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span class=SmPCsubheading><i><u><span
lang=EN-GB style='font-weight:normal'>Paediatric population</span></u></i></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Revatio solution
for injection is not recommended for use in children below 18&nbsp;years due to
insufficient data on safety and efficacy. Outside its authorised indications,
sildenafil should not be used in neonates with persistent pulmonary
hypertension of the newborn as risks outweigh the benefits (see section 5.1).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Discontinuation
of treatment</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Limited data
suggest that the abrupt discontinuation of oral Revatio is not associated with
rebound worsening of pulmonary arterial hypertension. However to avoid the
possible occurrence of sudden clinical deterioration during withdrawal, a
gradual dose reduction should be considered. Intensified monitoring is
recommended during the discontinuation period.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal><u><span lang=EN-GB>Method of administration</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Revatio solution for injection is for intravenous use as a bolus
injection.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>See section 6.6
for instructions of use.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.3&nbsp;&nbsp;&nbsp;&nbsp; Contraindications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hypersensitivity
to the active substance or to any of the excipients listed in section 6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Co-administration
with nitric oxide donors (such as amyl nitrite) or nitrates in any form due to
the hypotensive effects of nitrates (see section 5.1).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The
co-administration of PDE5 inhibitors, including sildenafil, with guanylate
cyclase stimulators, such as riociguat, is contraindicated as it may
potentially lead to symptomatic hypotension (see section 4.5).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Combination with
the most potent of the CYP3A4 inhibitors (eg, ketoconazole, itraconazole,
ritonavir) (see section 4.5).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>Patients who have loss of vision in one eye because of <span
lang=EN-GB>non-arteritic anterior ischaemic optic neuropathy (NAION),</span>
regardless of whether this episode was in connection or not with previous PDE5
inhibitor exposure (see section 4.4).</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>The safety of sildenafil has not
been studied in the following sub-groups of patients, and its use is therefore
contraindicated:</p>

<p class=MsoNormal style='line-height:normal'>Severe hepatic impairment,</p>

<p class=MsoNormal style='line-height:normal'>Recent history of stroke or
myocardial infarction,</p>

<p class=MsoNormal style='line-height:normal'>Severe hypotension (blood
pressure &lt;&nbsp;90/50&nbsp;mmHg) at initiation.</p>

<p class=MsoDate><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>4.4&nbsp;&nbsp;&nbsp;&nbsp; Special
warnings and precautions for use</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>No clinical data is available for
sildenafil IV administration in patients who are clinically or haemodynamically
unstable. Its use is accordingly not recommended in these patients.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The efficacy of
Revatio has not been established in patients with severe pulmonary arterial
hypertension (functional class IV). If the clinical situation deteriorates,
therapies that are recommended at the severe stage of the disease (eg,
epoprostenol) should be considered (see section&nbsp;4.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The benefit-risk
balance of sildenafil has not been established in patients assessed to be at WHO
functional class I pulmonary arterial hypertension.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Studies with
sildenafil have been performed in forms of pulmonary arterial hypertension
related to primary (idiopathic), connective tissue disease associated or
congenital heart disease associated forms of PAH (see section 5.1). The use of
sildenafil in other forms of PAH is not recommended.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Retinitis
pigmentosa</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The safety of
sildenafil has not been studied in patients with known hereditary degenerative
retinal disorders such as <i>retinitis pigmentosa</i> (a minority of these
patients have genetic disorders of retinal phosphodiesterases) and therefore
its use is not recommended.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Vasodilatory action</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>When prescribing
sildenafil</span><span lang=EN-GB>, physicians should carefully consider
whether patients with certain underlying conditions could be adversely affected
by sildenafil&#8217;s mild to moderate vasodilatory effects, for example
patients with hypotension, patients with fluid depletion, severe left
ventricular outflow obstruction or autonomic dysfunction (see section 4.4)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Cardiovascular
risk factors</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In
post-marketing experience with sildenafil for male erectile dysfunction,
serious cardiovascular events, including myocardial infarction, unstable
angina, sudden cardiac death, ventricular arrhythmia, cerebrovascular
haemorrhage, transient ischaemic attack, hypertension and hypotension have been
reported in temporal association with the use of sildenafil. Most, but not all,
of these patients had pre-existing cardiovascular risk factors. Many events
were reported to occur during or shortly after sexual intercourse and a few
were reported to occur shortly after the use of sildenafil without sexual
activity. It is not possible to determine whether these events are related
directly to these factors or to other factors.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-AU
style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-AU style='layout-grid-mode:line'>Priapism</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sildenafil
should be used with caution in patients with anatomical deformation of the
penis (such as angulation, cavernosal fibrosis or Peyronie&#8217;s disease), or
in patients who have conditions which may predispose them to priapism (such as
sickle cell anaemia, multiple myeloma or leukaemia).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Prolonged
erections and priapism have been reported with sildenafil in post-marketing
experience. In the event of an erection that persists longer than 4&nbsp;hours,
the patient should seek immediate medical assistance. If priapism is not
treated immediately, penile tissue damage and permanent loss of potency could
result (see section 4.8).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-AU
style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Vaso-occlusive crises in patients with s</span></u><u><span
lang=EN-AU style='layout-grid-mode:line'>ickle cell anaemia</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-AU style='layout-grid-mode:line'>Sildenafil should not be used in
patients with pulmonary hypertension secondary to sickle cell anaemia. In a
clinical study events of vaso-occlusive crises requiring hospitalisation were
reported more commonly by patients receiving Revatio than those receiving
placebo leading to the premature termination of this study.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-AU
style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-AU style='layout-grid-mode:line'>Visual events</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><em><span
lang=EN-GB style='font-style:normal'>Cases of visual defects have been reported
spontaneously in connection with the intake of sildenafil and other PDE5
inhibitors. Cases of non&#8209;arteritic anterior ischaemic optic neuropathy, a
rare condition, have been reported spontaneously and in an observational study
in connection with the intake of&nbsp;sildenafil and other PDE5 inhibitors (see
section 4.8). In the event of any sudden visual defect, the treatment should be
stopped immediately and alternative treatment should be considered (see section
4.3).</span></em></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-AU
style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-AU
style='layout-grid-mode:line'>Alpha-blockers</span></u></p>

<p class=MsoBodyText2 style='line-height:normal'><span lang=EN-AU
style='color:windowtext;layout-grid-mode:line'>Caution is advised when
sildenafil is administered </span><span style='color:windowtext'>to patients
taking an alpha-blocker as the co&#8209;administration may lead to symptomatic
hypotension in susceptible individuals (see section 4.5). </span><span
lang=EN-GB style='color:windowtext'>In order to minimise the potential for
developing postural hypotension, patients should be haemodynamically stable on
alpha-blocker therapy prior to initiating sildenafil treatment. Physicians
should advise patients what to do in the event of postural hypotensive
symptoms. </span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Bleeding
disorders</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Studies with human
platelets indicate that sildenafil potentiates the antiaggregatory effect of
sodium nitroprusside <i>in vitro</i>. There is no safety information on the
administration of sildenafil to patients with bleeding disorders or active
peptic ulceration. Therefore sildenafil should be administered to these
patients only after careful benefit-risk assessment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Vitamin K
antagonists</span></u></p>

<p class=MsoNormal style='line-height:normal'>In pulmonary arterial
hypertension patients, there may be a potential for increased risk of bleeding
when sildenafil is initiated in patients already using a Vitamin K antagonist,
particularly in patients with pulmonary arterial hypertension secondary to
connective tissue disease.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Veno-occlusive
disease</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No data are
available with sildenafil in patients with pulmonary hypertension associated with
pulmonary veno-occlusive disease. However, cases of life threatening pulmonary
oedema have been reported with vasodilators (mainly prostacyclin) when used in
those patients. Consequently, should signs of pulmonary oedema occur when
sildenafil is administered in patients with pulmonary hypertension, the
possibility of associated veno-occlusive disease should be considered.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in'><u><span lang=EN-GB
style='font-size:11.0pt'>Use of sildenafil with bosentan</span></u></p>

<p class=Paragraph style='margin-bottom:0in'><span style='font-size:11.0pt'>The
efficacy of sildenafil in patients already on bosentan therapy has not been
conclusively demonstrated (see sections 4.5 and 5.1).</span></p>

<p class=Paragraph style='margin-bottom:0in'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoCommentText><u><span lang=X-NONE style='font-size:11.0pt'>Concomitant
use with other PDE5 inhibitors</span></u></p>

<p class=Paragraph style='margin-bottom:0in'><span style='font-size:11.0pt'>The
safety and efficacy of sildenafil when co-administered with other PDE5
inhibitor products, including Viagra, has not been studied in PAH patients and</span><span
style='font-size:11.0pt'> such concomitant use is not recommended (see section
4.5).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=NormalBold><span style='font-size:11.0pt'>4.5&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt'>Interaction with other medicinal products and other
forms of interaction</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Unless otherwise
specified, drug interaction studies have been performed in healthy adult male
subjects using oral sildenafil. These results are relevant to other populations
and routes of administration.</span></p>

<p class=MsoNormal><span class=SmPCsubheading><i><u><span lang=EN-GB
style='font-weight:normal'><span style='text-decoration:none'>&nbsp;</span></span></u></i></span></p>

<p class=MsoNormal style='page-break-after:avoid'><span class=SmPCsubheading><u><span
lang=EN-GB style='font-weight:normal'>Effects of other medicinal products on
intravenous sildenafil</span></u></span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Predictions based on a pharmacokinetic model suggest that drug-drug
interactions with CYP3A4 inhibitors should be less than observed after oral
sildenafil administration. The magnitude of the interaction is expected to be
reduced for intravenous sildenafil, as interactions for oral sildenafil are
due, at least in part, to effects on oral first pass metabolism.</span></p>

<p class=MsoNormal><span class=SmPCsubheading><i><u><span lang=EN-GB
style='font-weight:normal'><span style='text-decoration:none'>&nbsp;</span></span></u></i></span></p>

<p class=MsoNormal><span class=SmPCsubheading><u><span lang=EN-GB
style='font-weight:normal'>Effects of other medicinal products on oral sildenafil</span></u></span></p>

<p class=MsoNormal><span class=SmPCsubheading><i><u><span lang=EN-GB
style='font-weight:normal'><span style='text-decoration:none'>&nbsp;</span></span></u></i></span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>In vitro
studies</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sildenafil
metabolism is principally mediated by the cytochrome P450 (CYP) isoforms 3A4
(major route) and 2C9 (minor route). Therefore, inhibitors of these isoenzymes
may reduce sildenafil clearance and inducers of these isoenzymes may increase
sildenafil clearance. For dose recommendations, see sections 4.2 and 4.3.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>In vivo
studies<b> </b></span></u></i></p>

<p class=MsoNormal><span lang=EN-GB>Co-administration of oral sildenafil and
intravenous epoprostenol has been evaluated (see sections 4.8 and 5.1).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The efficacy and safety of sildenafil
co-administered with other treatments for pulmonary arterial hypertension (eg, ambrisentan,
iloprost) has not been studied in controlled clinical trials. Therefore,
caution is recommended in case of co-administration.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>The safety and efficacy of sildenafil when co-administered
with other PDE5 inhibitors has not been studied in pulmonary arterial
hypertension patients (see section 4.4).</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Population
pharmacokinetic analysis of pulmonary arterial hypertension clinical trial data
indicated a reduction in sildenafil clearance and/or an increase of oral
bioavailability when co-administered with CYP3A4 substrates and the combination
of CYP3A4 substrates and beta-blockers. These were the only factors with a
statistically significant impact on oral sildenafil pharmacokinetics in
patients with pulmonary arterial hypertension. The exposure to sildenafil in
patients on CYP3A4 substrates and CYP3A4 substrates plus beta-blockers was 43&nbsp;%
and 66&nbsp;% higher, respectively, compared to patients not receiving these
classes of medicines. Sildenafil exposure was 5-fold higher at an oral dose of
80&nbsp;mg three times a day compared to the exposure at an oral dose of
20&nbsp;mg three times a day. This concentration range covers the increase in
sildenafil exposure observed in specifically designed drug interaction studies
with CYP3A4 inhibitors (except with the most potent of the CYP3A4 inhibitors
eg, ketoconazole, itraconazole, ritonavir).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>CYP3A4 inducers
seemed to have a substantial impact on the oral pharmacokinetics of sildenafil
in pulmonary arterial hypertension patients, which was confirmed in the in-vivo
interaction study with CYP3A4 inducer bosentan.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Co&#8209;administration
of bosentan (a moderate inducer of CYP3A4, CYP2C9 and possibly of CYP2C19)
125&nbsp;mg twice daily with oral sildenafil 80&nbsp;mg three times a day (at
steady state) concomitantly administered during 6&nbsp;days in healthy
volunteers resulted in a 63&nbsp;% decrease of sildenafil AUC. </span><span
lang=EN-GB>A population pharmacokinetic analysis of sildenafil data from adult
PAH patients in clinical trials including a 12 week study to assess the
efficacy and safety of oral sildenafil 20 mg three times a day when added to a
stable dose of bosentan (62.5 mg &#8211; 125 mg twice a day) indicated a
decrease in sildenafil exposure with bosentan co-administration, similar to
that observed in healthy volunteers (see sections 4.4 and 5.1).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Efficacy of
sildenafil should be closely monitored in patients using concomitant potent
CYP3A4 inducers, such as carbamazepine, phenytoin, phenobarbital, St
John&#8217;s wort and rifampicine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Co-administration
of the HIV protease inhibitor ritonavir, which is a highly potent P450
inhibitor, at steady state (500&nbsp;mg twice daily) with oral sildenafil
(100&nbsp;mg single dose) resulted in a 300&nbsp;% (4&#8209;fold) increase in
sildenafil C<sub>max</sub> and a 1,000&nbsp;% (11&#8209;fold) increase in
sildenafil plasma AUC. At 24&nbsp;hours, the plasma levels of sildenafil were
still approximately 200&nbsp;ng/ml, compared to approximately 5&nbsp;ng/ml when
sildenafil was administered alone. This is consistent with ritonavir&#8217;s
marked effects on a broad range of P450 substrates. Based on these
pharmacokinetic results co&#8209;administration of sildenafil with ritonavir is
contraindicated in pulmonary arterial hypertension patients (see section 4.3).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Co-administration
of the HIV protease inhibitor saquinavir, a CYP3A4 inhibitor, at steady state
(1200&nbsp;mg three times a day) with oral sildenafil (100&nbsp;mg single dose)
resulted in a 140&nbsp;% increase in sildenafil C<sub>max</sub> and a 210&nbsp;%
increase in sildenafil AUC. Sildenafil had no effect on saquinavir pharmacokinetics.
For dose recommendations, see section 4.2.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>When a single
100&nbsp;mg dose of oral sildenafil was administered with erythromycin, a moderate
CYP3A4 inhibitor, at steady state (500&nbsp;mg twice daily for 5&nbsp;days),
there was a 182&nbsp;% increase in sildenafil systemic exposure (AUC). For dose
recommendations, see section 4.2. In healthy male volunteers, there was no
evidence of an effect of azithromycin (500&nbsp;mg daily for 3&nbsp;days) on
the AUC, C<sub>max</sub>, T<sub>max</sub>, elimination rate constant, or
subsequent half-life of oral sildenafil or its principal circulating
metabolite. No dose adjustment is required. Cimetidine (800&nbsp;mg), a
cytochrome P450 inhibitor and a non-specific CYP3A4 inhibitor, caused a 56&nbsp;%
increase in plasma sildenafil concentrations when co-administered with oral
sildenafil (50&nbsp;mg) to healthy volunteers. No dose adjustment is required.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>The most potent of the CYP3A4
inhibitors such as ketoconazole and itraconazole would be expected to have
effects similar to ritonavir (see section 4.3). CYP3A4 inhibitors like<span
lang=EN-GB> clarithromycin, telithromycin and nefazodone) are expected to have
an effect in between that of ritonavir and CYP3A4 inhibitors like saquinavir or
erythromycin), a seven-fold increase in exposure is assumed. Therefore dose
adjustments are recommended when using CYP3A4 inhibitors (see section 4.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The population
pharmacokinetic analysis in pulmonary arterial hypertension patients receiving
oral sildenafil suggested that co-administration of beta-blockers in
combination with CYP3A4 substrates might result in an additional increase in
sildenafil exposure compared with administration of CYP3A4 substrates alone.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Grapefruit juice
is a weak inhibitor of CYP3A4 gut wall metabolism and may give rise to modest
increases in plasma levels of oral sildenafil. No dose adjustment is required
but the concomitant use of sildenafil and grapefruit juice is not recommended.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Single doses of
antacid (magnesium hydroxide/aluminium hydroxide) did not affect the oral
bioavailability of sildenafil.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Co-administration
of oral contraceptives (ethinyloestradiol 30&nbsp;</span><span lang=EN-GB
style='font-family:Symbol'>m</span><span lang=EN-GB>g and levonorgestrel
150&nbsp;</span><span lang=EN-GB style='font-family:Symbol'>m</span><span
lang=EN-GB>g) did not affect the oral pharmacokinetics of sildenafil.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Nicorandil is a
hybrid of potassium channel activator and nitrate. Due to the nitrate component
it has the potential to have serious interaction with sildenafil (see section
4.3).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span class=SmPCsubheading><u><span lang=EN-GB
style='font-weight:normal'>Effects of oral sildenafil on other medicinal
products</span></u></span></p>

<p class=MsoNormal><span class=SmPCsubheading><u><span lang=EN-GB
style='font-weight:normal'><span style='text-decoration:none'>&nbsp;</span></span></u></span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>In vitro
studies</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sildenafil is a
weak inhibitor of the cytochrome P450 isoforms 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4
(IC<sub>50</sub>&nbsp;&gt;&nbsp;150&nbsp;</span><span lang=EN-GB
style='font-family:Symbol'>m</span><span lang=EN-GB>M).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>There are no data on the
interaction of sildenafil and non-specific phosphodiesterase inhibitors such as
theophylline or dipyridamole.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>In vivo studies</span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>No significant interactions were shown when oral sildenafil
(50&nbsp;mg) was co-administered with tolbutamide (250&nbsp;mg) or warfarin
(40&nbsp;mg), both of which are metabolised by CYP2C9.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral sildenafil
had no significant effect on atorvastatin exposure (AUC increased 11&nbsp;%),
suggesting that sildenafil does not have a clinically relevant effect on
CYP3A4.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No interactions
were observed between sildenafil (100&nbsp;mg single oral dose) and
acenocoumarol. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral sildenafil
(50&nbsp;mg) did not potentiate the increase in bleeding time caused by acetyl
salicylic acid (150&nbsp;mg).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral sildenafil
(50&nbsp;mg) did not potentiate the hypotensive effects of alcohol in healthy
volunteers with mean maximum blood alcohol levels of 80&nbsp;mg/dl.</span></p>

<p class=MsoNormal style='line-height:normal'><s><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></s></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In a study of
healthy volunteers oral sildenafil at steady state (80&nbsp;mg three times a
day) resulted in a 50&nbsp;% increase in bosentan AUC (125&nbsp;mg twice
daily). </span><span lang=EN-GB>A population pharmacokinetic analysis of data
from a study of adult PAH patients on background bosentan therapy (62.5 mg -
125&nbsp;mg twice a day) indicated an increase (20% (95% CI: 9.8 - 30.8)) of
bosentan AUC with co-administration of steady-state sildenafil (20&nbsp;mg
three times a day) of a smaller magnitude than seen in healthy volunteers when
co-administered with 80 mg sildenafil three times a day (see sections 4.4 and
5.1).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In a specific
interaction study, where oral sildenafil (100&nbsp;mg) was co-administered with
amlodipine in hypertensive patients, there was an additional reduction on
supine systolic blood pressure of 8&nbsp;mmHg. The corresponding additional
reduction in supine diastolic blood pressure was 7&nbsp;mmHg. These additional
blood pressure reductions were of a similar magnitude to those seen when
sildenafil was administered alone to healthy volunteers.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>In three
specific drug-drug interaction studies, the alpha-blocker doxazosin (4&nbsp;mg
and 8&nbsp;mg) and oral sildenafil (25&nbsp;mg, 50&nbsp;mg, or 100&nbsp;mg)
were administered simultaneously to patients with benign prostatic hyperplasia
(BPH) stabilized on doxazosin therapy. In these study populations, mean
additional reductions of supine systolic and diastolic blood pressure of
7/7&nbsp;mmHg, 9/5&nbsp;mmHg, and 8/4&nbsp;mmHg, respectively, and mean
additional reductions of standing blood pressure of 6/6&nbsp;mmHg,
11/4&nbsp;mmHg, and 4/5&nbsp;mmHg, respectively were observed. When sildenafil
and doxazosin were administered simultaneously to patients stabilized on
doxazosin therapy, there were infrequent reports of patients who experienced
symptomatic postural hypotension. These reports included dizziness and
lightheadedness, but not syncope. Concomitant administration of sildenafil to
patients taking alpha&#8209;blocker therapy may lead to symptomatic hypotension
in susceptible individuals (see section 4.4).</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sildenafil
(100&nbsp;mg single oral dose) did not affect the steady state pharmacokinetics
of the HIV protease inhibitor saquinavir, which is a CYP3A4
substrate/inhibitor.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Consistent with
its known effects on the nitric oxide/cGMP pathway (see section 5.1),
sildenafil was shown to potentiate the hypotensive effects of nitrates, and its
co-administration with nitric oxide donors or nitrates in any form is therefore
contraindicated (see section 4.3).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Riociguat: Preclinical studies showed additive systemic blood
pressure lowering effect when PDE5 inhibitors were combined with riociguat. In
clinical studies, riociguat has been shown to augment the hypotensive effects
of PDE5 inhibitors. There was no evidence of favourable clinical effect of the
combination in the population studied. Concomitant use of riociguat with PDE5
inhibitors, including sildenafil, is contraindicated (see section 4.3).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral sildenafil
had no clinically significant impact on the plasma levels of oral
contraceptives (ethinyloestradiol 30&nbsp;</span><span lang=EN-GB
style='font-family:Symbol'>m</span><span lang=EN-GB>g and levonorgestrel
150&nbsp;</span><span lang=EN-GB style='font-family:Symbol'>m</span><span
lang=EN-GB>g).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'><u><span
lang=EN-GB>Paediatric population</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Interaction
studies have only been performed in adults.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.6&nbsp;&nbsp;&nbsp;&nbsp; Fertility,
pregnancy and lactation</span></b></p>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'><u><span
lang=EN-GB>Women of childbearing potential and contraception in males and
females</span></u></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>Due to lack of data
on effects of Revatio in pregnant women, Revatio is not recommended for women
of childbearing potential unless also using appropriate contraceptive measures.</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There are no
data from the use of sildenafil in pregnant women. Animal studies do not
indicate direct or indirect harmful effects with respect to pregnancy and
embryonal/foetal development. Studies in animals have shown toxicity with
respect to postnatal development (see section 5.3).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Due to lack of
data, Revatio should not be used in pregnant women unless strictly necessary.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Breast-feeding</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>There are no adequate and well controlled studies in
lactating women. Data from one lactating woman indicate that sildenafil and its
active metabolite N-desmethylsildenafil are excreted into breast milk at very
low levels. No clinical data are available regarding adverse events in
breast-fed infants, but amounts ingested would not be expected to cause any
adverse effects. Prescribers should carefully assess the mother&#8217;s
clinical need for sildenafil and any potential adverse effects on the breast&#8209;fed
child.</span></p>

<p class=MsoNormal style='text-align:justify'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='text-align:justify'><u><span lang=EN-GB>Fertility</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Non-clinical data revealed no special
hazard for humans based on conventional studies of fertility (see section 5.3).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.7&nbsp;&nbsp;&nbsp;&nbsp; Effects on ability to
drive and use machines</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Revatio has moderate influence on the
ability to drive and use machines.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>As dizziness
and altered vision were reported in clinical trials with sildenafil, patients
should be aware of how they might be affected by Revatio, before driving or using
machines.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.8&nbsp;&nbsp;&nbsp;&nbsp; Undesirable effects</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Adverse reactions that resulted from intravenous Revatio use are
similar to those associated with oral Revatio use. Since there are limited data
for intravenous Revatio use and since pharmacokinetic models predict that
20&nbsp;</span><span lang=EN-GB>mg</span><span lang=EN-GB> oral and 10&nbsp;mg
intravenous formulations will yield similar plasma exposures, the safety
information for intravenous Revatio is supported by that of oral Revatio.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Intravenous administration</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>A 10&nbsp;mg dose of Revatio solution for injection is predicted to
provide total exposure of free sildenafil and its N-desmethyl metabolite and
their combined pharmacological effects comparable to those of a 20&nbsp;mg oral
dose.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Study A1481262 was a single centre, single dose, open label study to
assess the safety, tolerability and pharmacokinetics of a single intravenous
dose of sildenafil (10&nbsp;mg) administered as a bolus injection to patients
with Pulmonary Arterial Hypertension (PAH) who were already receiving and
stable on oral Revatio 20&nbsp;mg three times per day.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>A total of 10 PAH subjects enrolled and
completed the study. </span><span lang=EN-GB>The mean postural changes in
systolic and diastolic blood pressure over time were small
(&lt;&nbsp;10&nbsp;mmHg) and returned towards baseline beyond 2&nbsp;hours. No
symptoms of hypotension were associated with these changes. The mean changes in
heart rate were clinically insignificant. Two subjects experienced a total of 3
adverse reactions (flushing, flatulence and hot flush). There was one serious
adverse reaction in a subject with severe ischaemic cardiomyopathy who
experienced ventricular fibrillation and death 6 days post study. It was judged
to be unrelated to the study medicinal product.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Oral
administration</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In the pivotal
placebo-controlled study of Revatio in pulmonary arterial hypertension, a total
of 207&nbsp;patients were </span>randomized to and treated with 20&nbsp;mg, 40&nbsp;mg
or 80&nbsp;mg TID doses of <span lang=EN-GB>oral Revatio and 70&nbsp;patients
were randomized to placebo. The duration of treatment was 12&nbsp;weeks. The
overall frequency of discontinuation in sildenafil treated patients at doses of
20&nbsp;mg, 40&nbsp;mg and 80&nbsp;mg TID was 2.9&nbsp;%, 3.0&nbsp;% and 8.5&nbsp;%
respectively, compared to 2.9&nbsp;% with placebo. Of the 277&nbsp;subjects treated
in the pivotal study, 259 entered a long-term extension study. Doses up to
80&nbsp;mg three times a day (4&nbsp;times the recommended dose of 20&nbsp;mg
three times a day) were administered and after 3&nbsp;years 87&nbsp;% of 183&nbsp;patients
on study treatment were receiving Revatio 80&nbsp;mg TID. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoCommentText><span lang=X-NONE style='font-size:11.0pt'>In a
placebo-controlled study of </span><span lang=X-NONE style='font-size:11.0pt'>Revatio
</span><span lang=X-NONE style='font-size:11.0pt'>as an adjunct to intravenous
epoprostenol in pulmonary arterial hypertension</span><span lang=X-NONE
style='font-size:11.0pt'>, a total of 134&nbsp;patients were treated with oral
Revatio (</span><span lang=X-NONE style='font-size:11.0pt'>in a fixed titration
starting from 20&nbsp;mg, to 40&nbsp;mg and then 80&nbsp;mg, three times a day
as tolerated) and epoprostenol, and 131&nbsp;patients were treated with placebo
and epoprostenol. The duration of treatment was 16&nbsp;weeks. The overall
frequency of discontinuations in sildenafil/epoprostenol treated patients due
to adverse events was 5.2&nbsp;% compared to 10.7&nbsp;% in the
placebo/epoprostenol treated patients. Newly reported adverse drug reactions,
which occurred more frequently in the sildenafil/ epoprostenol group, were ocular
hyperaemia, vision blurred, nasal congestion, night sweats, back pain and dry
mouth. The known adverse events headache, flushing, pain in extremity and
oedema were noted in a higher frequency in sildenafil/epoprostenol treated
patients compared to placebo/epoprostenol treated patients. Of the subjects who
completed the initial study, 242 entered a long-term extension study. Doses up
to 80&nbsp;mg TID were administered and after 3&nbsp;years 68&nbsp;% of 133&nbsp;patients
on study treatment were receiving Revatio 80&nbsp;mg TID.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>I<span
lang=EN-GB>n the two-placebo controlled oral Revatio studies adverse events
were generally mild to moderate in severity. The most commonly reported adverse
reactions that occurred (greater or equal to 10&nbsp;%) on </span>Revatio<span
lang=EN-GB> compared to placebo were headache, flushing, dyspepsia, diarrhoea
and pain in extremity.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Tabulated list of adverse reactions</span></u></p>

<p class=MsoNormal>Adverse reactions which occurred in &gt;&nbsp;1&nbsp;% of
Revatio-treated patients and were more frequent (&gt;&nbsp;1&nbsp;% difference)
on Revatio in the pivotal study or in the Revatio combined data set of both the
placebo&#8209;controlled studies in pulmonary arterial hypertension, at oral
doses of 20, 40 or 80&nbsp;mg <span lang=EN-GB>TID</span> are listed in the
table below by class and frequency grouping (very common (<span
style='font-family:Symbol'>&sup3;</span>&nbsp;1/10), common (<span
style='font-family:Symbol'>&sup3;</span>&nbsp;1/100 to &lt;&nbsp;1/10), <span
lang=EN-GB>uncommon (</span><span lang=EN-GB style='font-family:Symbol'>&sup3;</span><span
lang=EN-GB>&nbsp;1/1000 to &#8804;&nbsp;1/100) and not known (cannot be
estimated from the available data). </span>Within each frequency grouping,
undesirable effects are presented in order of decreasing seriousness.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Reports from post-marketing experience are included in
italics.</p>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:solid windowtext 1.0pt;
  border-right:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>MedDRA system organ class (V.14.0)</b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b>Adverse reaction</b></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>Infections and infestations</b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Common</p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  lang=EN-GB>cellulitis,influenza, bronchitis, </span></p>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  lang=EN-GB>sinusitis, rhinitis, gastroenteritis</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>Blood and lymphatic system disorders</b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Common</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=ES>anaemia</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>Metabolism and nutrition disorders</b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Common</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>fluid
  retention</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>Psychiatric disorders</b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Common</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>insomnia,
  anxiety</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>Nervous system disorders</b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'>Very common</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>headache </span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Common</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=PT>migraine, tremor, paraesthesia, burning
  sensation, hypoaesthesia</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b>Eye disorders</b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Common</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>retinal
  haemorrhage, visual impairment, vision blurred, photophobia, chromatopsia,
  cyanopsia, eye irritation, ocular hyperaemia </span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Uncommon</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>visual
  acuity reduced, diplopia, abnormal sensation in eye </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Not known</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Non-arteritic
  anterior ischaemic optic neuropathy (NAION)*, Retinal vascular occlusion*,
  Visual field defect*</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>Ear and labyrinth disorders</b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Common</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>vertigo</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Not known</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>sudden hearing
  loss</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>Vascular disorders</b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'>Very common</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>flushing</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Not Known</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>hypotension</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>Respiratory, thoracic and mediastinal disorders</b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Common</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=PT>epistaxis, cough,
  nasal congestion </span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>Gastrointestinal disorders</b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'>Very common</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>diarrhoea,
  dyspepsia </span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Common</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>gastritis,
  gastrooesophageal reflux disease, haemorrhoids, abdominal distension, dry
  mouth</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>Skin and subcutaneous tissue disorders</b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Common</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>alopecia,
  erythema, night sweats</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Not known</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>rash</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>Musculoskeletal and connective tissue disorders</b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Very common</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>pain in extremity</p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Common</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>myalgia, back pain </p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Renal and urinary disorders</span></b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>haematuria</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>Reproductive system and breast disorders </b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Uncommon</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>penile
  haemorrhage, haematospermia, </span>gynaecomastia</p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Not known</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i>priapism, erection
  increased</i></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>General disorders and administration site conditions</b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Common</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>pyrexia</p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span style='font-size:8.0pt'>*These
adverse events/reactions have been reported in patients taking sildenafil in
the treatment of male erectile dysfunction (MED). </span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB>Reporting of
suspected adverse reactions</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Reporting suspected adverse reactions after
authorisation of the medicinal product is important. It allows continued
monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via <span
style='background:silver'>the national reporting system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix
V</a></span>.</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
-28.35pt;line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>4.9&nbsp;&nbsp;&nbsp;&nbsp; Overdose</span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>In single dose volunteer studies of oral doses up to 800&nbsp;mg,
adverse reactions were similar to those seen at lower doses, but the incidence
rates and severities were increased. At single oral doses of 200&nbsp;mg the
incidence of adverse reactions (headache, flushing, dizziness, dyspepsia, nasal
congestion, and altered vision) was increased.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In cases of
overdose, standard supportive measures should be adopted as required. Renal
dialysis is not expected to accelerate clearance as sildenafil is highly bound
to plasma proteins and not eliminated in the urine.</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACOLOGICAL
PROPERTIES</span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
-28.35pt;line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>5.1 &nbsp;&nbsp;&nbsp; Pharmacodynamic
properties</span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Pharmacotherapeutic group: Urologicals, Drugs used in erectile
dysfunction, ATC code: G04BE03</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Mechanism of
action</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sildenafil is a
potent and selective inhibitor of cyclic guanosine monophosphate (cGMP)
specific phosphodiesterase type 5 (PDE5), the enzyme that is responsible for
degradation of cGMP. Apart from the presence of this enzyme in the corpus
cavernosum of the penis, PDE5 is also present in the pulmonary vasculature<i>. </i>Sildenafil,
therefore, increases cGMP within pulmonary vascular smooth muscle cells
resulting in relaxation. In patients with pulmonary arterial hypertension this
can lead to vasodilation of the pulmonary vascular bed and, to a lesser degree,
vasodilatation in the systemic circulation.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Pharmacodynamic
effects</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Studies <i>in
vitro</i> have shown that sildenafil is selective for PDE5. Its effect is more
potent on PDE5 than on other known phosphodiesterases. There is a 10&#8209;fold
selectivity over PDE6 which is involved in the phototransduction pathway in the
retina. There is an 80-fold selectivity over PDE1, and over 700&#8209;fold over
PDE 2, 3, 4, 7, 8, 9, 10 and 11. In particular, sildenafil has greater than
4,000&#8209;fold selectivity for PDE5 over PDE3, the cAMP-specific
phosphodiesterase isoform involved in the control of cardiac contractility.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sildenafil
causes mild and transient decreases in systemic blood pressure which, in the
majority of cases, do not translate into clinical effects. After chronic oral
dosing of 80&nbsp;mg three times a day to patients with systemic hypertension
the mean change from baseline in systolic and diastolic blood pressure was a
decrease of 9.4&nbsp;mmHg and 9.1&nbsp;mm Hg respectively. After chronic oral
dosing of 80&nbsp;mg three times a day to patients with pulmonary arterial
hypertension lesser effects in blood pressure reduction were observed (a
reduction in both systolic and diastolic pressure of 2&nbsp;mmHg). </span>At
the recommended oral dose of 20&nbsp;mg three times a day no reductions in systolic
or diastolic pressure were seen.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Single oral
doses of sildenafil up to 100&nbsp;mg in healthy volunteers produced no
clinically relevant effects on ECG. After chronic dosing of 80&nbsp;mg three
times a day to patients with pulmonary arterial hypertension no clinically
relevant effects on the ECG were reported.</span></p>

<p class=MsoBodyTextIndent style='margin-left:0in'><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In a study of
the hemodynamic effects of a single oral 100&nbsp;mg dose of sildenafil in 14&nbsp;patients
with severe coronary artery disease (CAD) (&gt;&nbsp;70&nbsp;% stenosis of at
least one coronary artery), the mean resting systolic and diastolic blood
pressures decreased by 7&nbsp;% and 6&nbsp;% respectively compared to baseline.
Mean pulmonary systolic blood pressure decreased by 9&nbsp;%. Sildenafil showed
no effect on cardiac output, and did not impair blood flow through the stenosed
coronary arteries.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Mild and
transient differences in colour discrimination (blue/green) were detected in
some subjects using the Farnsworth-Munsell 100 hue test at 1&nbsp;hour
following a 100&nbsp;mg dose, with no effects evident after 2&nbsp;hours
post-dose. The postulated mechanism for this change in colour discrimination is
related to inhibition of PDE6, which is involved in the phototransduction
cascade of the retina. Sildenafil has no effect on visual acuity or contrast
sensitivity. In a small size placebo-controlled study of patients with
documented early age-related macular degeneration (n&nbsp;=&nbsp;9), sildenafil
(single dose, 100&nbsp;mg) demonstrated no significant changes in visual tests
conducted (visual acuity, Amsler grid, colour discrimination simulated traffic
light, Humphrey perimeter and photostress).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Clinical efficacy and safety</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><u><span lang=EN-GB>Efficacy of intravenous sildenafil in adult
patients with pulmonary arterial hypertension (PAH)</span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>A 10&nbsp;mg dose of Revatio solution for injection is predicted to
provide total exposure of free sildenafil and its N-desmethyl metabolite and
their combined pharmacological effects comparable to those of a 20&nbsp;mg oral
dose. This is based on Pharmacokinetic data only (see section 5.2.
Pharmacokinetic Properties). The consequences of the subsequent lower exposure
to the active N-desmethyl metabolite observed after repeated IV administration
of Revatio have not been documented. No clinical studies have been performed to
demonstrate that these formulations have comparable efficacy</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Study A1481262 was a single centre, single dose, open label study to
assess the safety, tolerability and pharmacokinetics of a single intravenous
dose of sildenafil (10&nbsp;mg) administered as a bolus injection to patients
with PAH who were already receiving and stable on oral Revatio 20&nbsp;mg TID.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>A total of 10 PAH subjects enrolled and
completed the study. </span><span lang=EN-GB>Eight subjects were taking
bosentan and one subject was taking treprostinil in addition to bosentan and
Revatio. </span><span lang=EN-GB>After dosing, sitting and standing blood
pressure and heart rate were recorded at 30, 60, 120, 180 and 360&nbsp;minute
post dose. The mean changes from baseline in sitting blood pressure were
greatest at 1 hour, &#8209;9.1&nbsp;mmHg&nbsp;(SD&nbsp;&plusmn;&nbsp;12.5) and &#8209;3.0
(SD&nbsp;&plusmn;&nbsp;4.9)&nbsp;mmHg for systolic and diastolic pressure
respectively. </span><span lang=EN-GB>The mean postural changes in systolic and
diastolic blood pressure over time were small (&lt;&nbsp;10&nbsp;mmHg) and
returned towards baseline beyond 2&nbsp;hours.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Efficacy
of oral sildenafil in adult patients with pulmonary arterial hypertension (PAH)</span></u></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>A randomised,
double&#8209;blind, placebo&#8209;controlled study was conducted in 278&nbsp;patients
with primary pulmonary hypertension, PAH associated with connective tissue
disease, and PAH following surgical repair of congenital heart lesions.
Patients were randomised to one of four treatment groups: placebo, sildenafil
20&nbsp;mg, sildenafil 40&nbsp;mg or sildenafil 80&nbsp;mg, three times a day.
Of the 278&nbsp;patients randomised, 277&nbsp;patients received at least 1 dose
of study drug. The study population consisted of 68&nbsp;(25&nbsp;%) men and
209 (75&nbsp;%) women with a mean age of 49&nbsp;years (range: 18-81&nbsp;years)
and baseline 6&#8209;minute walk test distance between 100 and 450&nbsp;metres
inclusive (mean: 344&nbsp;metres). </span>175&nbsp;patients (63&nbsp;%)
included were diagnosed with primary pulmonary hypertension, 84 (30&nbsp;%)
were diagnosed with <span lang=EN-GB>PAH </span>associated with connective
tissue disease and 18 (7&nbsp;%) of the patients were diagnosed with <span
lang=EN-GB>PAH </span>following surgical repair of congenital heart lesions.
Most patients were WHO Functional Class II (107/277, 39&nbsp;%) or III
(160/277, 58&nbsp;%) with a mean baseline 6 minute walking distance of 378&nbsp;meters
and 326&nbsp;meters respectively; fewer patients were Class I (1/277, 0.4&nbsp;%)
or IV (9/277, 3&nbsp;%) at baseline.<span lang=EN-GB> Patients with left
ventricular ejection fraction &lt;&nbsp;45&nbsp;% or left ventricular
shortening fraction &lt;&nbsp;0.2 were not studied.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sildenafil (or
placebo) was added to patients&#8217; background therapy which could have
included a combination of anticoagulation, digoxin, calcium channel blockers,
diuretics or oxygen. The use of prostacyclin, prostacyclin analogues and
endothelin receptor antagonists was not permitted as add-on therapy, and
neither was arginine supplementation. Patients who previously failed bosentan
therapy were excluded from the study.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The primary
efficacy endpoint was the change from baseline at week 12 in 6-minute walk
distance (</span><span lang=EN-GB>6MWD)</span><span lang=EN-GB>. A
statistically significant increase in </span><span lang=EN-GB>6MWD</span><span
lang=EN-GB> was observed in all 3&nbsp;sildenafil dose groups compared to those
on placebo. Placebo corrected increases in </span><span lang=EN-GB>6MWD</span><span
lang=EN-GB> were 45&nbsp;metres (p&nbsp;&lt;&nbsp;0.0001), 46&nbsp;metres
(p&nbsp;&lt;&nbsp;0.0001) and 50&nbsp;metres (p&nbsp;&lt;&nbsp;0.0001) for
sildenafil 20&nbsp;mg, 40&nbsp;mg and 80&nbsp;mg TID respectively. There was no
significant difference in effect between sildenafil doses.</span><span
lang=EN-GB> For patients with a low baseline 6&nbsp;MWD &lt;&nbsp;325&nbsp;m
improved efficacy was observed with higher doses (</span><span lang=EN-GB>placebo-corrected
improvements of 58&nbsp;metres, 65&nbsp;metres and 87&nbsp;metres for 20&nbsp;mg,
40&nbsp;mg and 80&nbsp;mg doses TID, respectively).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>When analysed by
WHO functional class, a statistically </span><span lang=EN-GB>significant
increase in 6MWD was observed in the 20 mg dose group. For class II and class
III, placebo corrected increases of 49&nbsp;metres (p&nbsp;=&nbsp;0.0007) and
45&nbsp;metres (p&nbsp;=&nbsp;0.0031) were observed respectively.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The improvement
in </span><span lang=EN-GB>6MWD</span><span lang=EN-GB> was apparent after 4&nbsp;weeks
of treatment and this effect was maintained at weeks 8 and 12. </span><span
lang=EN-GB>Results were generally consistent in subgroups according to aetiology
(primary and connective tissue disease-associated PAH), WHO functional class,
gender, race, location, mean PAP and PVRI.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Patients on all sildenafil doses achieved a statistically
significant reduction in mean pulmonary arterial pressure (mPAP) </span><span
lang=EN-GB>and pulmonary vascular resistance (PVR</span><span lang=EN-GB>)
compared to those on placebo. Placebo&#8209;corrected treatment effects </span><span
lang=EN-GB>with mPAP</span><span lang=EN-GB> were &#8209;2.7&nbsp;mm Hg&nbsp;(p&nbsp;=&nbsp;0.04)</span><span
lang=EN-GB> , &#8209;3.0&nbsp;mm Hg&nbsp;(p&nbsp;=&nbsp;0.01) and &#8209;5.1&nbsp;mm
Hg (p&nbsp;&lt;&nbsp;0.0001) </span><span lang=EN-GB>for sildenafil 20&nbsp;mg</span><span
lang=EN-GB>, 40&nbsp;mg and 80&nbsp;mg TID, respectively. Placebo&#8209;corrected
treatment effects with PVR were &#8209;178&nbsp;dyne.sec/cm<sup>5</sup>
(p=0.0051), &#8209;195&nbsp;dyne.sec/cm<sup>5</sup> (p=0.0017) and &#8209;320&nbsp;dyne.sec/cm<sup>5
</sup>(p&lt;0.0001) for sildenafil 20&nbsp;mg, 40&nbsp;mg and 80&nbsp;mg TID,
respectively. The percent reduction at 12&nbsp;weeks for sildenafil 20&nbsp;mg,
40&nbsp;mg and 80&nbsp;mg TID in PVR (11.2&nbsp;%, 12.9&nbsp;%, 23.3&nbsp;%)
was proportionally greater than the reduction in systemic vascular resistance
(SVR) (7.2&nbsp;%, 5.9&nbsp;%, and 14.4&nbsp;%). </span><span lang=EN-GB>The
effect of sildenafil on mortality is unknown.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>A greater percentage of patients on each of the sildenafil doses
(i.e. 28&nbsp;%, 36&nbsp;% and 42&nbsp;% of subjects who received sildenafil
20&nbsp;mg, 40&nbsp;mg and 80&nbsp;mg TID doses, respectively) showed an
improvement by at least one WHO functional class at week 12 compared to placebo
(7&nbsp;%).<span style='color:red'> </span>The respective odds ratios were 2.92&nbsp;(p=0.0087),
4.32&nbsp;</span><span lang=EN-GB>(p=0.0004) and 5.75&nbsp;(p&lt;0.0001)</span><span
class=MsoCommentReference><span lang=EN-GB style='font-size:8.0pt'>.</span></span></p>

<p class=MsoNormal><i><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal><i><u><span lang=EN-GB>Long-term survival data in naive
population</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB>Patients enrolled into the pivotal oral
route study were eligible to enter a long term open label extension study. </span><span
lang=EN-GB>At 3&nbsp;years 87&nbsp;% of the patients were receiving a dose of
80&nbsp;mg TID. </span><span lang=EN-GB>A total of 207&nbsp;patients were</span><span
lang=EN-GB> treated with Revatio in the pivotal study, and their long term
survival status was assessed for a minimum of 3&nbsp;years. In this population,
Kaplan-Meier estimates of 1, 2 and 3&nbsp;year survival were 96&nbsp;%, 91&nbsp;%
and 82&nbsp;%, respectively. Survival in patients of WHO functional class II at
baseline at 1, 2 and 3&nbsp;years was 99&nbsp;%, 91&nbsp;%, and 84&nbsp;%
respectively, and for patients of</span> WHO functional class III at baseline
was <span lang=EN-GB>94&nbsp;%, 90&nbsp;%, and 81&nbsp;%, respectively.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><u><span lang=EN-GB>Efficacy of oral sildenafil in adult
patients with PAH (when used in combination with epoprostenol)</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB>A randomised, double-blind, placebo
controlled study was conducted in 267&nbsp;patients with PAH who were
stabilised on intravenous epoprostenol. The PAH patients included those with
Primary Pulmonary Arterial Hypertension (212/267, 79&nbsp;%) and PAH associated
with connective tissue disease (55/267, 21&nbsp;%).<b> </b>Most patients were
WHO Functional Class II (68/267, 26&nbsp;%) or III (175/267, 66&nbsp;%); fewer
patients were Class I (3/267, 1&nbsp;%) or IV (16/267, 6&nbsp;%) at baseline;
for a few patients (5/267, 2&nbsp;%), the WHO Functional Class was unknown.
Patients were randomised to placebo or sildenafil (in a fixed titration
starting from 20&nbsp;mg, to 40&nbsp;mg and then 80&nbsp;mg, three times a day
as tolerated) when used in combination with intravenous epoprostenol.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in'><span style='font-size:11.0pt'>The
primary efficacy endpoint was the change from baseline at week 16 in 6-minute
walk distance. There was a statistically significant benefit of sildenafil
compared to placebo in 6-minute walk distance. A mean placebo corrected
increase in walk distance of 26&nbsp;metres was observed in favour of
sildenafil (95&nbsp;% CI: 10.8, 41.2) (p&nbsp;=&nbsp;0.0009). </span><span
lang=EN-GB style='font-size:11.0pt'>For patients with a baseline walking
distance &#8805;&nbsp;325&nbsp;metres, the treatment effect was
38.4&nbsp;metres in favour of sildenafil; for patients with a baseline walking
distance &lt;&nbsp;325&nbsp;metres, the treatment effect was 2.3&nbsp;metres in
favour of placebo. For patients with primary PAH, the treatment effect was
31.1&nbsp;metres compared to 7.7&nbsp;metres for patients with PAH associated with</span><span
style='font-size:11.0pt'> connective tissue disease</span><span lang=EN-GB
style='font-size:11.0pt'>. The difference in results between these
randomisation subgroups may have arisen by chance in view of their limited
sample size.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Patients on sildenafil achieved a
statistically significant reduction in mean Pulmonary Arterial Pressure (mPAP)
compared to those on placebo. A mean placebo-corrected treatment effect of &#8209;3.9&nbsp;mmHg
was observed in favour of sildenafil (95&nbsp;% CI: &#8209;5.7, &#8209;2.1)
(p&nbsp;=&nbsp;0.00003). <strong><span style='font-weight:normal'>Time to
clinical worsening was a secondary endpoint as defined as the time from
randomisation to the first occurrence of a clinical worsening event (death,
lung transplantation, initiation of bosentan therapy, or clinical deterioration
requiring a change in epoprostenol therapy). Treatment with sildenafil
significantly delayed the time to clinical worsening of PAH compared to placebo
(p&nbsp;=&nbsp;0.0074). 23&nbsp;subjects experienced clinical worsening events
in the placebo group (17.6&nbsp;%) compared with 8&nbsp;subjects in the
sildenafil group (6.0&nbsp;%).</span></strong></span></p>

<p class=MsoNormal><strong><span lang=EN-GB style='font-weight:normal'>&nbsp;</span></strong></p>

<p class=MsoNormal style='text-align:justify'><i><u><span lang=EN-GB>Long-term
Survival Data in the background epoprostenol study</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB>Patients enrolled into the epoprostenol
add-on therapy study were eligible to enter a long term open label extension
study. </span><span lang=EN-GB>At 3&nbsp;years 68&nbsp;% of the patients were
receiving a dose of 80&nbsp;mg TID.</span><span lang=EN-GB> A total of 134&nbsp;patients
were</span><span lang=EN-GB> treated with Revatio in the initial study, and
their long term survival status was assessed for a minimum of 3&nbsp;years. In
this population, Kaplan-Meier estimates of 1, 2 and 3&nbsp;year survival were
92&nbsp;%, 81&nbsp;% and 74&nbsp;%, respectively.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Efficacy and safety in adult patients
with PAH (when used in combination with bosentan)</span></u></p>

<p class=MsoNormal><span lang=EN-GB>A randomized, double-blind, placebo
controlled study was conducted in 103 clinically stable subjects with PAH (WHO
FC II and III) who were on bosentan therapy for a minimum of three months. The
PAH patients included those with Primary PAH, and PAH associated with</span><span
lang=EN-GB> connective tissue disease</span><span lang=EN-GB>. Patients were
randomized to placebo or sildenafil (20 mg</span> three times a day<span
lang=EN-GB>) in combination with bosentan (62.5&#8209;125&nbsp;mg</span> twice
a day<span lang=EN-GB>). The primary efficacy endpoint was the change from
baseline at Week 12 in 6</span>MWD<span lang=EN-GB>. The results indicate that
there is no significant difference in mean change from baseline on 6MWD
observed between sildenafil (20 mg three times a day) and placebo (</span>13.62&nbsp;m
(95% CI: -3.89 to 31.12) and 14.08&nbsp;m (95% CI: -1.78 to 29.95), respectively<span
lang=EN-GB>).</span></p>

<p class=MsoNormal><span style='background:yellow'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Differences in 6MWD were observed between
patients with primary PAH and PAH associated with</span><span lang=EN-GB> connective
tissue disease</span><span lang=EN-GB>. For subjects with primary PAH (67
subjects), mean changes from baseline were 26.39 m (95% CI: 10.70 to 42.08) and
11.84 m (95% CI: -8.83 to 32.52) for the sildenafil and placebo groups,
respectively. However, for subjects with PAH associated with </span><span
lang=EN-GB>connective tissue disease</span><span lang=EN-GB> (36 subjects) mean
changes from baseline were -18.32 m (95% CI: -65.66 to 29.02) and 17.50&nbsp;m (95%
CI: -9.41 to 44.41) for the sildenafil and placebo groups, respectively.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Overall, the adverse events were generally
similar between the two treatment groups (sildenafil plus bosentan vs. bosentan
alone), and consistent with the known safety profile of sildenafil when used as
monotherapy (see sections 4.4 and 4.5).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Paediatric population</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>Persistent pulmonary hypertension of the
newborn</span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>A randomized, double-blind, two-arm,
parallel-group, placebo-controlled study was conducted in 59&nbsp;neonates with
persistent pulmonary hypertension of the newborn (PPHN), or hypoxic respiratory
failure (HRF) and at risk for PPHN with oxygenation index (OI) &gt;15 and
&lt;60. The primary objective was to evaluate the efficacy and safety of IV
sildenafil when added to inhaled nitric oxide (iNO) compared with iNO alone.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The co-primary endpoints were treatment
failure rate, defined as need for additional treatment targeting PPHN, need for
</span><span lang=EN-GB>extracorporeal membrane oxygenation (</span><span
lang=EN-GB>ECMO), or death during the study; and time on iNO treatment after
initiation of IV study drug for patients without treatment failure. The
difference in </span><span lang=EN-GB>treatment failure rates was not
statistically significant between the two treatment groups (27.6% and 20.0% in
the iNO + IV sildenafil group and iNO + placebo group, respectively). For
patients without treatment failure, the mean time on iNO treatment </span><span
lang=EN-GB>after initiation of IV study drug </span><span lang=EN-GB>was the
same, approximately 4.1&nbsp;days, for the two&nbsp;treatment groups.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Treatment-emergent adverse events and
serious adverse events were reported in 22&nbsp;(75.9%) and 7&nbsp;(24.1%)
subjects in the iNO + IV sildenafil treatment group, respectively, and in 19
(63.3%) and 2&nbsp;(6.7%) subjects in the iNO + placebo group, respectively.
The most commonly reported treatment&#8209;emergent adverse events were
hypotension (8 [27.6%] subjects), hypokalaemia (7 [24.1%] subjects), anaemia
and drug withdrawal syndrome (4 [13.8%] subjects each) and bradycardia (3&nbsp;[10.3%]
subjects) in the iNO + IV sildenafil treatment group and pneumothorax (4
[13.3%] subjects), anaemia, oedema, hyperbilirubinaemia, C-reactive protein
increased, and hypotension (3&nbsp;[10.0%] subjects each) in the iNO + placebo
treatment group (see section 4.2).</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=NormalBold style='text-align:justify'><span style='font-size:11.0pt'>5.2&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt'>Pharmacokinetic properties</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span class=SmPCsubheading><u><span
lang=EN-GB style='font-weight:normal'>Absorption</span></u></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The mean
absolute oral bioavailability for sildenafil is 41&nbsp;% (range 25&#8209;63&nbsp;%).
In study A1481262 </span><span lang=EN-GB>C</span><sub><span lang=EN-GB>max</span></sub><span
lang=EN-GB>, CL and AUC (0-8) </span><span lang=EN-GB>of 248&nbsp;ng/ml,
30.3&nbsp;l/h and 330&nbsp;ng h/ml, were observed respectively. The C<sub>max</sub>
and AUC </span><span lang=EN-GB>(0-8) </span><span lang=EN-GB>of the
N-desmethyl metabolite were 30.8&nbsp;ng/ml and 147&nbsp;ng h/ml, respectively.</span></p>

<p class=MsoNormal style='line-height:normal'><span class=SmPCsubheading><span
lang=EN-GB>&nbsp;</span></span></p>

<p class=MsoNormal style='line-height:normal'><span class=SmPCsubheading><u><span
lang=EN-GB style='font-weight:normal'>Distribution</span></u></span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The mean steady state volume of distribution (Vss) for sildenafil is
105&nbsp;l, indicating distribution into the tissues. After oral doses of
20&nbsp;mg three times a day, the mean maximum total plasma concentration of
sildenafil at steady state is approximately 113&nbsp;ng/ml. Sildenafil and its
major circulating N-desmethyl metabolite are approximately 96&nbsp;% bound to
plasma proteins. Protein binding is independent of total drug concentrations.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
class=SmPCsubheading><u><span lang=EN-GB style='font-weight:normal'>Biotransformation</span></u></span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Sildenafil is cleared predominantly by the CYP3A4 (major route) and
CYP2C9 (minor route) hepatic microsomal isoenzymes. The major circulating
metabolite results from N-demethylation of sildenafil. This metabolite has a
phosphodiesterase selectivity profile similar to sildenafil and an <i>in vitro</i>
potency for PDE5 approximately 50&nbsp;% that of the parent drug. The
N-desmethyl metabolite is further metabolised, with a terminal half-life of
approximately 4&nbsp;h. </span>In patients with pulmonary arterial
hypertension, plasma concentrations of <span lang=EN-GB>N-desmethyl metabolite</span>
are approximately 72&nbsp;% those of sildenafil after 20&nbsp;mg three times a
day oral dosing (translating into a 36&nbsp;% contribution to
sildenafil&#8217;s pharmacological effects). The subsequent effect on efficacy
is unknown. <span lang=EN-GB>In healthy volunteers, the plasma levels of the
N-desmethyl metabolite following intravenous dosing are significantly lower
than those observed following oral dosing</span><span lang=EN-GB>. At steady
state plasma concentrations of N-desmethyl metabolite are approximately 16&nbsp;%
versus 61&nbsp;% those of sildenafil after IV and oral dosing, respectively.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span class=SmPCsubheading><u><span
lang=EN-GB style='font-weight:normal'>Elimination</span></u></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The total body
clearance of sildenafil is 41&nbsp;l/h with a resultant terminal phase
half-life of 3-5&nbsp;h. After either oral or intravenous administration,
sildenafil is excreted as metabolites predominantly in the faeces
(approximately 80&nbsp;% of administered oral dose) and to a lesser extent in
the urine (approximately 13&nbsp;% of administered oral dose).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
class=SmPCsubheading><u><span lang=EN-GB style='font-weight:normal'>Pharmacokinetics
in special patient groups</span></u></span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
class=SmPCsubheading><u><span lang=EN-GB style='font-weight:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Elderly</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Healthy elderly volunteers (65&nbsp;years or over) had a reduced
clearance of sildenafil, resulting in approximately 90&nbsp;% higher plasma
concentrations of sildenafil and the active N-desmethyl metabolite compared to
those seen in healthy younger volunteers (18-45&nbsp;years). Due to
age-differences in plasma protein binding, the corresponding increase in free
sildenafil plasma concentration was approximately 40&nbsp;%.</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Renal
insufficiency</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In volunteers
with mild to moderate renal impairment (creatinine clearance
=&nbsp;30-80&nbsp;ml/min), the pharmacokinetics of sildenafil were not altered
after receiving a 50&nbsp;mg single oral dose. In volunteers with severe renal
impairment (creatinine clearance &lt;&nbsp;30&nbsp;ml/min), sildenafil
clearance was reduced, resulting in mean increases in AUC and C<sub>max</sub>
of 100&nbsp;% and 88&nbsp;% respectively compared to age&#8209;matched
volunteers with no renal impairment. In addition, N-desmethyl metabolite AUC
and C<sub>max</sub> values were significantly increased by 200&nbsp;% and 79&nbsp;%
respectively in subjects with severe renal impairment compared to subjects with
normal renal function.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Hepatic insufficiency</span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>In volunteers with mild to moderate hepatic cirrhosis (Child-Pugh
class A and B) sildenafil clearance was reduced, resulting in increases in AUC
(85&nbsp;%) and C<sub>max</sub> (47&nbsp;%) compared to age-matched volunteers
with no hepatic impairment. In addition, N-desmethyl metabolite AUC and C<sub>max</sub>
values were significantly increased by 154&nbsp;% and 87&nbsp;%, respectively
in cirrhotic subjects compared to subjects with normal hepatic function. The
pharmacokinetics of sildenafil in patients with severely impaired hepatic
function have not been studied.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Population
pharmacokinetics</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In patients with
pulmonary arterial hypertension, the average steady state concentrations were
20&#8209;50&nbsp;% higher over the investigated oral dose range of
20&#8211;80&nbsp;mg three times a day compared to healthy volunteers. There was
a doubling of the C<sub>min</sub> compared to healthy volunteers. Both findings
suggest a lower clearance and/or a higher oral bioavailability of sildenafil in
patients with pulmonary arterial hypertension compared to healthy volunteers.</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
-28.35pt;line-height:normal'><b><span lang=EN-GB>5.3&nbsp;&nbsp;&nbsp;&nbsp; Preclinical
safety data</span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Non-clinical data revealed no special hazard for humans based on
conventional studies of safety pharmacology, repeated dose toxicity,
genotoxicity and carcinogenic potential, toxicity to reproduction and
development.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In pups of rats which were pre- and postnatally treated with
60&nbsp;mg/kg sildenafil, a decreased litter size, a lower pup weight on day 1
and a decreased 4-day survival were seen at exposures which were approximately
fifty times the expected human intravenous exposure at 10&nbsp;mg three times a
day. Effects in non-clinical studies were observed at exposures considered
sufficiently in excess of the maximum human exposure indicating little
relevance to clinical use.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>There were no
adverse reactions, with possible relevance to clinical use, seen in animals at
clinically relevant exposure levels which were not also observed in clinical
studies.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
-28.35pt;line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
PARTICULARS</span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.5pt;text-align:justify;text-indent:
-28.5pt;line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>6.1<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>List of excipients</span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Glucose</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Water for injections</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.2&nbsp;&nbsp;&nbsp;&nbsp; Incompatibilities</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>This medicinal product must not be mixed with other medicinal
products or intravenous diluents except those mentioned in section 6.6.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.3&nbsp;&nbsp;&nbsp;&nbsp; Shelf life</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>3&nbsp;years.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>6.4&nbsp;&nbsp;&nbsp; Special
precautions for storage</span></b></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This medicinal
product does not require any special storage conditions.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.5&nbsp;&nbsp;&nbsp;&nbsp; Nature and contents of
container</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Each pack contains one 20&nbsp;ml clear, type I glass vial with a
chlorobutyl rubber stopper and an aluminium overseal.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.6&nbsp;&nbsp;&nbsp;&nbsp; 
Special precautions for disposal and other handling </span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>This medicinal product does not require dilution or
reconstitution before use.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>One 20&nbsp;ml vial contains 10&nbsp;mg of sildenafil (as citrate).
The recommended dose of 10&nbsp;mg requires a volume of 12.5&nbsp;ml, to be
administered as an intravenous bolus injection.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Chemical and physical compatibility has been demonstrated with the
following diluents:</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>5&nbsp;% glucose solution</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>sodium chloride 9&nbsp;mg/ml (0.9&nbsp;%) solution</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Lactated Ringer&#8217;s solution</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>5&nbsp;% glucose/0.45&nbsp;% sodium chloride solution</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>5&nbsp;% glucose/lactated Ringer&#8217;s solution</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>5&nbsp;% glucose/20&nbsp;mEq potassium chloride solution</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Any unused medicinal product or waste material should be disposed of
in accordance with local requirements.</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
-28.35pt;line-height:normal'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pfizer Europe MA
EEIG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Boulevard de la
Plaine 17</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1050 Bruxelles</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Belgium</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
-28.35pt;line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S) </span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
-28.35pt;line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>EU/1/05/318/002</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
-28.35pt;line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DATE
OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Date of first authorisation: 28 October 2005</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Date of latest renewal: 23 September 2010</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
-28.35pt;line-height:normal'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; DATE
OF REVISION OF THE TEXT</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
-28.35pt;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>Detailed
information on this product is available on the website of the European
Medicines Agency <a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>1</span></b><span lang=EN-GB>. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span
lang=EN-GB>NAME OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Revatio 10&nbsp;mg/ml
powder for oral suspension</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; QUALITATIVE
AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>After
reconstitution, each ml of the oral suspension contains 10&nbsp;mg of sildenafil
(as citrate)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>One bottle of
reconstituted oral suspension (112&nbsp;ml) contains 1.12&nbsp;g of sildenafil
(as citrate)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Excipient(s)
with known effect</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each ml of oral
suspension contains 250&nbsp;mg sorbitol.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For the full
list of excipients, see section 6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
<span style='text-transform:uppercase'>form</span></span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder for oral suspension.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>White to
off-white powder.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB style='text-transform:uppercase'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clinical
particulars</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.1&nbsp;&nbsp;&nbsp;&nbsp; Therapeutic indications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Adults</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Treatment of adult patients with pulmonary
arterial hypertension classified as WHO functional class II and III, to improve
exercise capacity. Efficacy has been shown in primary pulmonary hypertension
and pulmonary hypertension associated with connective tissue disease.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><u><span lang=EN-GB>Paediatric
population</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Treatment of paediatric patients aged 1&nbsp;year
to 17&nbsp;years old with pulmonary arterial hypertension. Efficacy in terms of
improvement of exercise capacity or pulmonary haemodynamics has been shown in
primary pulmonary hypertension and pulmonary hypertension associated with
congenital heart disease (see section 5.1).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.5pt;text-indent:-28.5pt;line-height:
normal'><b><span lang=EN-GB>4.2<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>Posology and method of administration</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Treatment should
only be initiated and monitored by a physician experienced in the treatment of
pulmonary arterial hypertension. In case of clinical deterioration in spite of
Revatio treatment, alternative therapies should be considered.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span class=SmPCsubheading><i><u><span
lang=EN-GB style='font-weight:normal'>Adults</span></u></i></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The recommended
dose is 20&nbsp;mg three times a day (TID). Physicians should advise patients
who forget to take Revatio to take a dose as soon as possible and then continue
with the normal dose. Patients should not take a double dose to compensate for
the missed dose.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Paediatric
population (1 year to 17 years)</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB>For paediatric patients aged 1&nbsp;year to
17&nbsp;years old, the recommended dose in patients &#8804;&nbsp;20&nbsp;kg is
10&nbsp;mg (1&nbsp;ml of reconstituted suspension) three times a day and for
patients &gt;&nbsp;20 kg is 20&nbsp;mg (2&nbsp;ml of reconstituted suspension)
three times a day. </span><span lang=EN-GB>Higher than recommended doses should
not be used in paediatric patients with PAH (see also sections 4.4 and 5.1). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Patients using other medicinal products</span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>In
general, any dose adjustment should be administered only after a careful
benefit-risk assessment. A downward dose adjustment to 20&nbsp;mg twice daily
should be considered when sildenafil is co&#8209;administered to patients
already receiving CYP3A4 inhibitors like erythromycin or saquinavir. A downward
dose adjustment to 20&nbsp;mg once daily is recommended in case of co&#8209;administration
with more potent CYP3A4 inhibitors <span lang=EN-GB>clarithromycin,
telithromycin and nefazodone</span>. <span lang=EN-GB>For the use of sildenafil
with the most potent CYP3A4 inhibitors, see section 4.3. </span>Dose adjustments
for sildenafil may be required when co-administered with CYP3A4 inducers (see
section 4.5).</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
class=SmPCsubheading><u><span lang=EN-GB style='font-weight:normal'>Special
populations</span></u></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span class=SmPCsubheading><i><u><span
lang=EN-GB style='font-weight:normal'>Elderly (&#8805;&nbsp;65&nbsp;years)</span></u></i></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Dose adjustments
are not required in elderly patients. Clinical efficacy as measured by 6-minute
walk distance could be less in elderly patients.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span class=SmPCsubheading><i><u><span
lang=EN-GB style='font-weight:normal'>Renal impairment</span></u></i></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Initial dose
adjustments are not required in patients with renal impairment, including
severe renal impairment (creatinine clearance &lt;&nbsp;30&nbsp;ml/min<i>).</i>
A downward dose adjustment to 20&nbsp;mg twice daily should be considered after
a careful benefit-risk assessment only if therapy is not well-tolerated.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span class=SmPCsubheading><i><u><span
lang=EN-GB style='font-weight:normal'>Hepatic impairment</span></u></i></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Initial dose
adjustments are not required in patients with hepatic impairment (Child-Pugh
class A and B). A downward dose adjustment to 20&nbsp;mg twice daily should be
considered after a careful benefit&#8209;risk assessment only if therapy is not
well-tolerated.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Revatio is
contraindicated in patients with severe hepatic impairment (Child-Pugh class
C), (see section 4.3).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span class=SmPCsubheading><i><u><span
lang=EN-GB style='font-weight:normal'>Paediatric population (children less than
1 year and neonates) </span></u></i></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Outside its
authorised indications, sildenafil should not be used in neonates with persistent
pulmonary hypertension of the newborn as risks outweigh the benefits (see
section 5.1). The safety and efficacy of Revatio in other conditions in
children below 1&nbsp;year of age has not been established. No data are
available.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Discontinuation
of treatment</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Limited data
suggest that the abrupt discontinuation of Revatio is not associated with
rebound worsening of pulmonary arterial hypertension. However to avoid the
possible occurrence of sudden clinical deterioration during withdrawal, a
gradual dose reduction should be considered. Intensified monitoring is
recommended during the discontinuation period.</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='text-align:justify'><u><span lang=EN-GB>Method of
administration</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Revatio powder for oral suspension is for
oral use only. The reconstituted oral suspension (a white, grape flavoured oral
suspension) should be taken approximately 6 to 8&nbsp;hours apart with or
without food.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Before withdrawing the required dose, shake
the bottle vigorously for a minimum of 10&nbsp;seconds.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span
lang=EN-GB>For instructions on reconstitution of the medicinal product before
administration, see section 6.6.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.3&nbsp;&nbsp;&nbsp;&nbsp; Contraindications</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Hypersensitivity to the active substance or to any of the excipients
listed in section 6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Co-administration
with nitric oxide donors (such as amyl nitrite) or nitrates in any form due to
the hypotensive effects of nitrates (see section 5.1).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The
co-administration of PDE5 inhibitors, including sildenafil, with guanylate
cyclase stimulators, such as riociguat, is contraindicated as it may
potentially lead to symptomatic hypotension (see section 4.5).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Combination with
the most potent of the CYP3A4 inhibitors (eg, ketoconazole, itraconazole,
ritonavir) (see section 4.5).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>Patients who have loss of vision in one eye because of <span
lang=EN-GB>non-arteritic anterior ischaemic optic neuropathy (NAION),</span>
regardless of whether this episode was in connection or not with previous PDE5
inhibitor exposure (see section 4.4).</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>The safety of sildenafil has not
been studied in the following sub-groups of patients and its use is therefore
contraindicated:</p>

<p class=MsoNormal style='line-height:normal'>Severe hepatic impairment,</p>

<p class=MsoNormal style='line-height:normal'>Recent history of stroke or
myocardial infarction,</p>

<p class=MsoNormal style='line-height:normal'>Severe hypotension (blood
pressure &lt;&nbsp;90/50&nbsp;mmHg) at initiation.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.5pt;text-indent:-28.5pt;line-height:
normal'><b><span lang=EN-GB>4.4<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>Special warnings and precautions for use</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The efficacy of
Revatio has not been established in patients with severe pulmonary arterial
hypertension (functional class IV). If the clinical situation deteriorates,
therapies that are recommended at the severe stage of the disease (eg,
epoprostenol) should be considered (see section 4.2). The benefit-risk balance
of sildenafil has not been established in patients assessed to be at WHO
functional class I pulmonary arterial hypertension.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Studies with
sildenafil have been performed in forms of pulmonary arterial hypertension
related to primary (idiopathic), connective tissue disease associated or
congenital heart disease associated forms of PAH (see section 5.1). The use of
sildenafil in other forms of PAH is not recommended.</span></p>

<p class=MsoPlainText><span lang=X-NONE style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoPlainText><span lang=X-NONE style='font-size:11.0pt'>In the long
term paediatric extension study, an increase in deaths was observed in patients
administered doses higher than the recommended dose. Therefore, doses higher
than the recommended doses should not be used in paediatric patients with PAH (see
also sections 4.2 and 5.1).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Retinitis
pigmentosa</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The safety of
sildenafil has not been studied in patients with known hereditary degenerative
retinal disorders such as <i>retinitis pigmentosa</i> (a minority of these
patients have genetic disorders of retinal phosphodiesterases) and therefore its
use is not recommended.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Vasodilatory
action</span></u></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>When prescribing
sildenafil</span><span lang=EN-GB>, physicians should carefully consider
whether patients with certain underlying conditions could be adversely affected
by sildenafil&#8217;s mild to moderate vasodilatory </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>effects, for example
patients with hypotension, patients with fluid depletion, severe left
ventricular outflow obstruction or autonomic dysfunction (see section 4.4).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Cardiovascular
risk factors</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In
post-marketing experience with sildenafil for male erectile dysfunction, serious
cardiovascular events, including myocardial infarction, unstable angina, sudden
cardiac death, ventricular arrhythmia, cerebrovascular haemorrhage, transient
ischaemic attack, hypertension and hypotension have been reported in temporal
association with the use of sildenafil. Most, but not all, of these patients
had pre-existing cardiovascular risk factors. Many events were reported to
occur during or shortly after sexual intercourse and a few were reported to
occur shortly after the use of sildenafil without sexual activity. It is not
possible to determine whether these events are related directly to these
factors or to other factors.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-AU
style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-AU style='layout-grid-mode:line'>Priapism</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Sildenafil should be used with caution in patients with anatomical
deformation of the penis (such as angulation, cavernosal fibrosis or
Peyronie&#8217;s disease), or in patients who have conditions which may
predispose them to priapism (such as sickle cell anaemia, multiple myeloma or
leukaemia).</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Prolonged erections and priapism have been reported with sildenafil
in post-marketing experience. In the event of an erection that persists longer
than 4&nbsp;hours, the patient should seek immediate medical assistance. If
priapism is not treated immediately, penile tissue damage and permanent loss of
potency could result (see section 4.8).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-AU
style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Vaso-occlusive
crises in patients with s</span></u><u><span lang=EN-AU style='layout-grid-mode:
line'>ickle cell anaemia</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-AU
style='layout-grid-mode:line'>Sildenafil should not be used in patients with
pulmonary hypertension secondary to sickle cell anaemia. In a clinical study
events of vaso-occlusive crises requiring hospitalisation were reported more
commonly by patients receiving Revatio than those receiving placebo leading to
the premature termination of this study.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-AU style='layout-grid-mode:line'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-AU style='layout-grid-mode:line'>Visual events</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><em><span
lang=EN-GB style='font-style:normal'>Cases of visual defects have been reported
spontaneously in connection with the intake of&nbsp;sildenafil and other PDE5
inhibitors. Cases of non&#8209;arteritic anterior ischaemic optic neuropathy, a
rare condition, have been reported spontaneously and in an observational study
in connection with the intake of&nbsp;sildenafil and other PDE5 inhibitors (see
section 4.8). In the event of any sudden visual defect, the treatment should be
stopped immediately and alternative treatment should be considered (see section
4.3).</span></em></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-AU
style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-AU style='layout-grid-mode:line'>Alpha-blockers</span></u></p>

<p class=MsoBodyText2 style='line-height:normal;page-break-after:avoid'><span
lang=EN-AU style='color:windowtext;layout-grid-mode:line'>Caution is advised
when sildenafil is administered </span><span style='color:windowtext'>to
patients taking an alpha-blocker as the co&#8209;administration may lead to
symptomatic hypotension in susceptible individuals (see section 4.5). </span><span
lang=EN-GB style='color:windowtext'>In order to minimise the potential for
developing postural hypotension, patients should be haemodynamically stable on
alpha-blocker therapy prior to initiating sildenafil treatment. Physicians
should advise patients what to do in the event of postural hypotensive
symptoms. </span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Bleeding disorders</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Studies with human platelets indicate that sildenafil potentiates
the antiaggregatory effect of sodium nitroprusside <i>in vitro</i>. There is no
safety information on the administration of sildenafil to patients with
bleeding disorders or active peptic ulceration. Therefore sildenafil should be
administered to these patients only after careful benefit-risk assessment.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Vitamin K
antagonists</span></u></p>

<p class=MsoNormal style='line-height:normal'>In pulmonary arterial
hypertension patients, there may be a potential for increased risk of bleeding
when sildenafil is initiated in patients already using a Vitamin K antagonist,
particularly in patients with pulmonary arterial hypertension secondary to
connective tissue disease.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Veno-occlusive
disease</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No data are
available with sildenafil in patients with pulmonary hypertension associated
with pulmonary veno-occlusive disease. However, cases of life threatening
pulmonary oedema have been reported with vasodilators (mainly prostacyclin)
when used in those patients. Consequently, should signs of pulmonary oedema
occur when sildenafil is administered in patients with pulmonary hypertension,
the possibility of associated veno-occlusive disease should be considered.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Fructose
intolerance</span></u></p>

<p class=MsoNormal style='line-height:normal'>The powder contains sorbitol. <span
lang=EN-GB>Patients with rare hereditary problems of fructose intolerance
should not take this medicine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in'><u><span lang=EN-GB
style='font-size:11.0pt'>Use of sildenafil with bosentan</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The efficacy of
sildenafil in patients already on bosentan therapy has not been conclusively
demonstrated (see sections 4.5 and 5.1).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoCommentText><u><span lang=X-NONE style='font-size:11.0pt'>Concomitant
use with other PDE5 inhibitors</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The safety and
efficacy of sildenafil when co-administered with other PDE5 inhibitor products,
including Viagra, has not been studied in PAH patients and</span><span
lang=EN-GB> such concomitant use is not recommended (see section 4.5).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=NormalBold><span style='font-size:11.0pt'>4.5&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt'>Interaction with other medicinal products and other
forms of interaction</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span class=SmPCsubheading><u><span lang=EN-GB
style='font-weight:normal'>Effects of other medicinal products on sildenafil</span></u></span></p>

<p class=MsoNormal><span class=SmPCsubheading><i><u><span lang=EN-GB
style='font-weight:normal'><span style='text-decoration:none'>&nbsp;</span></span></u></i></span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=IT>In vitro
studies</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sildenafil
metabolism is principally mediated by the cytochrome P450 (CYP) isoforms 3A4
(major route) and 2C9 (minor route). Therefore, inhibitors of these isoenzymes
may reduce sildenafil clearance and inducers of these isoenzymes may increase
sildenafil clearance. For dose recommendations, see sections 4.2 and 4.3.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=NL>In vivo studies<b> </b></span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Co-administration
of oral sildenafil and intravenous epoprostenol has been evaluated (see
sections 4.8 and 5.1).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The efficacy and safety of sildenafil
co-administered with other treatments for pulmonary arterial hypertension (eg, ambrisentan,
iloprost) has not been studied in controlled clinical trials. Therefore,
caution is recommended in case of co-administration.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>The safety and efficacy of sildenafil when co-administered
with other PDE5 inhibitors has not been studied in pulmonary arterial
hypertension patients (see section 4.4).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Population
pharmacokinetic analysis of pulmonary arterial hypertension clinical trial data
indicated a reduction in sildenafil clearance and/or an increase of oral bioavailability
when co-administered with CYP3A4 substrates and the combination of CYP3A4
substrates and beta-blockers. These were the only factors with a statistically
significant impact on sildenafil pharmacokinetics in patients with pulmonary
arterial hypertension. The exposure to sildenafil in patients on CYP3A4
substrates and CYP3A4 substrates plus beta-blockers was 43&nbsp;% and 66&nbsp;%
higher, respectively, compared to patients not receiving these classes of
medicines. Sildenafil exposure was 5&#8209;fold higher at a dose of 80&nbsp;mg
three times a day compared to the exposure at a dose of 20&nbsp;mg three times
a day. This concentration range covers the increase in sildenafil exposure
observed in specifically designed drug interaction studies with CYP3A4
inhibitors (except with the most potent of the CYP3A4 inhibitors eg,
ketoconazole, itraconazole, ritonavir).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>CYP3A4 inducers
seemed to have a substantial impact on the pharmacokinetics of sildenafil in
pulmonary arterial hypertension patients, which was confirmed in the <i>in-vivo</i>
interaction study with CYP3A4 inducer bosentan.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Co-administration
of bosentan (a moderate inducer of CYP3A4, CYP2C9 and possibly of CYP2C19)
125&nbsp;mg twice daily with sildenafil 80&nbsp;mg three times a day (at steady
state) concomitantly administered during 6&nbsp;days in healthy volunteers
resulted in a 63&nbsp;% decrease of sildenafil AUC. </span><span lang=EN-GB>A
population pharmacokinetic analysis of sildenafil data from adult PAH patients
in clinical trials including a 12 week study to assess the efficacy and safety
of oral sildenafil 20 mg three times a day when added to a stable dose of
bosentan (62.5 mg &#8211; 125 mg twice a day) indicated a decrease in
sildenafil exposure with bosentan co-administration, similar to that observed
in healthy volunteers (see sections 4.4 and 5.1).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Efficacy of sildenafil
should be closely monitored in patients using concomitant potent CYP3A4
inducers, such as carbamazepine, phenytoin, phenobarbital, St John&#8217;s wort
and rifampicine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Co-administration
of the HIV protease inhibitor ritonavir, which is a highly potent P450
inhibitor, at steady state (500&nbsp;mg twice daily) with sildenafil
(100&nbsp;mg single dose) resulted in a 300&nbsp;% (4&#8209;fold) increase in
sildenafil C<sub>max</sub> and a 1,000&nbsp;% (11&#8209;fold) increase in
sildenafil plasma AUC. At 24 hours, the plasma levels of sildenafil were still
approximately 200&nbsp;ng/ml, compared to approximately 5&nbsp;ng/ml when
sildenafil was administered alone. This is consistent with ritonavir&#8217;s
marked effects on a broad range of P450 substrates. Based on these
pharmacokinetic results co-administration of sildenafil with ritonavir is
contraindicated in pulmonary arterial hypertension patients (see section 4.3).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Co-administration
of the HIV protease inhibitor saquinavir, a CYP3A4 inhibitor, at steady state
(1200&nbsp;mg three times a day) with sildenafil (100&nbsp;mg single dose)
resulted in a 140&nbsp;% increase in sildenafil C<sub>max</sub> and a 210&nbsp;%
increase in sildenafil AUC. Sildenafil had no effect on saquinavir
pharmacokinetics. For dose recommendations, see section 4.2.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>When a single
100&nbsp;mg dose of sildenafil was administered with erythromycin, a moderate
CYP3A4 inhibitor, at steady state (500&nbsp;mg twice daily for 5&nbsp;days),
there was a 182&nbsp;% increase in sildenafil systemic exposure (AUC). For dose
recommendations, see section 4.2. In healthy male volunteers, there was no
evidence of an effect of azithromycin (500&nbsp;mg daily for 3&nbsp;days) on
the AUC, C<sub>max</sub>, T<sub>max</sub>, elimination rate constant, or
subsequent half-life of sildenafil or its principal circulating metabolite. No
dose adjustment is required. Cimetidine (800&nbsp;mg), a cytochrome P450
inhibitor and a non-specific CYP3A4 inhibitor, caused a 56&nbsp;% increase in
plasma sildenafil concentrations when co&#8209;administered with sildenafil
(50&nbsp;mg) to healthy volunteers. No dose adjustment is required.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>The most potent of the CYP3A4
inhibitors such as ketoconazole and itraconazole would be expected to have
effects similar to ritonavir (see section 4.3). CYP3A4 inhibitors like<span
lang=EN-GB> clarithromycin, telithromycin and nefazodone are expected to have
an effect in between that of ritonavir and CYP3A4 inhibitors like saquinavir or
erythromycin, a seven-fold increase in exposure is assumed. Therefore dose
adjustments are recommended when using CYP3A4 inhibitors (see section 4.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The population
pharmacokinetic analysis in pulmonary arterial hypertension patients suggested
that co-administration of beta-blockers in combination with CYP3A4 substrates
might result in an additional increase in sildenafil exposure compared with
administration of CYP3A4 substrates alone.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Grapefruit juice
is a weak inhibitor of CYP3A4 gut wall metabolism and may give rise to modest
increases in plasma levels of sildenafil. No dose adjustment is required but
the concomitant use of sildenafil and grapefruit juice is not recommended. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Single doses of
antacid (magnesium hydroxide/aluminium hydroxide) did not affect the
bioavailability of sildenafil.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Co-administration
of oral contraceptives (ethinyloestradiol 30&nbsp;</span><span lang=EN-GB
style='font-family:Symbol'>m</span><span lang=EN-GB>g and levonorgestrel 150&nbsp;</span><span
lang=EN-GB style='font-family:Symbol'>m</span><span lang=EN-GB>g) did not
affect the pharmacokinetics of sildenafil.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Nicorandil is a
hybrid of potassium channel activator and nitrate. Due to the nitrate component
it has the potential to have serious interaction with sildenafil (see section
4.3).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span class=SmPCsubheading><u><span
lang=EN-GB style='font-weight:normal'>Effects of sildenafil on other medicinal
products</span></u></span></p>

<p class=MsoNormal style='page-break-after:avoid'><span class=SmPCsubheading><i><u><span
lang=EN-GB style='font-weight:normal'><span style='text-decoration:none'>&nbsp;</span></span></u></i></span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=IT>In vitro
studies</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sildenafil is a
weak inhibitor of the cytochrome P450 isoforms 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4
(IC<sub>50</sub>&nbsp;&gt;&nbsp;150&nbsp;</span><span lang=EN-GB
style='font-family:Symbol'>m</span><span lang=EN-GB>M).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>There are no data on the
interaction of sildenafil and non-specific phosphodiesterase inhibitors such as
theophylline or dipyridamole.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=NL>In vivo studies</span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>No significant interactions were shown when sildenafil (50&nbsp;mg)
was co-administered with tolbutamide (250&nbsp;mg) or warfarin (40&nbsp;mg),
both of which are metabolised by CYP2C9.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sildenafil had
no significant effect on atorvastatin exposure (AUC increased 11&nbsp;%),
suggesting that sildenafil does not have a clinically relevant effect on
CYP3A4.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No interactions
were observed between sildenafil (100&nbsp;mg single dose) and acenocoumarol. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sildenafil
(50&nbsp;mg) did not potentiate the increase in bleeding time caused by acetyl
salicylic acid (150&nbsp;mg).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sildenafil (50&nbsp;mg)
did not potentiate the hypotensive effects of alcohol in healthy volunteers
with mean maximum blood alcohol levels of 80&nbsp;mg/dl.</span></p>

<p class=MsoNormal style='line-height:normal'><s><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></s></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In a study of
healthy volunteers sildenafil at steady state (80&nbsp;mg three times a day)
resulted in a 50&nbsp;% increase in bosentan AUC (125&nbsp;mg twice daily). </span><span
lang=EN-GB>A population pharmacokinetic analysis of data from a study of adult PAH
patients on background bosentan therapy (62.5 mg - 125&nbsp;mg twice a day)
indicated an increase (20% (95% CI: 9.8 - 30.8)) of bosentan AUC with
co-administration of steady&#8209;state sildenafil (20&nbsp;mg three times a
day) of a smaller magnitude than seen in healthy volunteers when
co-administered with 80 mg sildenafil three times a day (see sections 4.4 and
5.1).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In a specific
interaction study, where sildenafil (100&nbsp;mg) was co-administered with
amlodipine in hypertensive patients, there was an additional reduction on
supine systolic blood pressure of 8&nbsp;mmHg. The corresponding additional
reduction in supine diastolic blood pressure was 7&nbsp;mmHg. These additional
blood pressure reductions were of a similar magnitude to those seen when
sildenafil was administered alone to healthy volunteers.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>In three
specific drug-drug interaction studies, the alpha-blocker doxazosin (4&nbsp;mg
and 8&nbsp;mg) and sildenafil (25&nbsp;mg, 50&nbsp;mg, or 100&nbsp;mg) were
administered simultaneously to patients with benign prostatic hyperplasia (BPH)
stabilized on doxazosin therapy. In these study populations, mean additional
reductions of supine systolic and diastolic blood pressure of 7/7&nbsp;mmHg,
9/5&nbsp;mmHg, and 8/4&nbsp;mmHg, respectively, and mean additional reductions
of standing blood pressure of 6/6&nbsp;mmHg, 11/4&nbsp;mmHg, and 4/5&nbsp;mmHg,
respectively were observed. When sildenafil and doxazosin were administered
simultaneously to patients stabilized on doxazosin therapy, there were
infrequent reports of patients who experienced symptomatic postural
hypotension. These reports included dizziness and lightheadedness, but not
syncope. Concomitant administration of sildenafil to patients taking alpha&#8209;blocker
therapy may lead to symptomatic hypotension in susceptible individuals (see
section 4.4).</p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sildenafil (100&nbsp;mg
single dose) did not affect the steady state pharmacokinetics of the HIV
protease inhibitor saquinavir, which is a CYP3A4 substrate/inhibitor.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Consistent with
its known effects on the nitric oxide/cGMP pathway (see section 5.1),
sildenafil was shown to potentiate the hypotensive effects of nitrates, and its
co-administration with nitric oxide donors or nitrates in any form is therefore
contraindicated (see section 4.3).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Riociguat: Preclinical studies showed additive systemic blood
pressure lowering effect when PDE5 inhibitors were combined with riociguat. In
clinical studies, riociguat has been shown to augment the hypotensive effects
of PDE5 inhibitors. There was no evidence of favourable clinical effect of the
combination in the population studied. Concomitant use of riociguat with PDE5
inhibitors, including sildenafil, is contraindicated (see section 4.3).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Sildenafil had no clinically significant
impact on the plasma levels of oral contraceptives (ethinyloestradiol 30&nbsp;</span><span
lang=EN-GB style='font-family:Symbol'>m</span><span lang=EN-GB>g and
levonorgestrel 150&nbsp;</span><span lang=EN-GB style='font-family:Symbol'>m</span><span
lang=EN-GB>g).</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'><u><span
lang=EN-GB>Paediatric population</span></u></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>Interaction
studies have only been performed in adults.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.6&nbsp;&nbsp;&nbsp;&nbsp; Fertility,
pregnancy and lactation</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'><u><span
lang=EN-GB>Women of childbearing potential and contraception in males and
females</span></u></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>Due to lack of
data on effects of Revatio in pregnant women, Revatio is not recommended for
women of childbearing potential unless also using appropriate contraceptive
measures.</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There are no
data from the use of sildenafil in pregnant women. Animal studies do not
indicate direct or indirect harmful effects with respect to pregnancy and
embryonal/foetal development. Studies in animals have shown toxicity with
respect to postnatal development (see section 5.3).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Due to lack of
data, Revatio should not be used in pregnant women unless strictly necessary.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Breast-feeding</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>There are no adequate and well controlled studies in
lactating women. Data from one lactating woman indicate that sildenafil and its
active metabolite N-desmethylsildenafil are excreted into breast milk at very
low levels. No clinical data are available regarding adverse events in
breast-fed infants, but amounts ingested would not be expected to cause any
adverse effects. Prescribers should carefully assess the mother&#8217;s clinical
need for sildenafil and any potential adverse effects on the breast&#8209;fed
child.</span></p>

<p class=MsoNormal style='text-align:justify'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='text-align:justify'><u><span lang=EN-GB>Fertility</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Non-clinical data revealed no special
hazard for humans based on conventional studies of fertility (see section 5.3).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.7&nbsp;&nbsp;&nbsp;&nbsp; Effects on ability to
drive and use machines</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Revatio has moderate influence on the
ability to drive and use machines.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>As dizziness
and altered vision were reported in clinical trials with sildenafil, patients
should be aware of how they might be affected by Revatio, before driving or
using machines.</p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.8&nbsp;&nbsp;&nbsp;&nbsp; Undesirable
effects</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u>Summary of the safety profile</u></p>

<p class=MsoCommentText><span style='font-size:11.0pt'>In the pivotal
placebo-controlled study of Revatio in pulmonary arterial hypertension, a total
of 207&nbsp;patients were randomized to and treated with 20&nbsp;mg, 40&nbsp;mg,
or 80&nbsp;mg TID doses of Revatio and 70&nbsp;patients were randomized to placebo.
The duration of treatment was 12&nbsp;weeks.</span><span lang=X-NONE
style='font-size:11.0pt'> The overall frequency of discontinuation in
sildenafil treated patients at doses of 20&nbsp;mg, 40&nbsp;mg and 80&nbsp;mg
TID was 2.9&nbsp;%, 3.0&nbsp;% and 8.5&nbsp;% respectively, compared to 2.9&nbsp;%
with placebo. Of the</span><span lang=X-NONE style='font-size:11.0pt'> </span><span
style='font-size:11.0pt'>277&nbsp;subjects treated in the pivotal study, 259
entered a long-term extension study. Doses up to 80&nbsp;mg three times a day
(4&nbsp;times the recommended dose of 20&nbsp;mg </span><span lang=X-NONE
style='font-size:11.0pt'>three times a day</span><span style='font-size:11.0pt'>)
were administered and after </span><span lang=X-NONE style='font-size:11.0pt'>3&nbsp;years
87&nbsp;% of 183&nbsp;patients on study treatment were receiving Revatio 80&nbsp;mg
TID.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>

<p class=MsoCommentText><span lang=X-NONE style='font-size:11.0pt'>In a
placebo-controlled study of </span><span lang=X-NONE style='font-size:11.0pt'>Revatio
</span><span lang=X-NONE style='font-size:11.0pt'>as an adjunct to intravenous
epoprostenol in pulmonary arterial hypertension</span><span lang=X-NONE
style='font-size:11.0pt'>, a total of 134&nbsp;patients were treated with
Revatio (</span><span lang=X-NONE style='font-size:11.0pt'>in a fixed titration
starting from 20&nbsp;mg, to 40&nbsp;mg and then 80&nbsp;mg, three times a day
as tolerated) and epoprostenol, and 131&nbsp;patients were treated with placebo
and epoprostenol. The duration of treatment was 16&nbsp;weeks. The overall
frequency of discontinuations in sildenafil/epoprostenol treated patients due
to adverse events was 5.2&nbsp;% compared to 10.7&nbsp;% in the
placebo/epoprostenol treated patients. Newly reported adverse reactions, which
occurred more frequently in the sildenafil/ epoprostenol group, were ocular
hyperaemia, vision blurred, nasal congestion, night sweats, back pain and dry
mouth. The known adverse reactions headache, flushing, pain in extremity and
oedema were noted in a higher frequency in sildenafil/epoprostenol treated
patients compared to placebo/epoprostenol treated patients. Of the subjects who
completed the initial study, 242 entered a long-term extension study. Doses up
to 80&nbsp;mg TID were administered and after 3&nbsp;years 68&nbsp;% of 133&nbsp;patients
on study treatment were receiving Revatio 80&nbsp;mg TID.</span></p>

<p class=Paragraph style='margin-bottom:0in'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>I<span
lang=EN-GB>n the two-placebo controlled studies adverse events were generally
mild to moderate in severity. The most commonly reported adverse reactions that
occurred (greater or equal to 10&nbsp;%) on </span>Revatio<span lang=EN-GB>
compared to placebo were headache, flushing, dyspepsia, diarrhoea and pain in
extremity.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Tabulated list of adverse reactions</span></u></p>

<p class=MsoNormal>Adverse reactions which occurred in &gt;&nbsp;1&nbsp;% of
Revatio-treated patients and were more frequent (&gt;&nbsp;1&nbsp;% difference)
on Revatio in the pivotal study or in the Revatio combined data set of both the
placebo&#8209;controlled studies in pulmonary arterial hypertension,, at doses
of 20, 40 or 80<span lang=EN-GB>&nbsp;</span>mg <span lang=EN-GB>TID</span> are
listed in the table below by class and frequency grouping (very common (<span
style='font-family:Symbol'>&sup3;</span>&nbsp;1/10), common (<span
style='font-family:Symbol'>&sup3;</span>&nbsp;1/100 to &lt;&nbsp;1/10), <span
lang=EN-GB>uncommon (</span><span lang=EN-GB style='font-family:Symbol'>&sup3;</span><span
lang=EN-GB>&nbsp;1/1000 to <u>&lt;&nbsp;</u>1/100) and not known (cannot be
estimated from the available data). </span>Within each frequency grouping,
adverse reactions are presented in order of decreasing seriousness.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Reports from post-marketing experience are included in
italics.</p>

<p class=MsoNormal>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:solid windowtext 1.0pt;
  border-right:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>MedDRA system organ class (V.14.0)</b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b>Adverse reaction</b></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>Infections and infestations</b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Common</p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>cellulitis,
  influenza, bronchitis, sinusitis, rhinitis, gastroenteritis</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>Blood and lymphatic system disorders</b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Common</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=ES>anaemia </span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>Metabolism and nutrition disorders</b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Common</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>fluid
  retention</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>Psychiatric disorders</b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Common</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>insomnia,
  anxiety</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>Nervous system disorders</b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Very common</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>headache </span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Common</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=PT>migraine,
  tremor, paraesthesia, burning sensation, hypoaesthesia</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>Eye disorders</b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Common</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>retinal
  haemorrhage, visual impairment, vision blurred, photophobia, chromatopsia,
  cyanopsia, eye irritation, ocular hyperaemia&nbsp; </span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Uncommon</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>visual
  acuity reduced, diplopia, abnormal sensation in eye </span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Not known</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Non-arteritic
  anterior ischaemic optic neuropathy (NAION)*, Retinal vascular occlusion*,
  Visual field defect*</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>Ear and labyrinth disorders</b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Common</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>vertigo</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Not known</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>sudden hearing
  loss</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>Vascular disorders</b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Very common</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>flushing</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Not known</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>hypotension</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>Respiratory, thoracic and mediastinal disorders</b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Common</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=FR>epistaxis, cough,
  nasal congestion </span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b>Gastrointestinal
  disorders</b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Very common</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>diarrhoea,
  dyspepsia </span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Common</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>gastritis,
  gastrooesophageal reflux disease, haemorrhoids, abdominal distension, dry
  mouth</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b>Skin and subcutaneous
  tissue disorders</b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Common</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>alopecia,
  erythema, night sweats</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Not known</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>rash</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>Musculoskeletal and connective tissue disorders</b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Very common</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>pain in extremity</p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Common</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>myalgia, back pain </p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Renal and urinary disorders</span></b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>haematuria</span></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>Reproductive system and breast disorders </b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Uncommon</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>penile
  haemorrhage, haematospermia, </span>gynaecomastia</p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Not known</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i>priapism, erection
  increased</i></p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>General disorders and administration site conditions</b></p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=319 valign=top style='width:239.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Common</p>
  </td>
  <td width=249 valign=top style='width:186.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>pyrexia</p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span style='font-size:8.0pt'>*These
adverse events/reactions have been reported in patients taking sildenafil for
the treatment of male erectile dysfunction (MED).</span> </p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'><u><span
lang=EN-GB>Paediatric population</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>In the placebo-controlled study of Revatio in patients 1 to 17</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>years of age with pulmonary arterial
hypertension, a total of 174&nbsp;patients were treated three times a day with
either<i> </i>low (10</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>mg
in patients &gt;&nbsp;20&nbsp;kg; no patients&nbsp;&#8804;&nbsp;20</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>kg received the low dose), medium (10</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>mg in patients&nbsp;&#8805;&nbsp;8-20&nbsp;kg;
20</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>mg in patients&nbsp;&#8805;&nbsp;20-45&nbsp;kg;
40&nbsp;mg in patients&nbsp;&gt;&nbsp;45&nbsp;kg) or high dose (20</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>mg in patients &#8805;&nbsp;8-20&nbsp;kg;
40</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>mg in patients&nbsp;&#8805;&nbsp;20-45&nbsp;kg;
80&nbsp;mg in patients&nbsp;&gt;&nbsp;45&nbsp;kg) regimens of Revatio and 60
were treated with placebo.<i>&nbsp; </i></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The adverse
reactions profile seen in this paediatric study was generally consistent with
that in adults (see table above). The most common adverse reactions that
occurred (with a frequency &#8805;&nbsp;1&nbsp;%) in Revatio patients (combined
doses) and with a frequency&nbsp;&gt; 1&nbsp;%&nbsp;over placebo patients were </span><span
lang=EN-GB>pyrexia, upper respiratory tract infection (each 11.5%), vomiting
(10.9%), erection increased (including spontaneous penile erections in male
subjects) (9.0%), nausea, bronchitis (each 4.6%), pharyngitis (4.0%),
rhinorrhoea (3.4%), and pneumonia, rhinitis (each 2.9%).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Of the 234
paediatric subjects treated in the short-term, placebo-controlled study, 220
subjects entered the long-term extension study. Subjects on active sildenafil
therapy continued on the same treatment regimen, while those in the placebo group
in the short-term study were randomly reassigned to sildenafil treatment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The most common
adverse reactions reported across the duration of the short-term and long-term
studies were generally similar to those observed in the short-term study.
Adverse reactions reported in &gt;10% of 229 subjects treated with sildenafil
(combined dose group, including 9 patients that did not continue into the
long-term study) were upper respiratory infection (31%), headache (26%),
vomiting (22%), bronchitis (20%), pharyngitis (18%), pyrexia (17%), diarrhoea
(15%), and influenza, epistaxis (12% each). Most of these adverse reactions
were considered mild to moderate in severity.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>Serious adverse events were
reported in 94 (41%) of the 229 subjects receiving sildenafil. Of the 94
subjects reporting a serious adverse event, 14/55 (25.5%) subjects were in the
low dose group, 35/74 (47.3%) in the medium dose group, and 45/100 (45%) in the
high dose group. The most common serious adverse events that occurred with a
frequency &#8805;&nbsp;1&nbsp;% in sildenafil patients (combined doses) were
pneumonia (7.4%), cardiac failure, pulmonary hypertension (each 5.2%), upper
respiratory tract infection (3.1%), right ventricular failure, gastroenteritis
(each 2.6%), syncope, bronchitis, bronchopneumonia, pulmonary arterial
hypertension (each 2.2%), chest pain, dental caries (each 1.7%), and
cardiogenic shock, gastroenteritis viral, urinary tract infection (each 1.3%).</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The following
serious adverse events were considered to be treatment related, enterocolitis,
convulsion, hypersensitivity, stridor, hypoxia, neurosensory deafness and
ventricular arrhythmia.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB>Reporting of suspected adverse reactions</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Reporting
suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the
medicinal product. Healthcare professionals are asked to report any suspected
adverse reactions via <span style='background:silver'>the national reporting
system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix
V</a></span>.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.9&nbsp;&nbsp;&nbsp;&nbsp; Overdose</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In single dose
volunteer studies of doses up to 800&nbsp;mg, adverse reactions were similar to
those seen at lower doses, but the incidence rates and severities were
increased. At single doses of 200&nbsp;mg the incidence of adverse reactions
(headache, flushing, dizziness, dyspepsia, nasal congestion, and altered
vision) was increased.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In cases of
overdose, standard supportive measures should be adopted as required. Renal
dialysis is not expected to accelerate clearance as sildenafil is highly bound
to plasma proteins and not eliminated in the urine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACOLOGICAL
PROPERTIES</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.1 &nbsp;&nbsp;&nbsp; Pharmacodynamic properties</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pharmacotherapeutic
group: Urologicals, Drugs used in erectile dysfunction, ATC code: G04BE03</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Mechanism of
action</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sildenafil is a
potent and selective inhibitor of cyclic guanosine monophosphate (cGMP)
specific phosphodiesterase type 5 (PDE5), the enzyme that is responsible for
degradation of cGMP. Apart from the presence of this enzyme in the corpus
cavernosum of the penis, PDE5 is also present in the pulmonary vasculature<i>. </i>Sildenafil,
therefore, increases cGMP within pulmonary vascular smooth muscle cells
resulting in relaxation. In patients with pulmonary arterial hypertension this
can lead to vasodilation of the pulmonary vascular bed and, to a lesser degree,
vasodilatation in the systemic circulation.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Pharmacodynamic
effects</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Studies <i>in
vitro</i> have shown that sildenafil is selective for PDE5. Its effect is more
potent on PDE5 than on other known phosphodiesterases. There is a10&#8209;fold
selectivity over PDE6 which is involved in the phototransduction pathway in the
retina. There is an 80-fold selectivity over PDE1, and over 700&#8209;fold over
PDE 2, 3, 4, 7, 8, 9, 10 and 11. In particular, sildenafil has greater than
4,000&#8209;fold selectivity for PDE5 over PDE3, the cAMP-specific
phosphodiesterase isoform involved in the control of cardiac contractility.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sildenafil
causes mild and transient decreases in systemic blood pressure which, in the
majority of cases, do not translate into clinical effects. After chronic dosing
of 80&nbsp;mg three times a day to patients with systemic hypertension the mean
change from baseline in systolic and diastolic blood pressure was a decrease of
9.4&nbsp;mm Hg and 9.1&nbsp;mm Hg respectively. After chronic dosing of 80&nbsp;mg
three times a day to patients with pulmonary arterial hypertension lesser
effects in blood pressure reduction were observed (a reduction in both systolic
and diastolic pressure of 2&nbsp;mm Hg). </span>At the recommended dose of 20&nbsp;mg
three times a day no reductions in systolic or diastolic pressure were seen.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Single oral
doses of sildenafil up to 100&nbsp;mg in healthy volunteers produced no
clinically relevant effects on ECG. After chronic dosing of 80&nbsp;mg three
times a day to patients with pulmonary arterial hypertension no clinically
relevant effects on the ECG were reported.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In a study of
the hemodynamic effects of a single oral 100&nbsp;mg dose of sildenafil in 14&nbsp;patients
with severe coronary artery disease (CAD) (&gt;&nbsp;70&nbsp;% stenosis of at
least one coronary artery), the mean resting systolic and diastolic blood
pressures decreased by 7&nbsp;% and 6&nbsp;% respectively compared to baseline.
Mean pulmonary systolic blood pressure decreased by 9&nbsp;%. Sildenafil showed
no effect on cardiac output, and did not impair blood flow through the stenosed
coronary arteries.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Mild and
transient differences in colour discrimination (blue/green) were detected in
some subjects using the Farnsworth-Munsell 100 hue test at 1 hour following a
100&nbsp;mg dose, with no effects evident after 2&nbsp;hours post-dose. The
postulated mechanism for this change in colour discrimination is related to
inhibition of PDE6, which is involved in the phototransduction cascade of the
retina. Sildenafil has no effect on visual acuity or contrast sensitivity. In a
small size placebo-controlled study of patients with documented early
age-related macular degeneration (n&nbsp;=&nbsp;9), sildenafil (single dose,
100&nbsp;mg) demonstrated no significant changes in visual tests conducted
(visual acuity, Amsler grid, colour discrimination simulated traffic light,
Humphrey perimeter and photostress).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Clinical
efficacy and safety</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Efficacy
in adult patients with pulmonary arterial hypertension (PAH)</span></u></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>A randomised,
double&#8209;blind, placebo&#8209;controlled study was conducted in 278&nbsp;patients
with primary pulmonary hypertension, PAH associated with connective tissue
disease, and PAH following surgical repair of congenital heart lesions.
Patients were randomised to one of four treatment groups: placebo, sildenafil
20&nbsp;mg, sildenafil 40&nbsp;mg or sildenafil 80&nbsp;mg, three times a day.
Of the 278&nbsp;patients randomised, 277&nbsp;patients received at least 1 dose
of study drug. The study population consisted of 68 (25&nbsp;%) men and 209 (75&nbsp;%)
women with a mean age of 49&nbsp;years (range: 18-81&nbsp;years) and baseline 6&#8209;minute
walk test distance between 100 and 450&nbsp;metres inclusive (mean: 344&nbsp;metres).
</span>175&nbsp;patients (63&nbsp;%) included were diagnosed with primary
pulmonary hypertension, 84&nbsp;(30&nbsp;%) were diagnosed with <span
lang=EN-GB>PAH </span>associated with connective tissue disease and 18 (7&nbsp;%)
of the patients were diagnosed with <span lang=EN-GB>PAH </span>following
surgical repair of congenital heart lesions. Most patients were WHO Functional
Class II (107/277, 39&nbsp;%) or III (160/277, 58&nbsp;%) with a mean baseline
6 minute walking distance of 378&nbsp;meters and 326&nbsp;meters respectively;
fewer patients were Class I (1/277, 0.4&nbsp;%) or IV (9/277, 3&nbsp;%) at
baseline.<span lang=EN-GB> Patients with left ventricular ejection fraction
&lt;&nbsp;45&nbsp;% or left ventricular shortening fraction &lt;&nbsp;0.2 were
not studied.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sildenafil (or
placebo) was added to patients&#8217; background therapy which could have
included a combination of anticoagulation, digoxin, calcium channel blockers,
diuretics or oxygen. The use of prostacyclin, prostacyclin analogues and
endothelin receptor antagonists was not permitted as add-on therapy, and
neither was arginine supplementation. Patients who previously failed bosentan
therapy were excluded from the study.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The primary
efficacy endpoint was the change from baseline at week 12 in 6-minute walk
distance </span><span lang=EN-GB>(6MWD)</span><span lang=EN-GB>. A
statistically significant increase in </span><span lang=EN-GB>6MWD</span><span
lang=EN-GB> was observed in all 3&nbsp;sildenafil dose groups compared to those
on placebo. Placebo corrected increases in </span><span lang=EN-GB>6MWD</span><span
lang=EN-GB> were 45&nbsp;metres (p&nbsp;&lt;&nbsp;0.0001), 46&nbsp;metres
(p&nbsp;&lt;&nbsp;0.0001) and 50&nbsp;metres (p&nbsp;&lt;&nbsp;0.0001) for
sildenafil 20&nbsp;mg, 40&nbsp;mg and 80&nbsp;mg TID, respectively. There was
no significant difference in effect between sildenafil doses.</span><span
lang=EN-GB> For patients with a baseline 6MWD &lt;&nbsp;325&nbsp;m improved
efficacy was observed with higher doses (</span><span lang=EN-GB>placebo-corrected
improvements of 58&nbsp;metres, 65&nbsp;metres and 87&nbsp;metres for 20&nbsp;mg,
40&nbsp;mg and 80&nbsp;mg doses TID, respectively).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>When analysed by
WHO functional class, a statistically </span><span lang=EN-GB>significant
increase in 6MWD was observed in the 20&nbsp;mg dose group. For class II and
class III, placebo corrected increases of 49&nbsp;metres (p&nbsp;=&nbsp;0.0007)
and 45&nbsp;metres (p&nbsp;=&nbsp;0.0031) were observed respectively.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The improvement
in </span><span lang=EN-GB>6MWD</span><span lang=EN-GB> was apparent after 4&nbsp;weeks
of treatment and this effect was maintained at weeks 8 and 12. </span><span
lang=EN-GB>Results were generally consistent in subgroups according to
aetiology (primary and connective tissue disease-associated PAH), WHO
functional class, gender, race, location, mean PAP and PVRI.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Patients on all sildenafil doses achieved a statistically
significant reduction in mean pulmonary arterial pressure (mPAP) </span><span
lang=EN-GB>and pulmonary vascular resistance (PVR) </span><span lang=EN-GB>compared
to those on placebo. Placebo-corrected treatment effects</span><span
lang=EN-GB> with mPAP were</span><span lang=EN-GB> &#8209;2.7&nbsp;mmHg
(p&nbsp;=&nbsp;0.04),</span><span lang=EN-GB> &#8209;3.0&nbsp;mm Hg
(p&nbsp;=&nbsp;0.01) and &#8209;5.1&nbsp;mm Hg (p&nbsp;&lt;&nbsp;0.0001)</span><span
lang=EN-GB> for sildenafil 20&nbsp;mg,</span><span lang=EN-GB> 40&nbsp;mg and
80&nbsp;mg</span><span lang=EN-GB> TID respectively. </span><span lang=EN-GB>Placebo&#8209;corrected
treatment effects with PVR were &#8209;178&nbsp;dyne.sec/cm<sup>5</sup>
(p=0.0051), &#8209;195 dyne.sec/cm<sup>5</sup> (p=0.0017) and &#8209;320&nbsp;dyne.sec/cm<sup>5&nbsp;</sup>(p&lt;0.0001)
for sildenafil 20&nbsp;mg, 40&nbsp;mg and 80&nbsp;mg TID, respectively.</span><span
lang=EN-GB>The percent reduction at 12&nbsp;weeks for sildenafil 20&nbsp;mg, 40&nbsp;mg
and 80&nbsp;mg TID in PVR (11.2&nbsp;%, 12.9&nbsp;%, 23.3&nbsp;%) was
proportionally greater than the reduction in systemic vascular resistance (SVR)
(7.2&nbsp;%, 5.9&nbsp;%, 14.4&nbsp;%). </span><span lang=EN-GB>The effect of
sildenafil on mortality is unknown.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>A greater percentage of patients on each of
the sildenafil doses (i.e. 28&nbsp;%, 36&nbsp;% and 42&nbsp;% of subjects who
received sildenafil 20&nbsp;mg, 40&nbsp;mg and 80&nbsp;mg TID doses, respectively)
showed an improvement by at least one WHO functional class at week 12 compared
to placebo (7&nbsp;%). The respective odds ratios were 2.92 (p=0.0087), 4.32 </span><span
lang=EN-GB>(p=0.0004) and 5.75 (p&lt;0.0001)</span><span
class=MsoCommentReference><span lang=EN-GB style='font-size:8.0pt'>.</span></span></p>

<p class=MsoNormal><i><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal><i><u><span lang=EN-GB>Long-term survival data in naive
population</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB>Patients enrolled into the pivotal study
were eligible to enter a long term open label extension study. </span><span
lang=EN-GB>At 3 years 87&nbsp;% of the patients were receiving a dose of 80&nbsp;mg
TID.</span><span lang=EN-GB> A total of 207&nbsp;patients were</span><span
lang=EN-GB> treated with Revatio in the pivotal study, and their long term
survival status was assessed for a minimum of 3&nbsp;years. In this population,
Kaplan-Meier estimates of 1, 2 and 3&nbsp;year survival were 96&nbsp;%, 91&nbsp;%
and 82&nbsp;%, respectively. Survival in patients of WHO functional class II at
baseline at 1, 2 and 3&nbsp;years was 99&nbsp;%, 91&nbsp;%, and 84&nbsp;%
respectively, and for patients of</span> WHO functional class III at baseline
was <span lang=EN-GB>94&nbsp;%, 90&nbsp;%, and 81&nbsp;%, respectively.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><u><span lang=EN-GB>Efficacy in adult patients with PAH
(when used in combination with epoprostenol)</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB>A randomised, double-blind, placebo
controlled study was conducted in 267&nbsp;patients with PAH who were
stabilised on intravenous epoprostenol. The PAH patients included those with
Primary Pulmonary Arterial Hypertension (212/267, 79&nbsp;%) and PAH associated
with connective tissue disease (55/267, 21&nbsp;%).<b> </b>Most patients were
WHO Functional Class II (68/267, 26&nbsp;%) or III (175/267, 66&nbsp;%); fewer
patients were Class I (3/267, 1&nbsp;%) or IV (16/267, 6&nbsp;%) at baseline;
for a few patients (5/267, 2&nbsp;%), the WHO Functional Class was unknown.
Patients were randomised to placebo or sildenafil (in a fixed titration
starting from 20&nbsp;mg, to 40&nbsp;mg and then 80&nbsp;mg, three times a day
as tolerated) when used in combination with intravenous epoprostenol.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in'><span style='font-size:11.0pt'>The
primary efficacy endpoint was the change from baseline at week 16 in 6-minute
walk distance. There was a statistically significant benefit of sildenafil
compared to placebo in 6-minute walk distance. A mean placebo corrected
increase in walk distance of 26&nbsp;metres was observed in favour of
sildenafil (95&nbsp;% CI: 10.8, 41.2) (p&nbsp;=&nbsp;0.0009). </span><span
lang=EN-GB style='font-size:11.0pt'>For patients with a baseline walking
distance &#8805;&nbsp;325&nbsp;metres, the treatment effect was 38.4&nbsp;metres
in favour of sildenafil; for patients with a baseline walking distance
&lt;&nbsp;325&nbsp;metres, the treatment effect was 2.3&nbsp;metres in favour
of placebo. For patients with primary PAH, the treatment effect was 31.1&nbsp;metres
compared to 7.7&nbsp;metres for patients with PAH associated with </span><span
style='font-size:11.0pt'>connective tissue disease</span><span lang=EN-GB
style='font-size:11.0pt'>. The difference in results between these
randomisation subgroups may have arisen by chance in view of their limited
sample size.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Patients on sildenafil achieved a
statistically significant reduction in mean Pulmonary Arterial Pressure (mPAP)
compared to those on placebo. A mean placebo-corrected treatment effect of &#8209;3.9&nbsp;mmHg
was observed in favour of sildenafil (95&nbsp;% CI: &#8209;5.7, &#8209;2.1)
(p&nbsp;=&nbsp;0.00003). <strong><span style='font-weight:normal'>Time to
clinical worsening was a secondary endpoint as defined as the time from
randomisation to the first occurrence of a clinical worsening event (death,
lung transplantation, initiation of bosentan therapy, or clinical deterioration
requiring a change in epoprostenol therapy). Treatment with sildenafil
significantly delayed the time to clinical worsening of PAH compared to placebo
(p&nbsp;=&nbsp;0.0074). 23&nbsp;subjects experienced clinical worsening events
in the placebo group (17.6&nbsp;%) compared with 8 subjects in the sildenafil
group (6.0&nbsp;%).</span></strong></span></p>

<p class=MsoNormal><strong><span lang=EN-GB style='font-weight:normal'>&nbsp;</span></strong></p>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'><i><u><span
lang=EN-GB>Long-term Survival Data in the background epoprostenol study</span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Patients
enrolled into the epoprostenol add-on therapy study were eligible to enter a
long term open label extension study. </span><span lang=EN-GB>At 3&nbsp;years
68&nbsp;% of the patients were receiving a dose of 80&nbsp;mg TID. </span><span
lang=EN-GB>A total of 134&nbsp;patients were</span><span lang=EN-GB> treated
with Revatio in the initial study, and their long term survival status was
assessed for a minimum of 3&nbsp;years. In this population, Kaplan-Meier
estimates of 1, 2 and 3&nbsp;year survival were 92&nbsp;%, 81&nbsp;% and 74&nbsp;%,
respectively.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Efficacy and safety in adult patients
with PAH (when used in combination with bosentan)</span></u></p>

<p class=MsoNormal><span lang=EN-GB>A randomized, double-blind, placebo
controlled study was conducted in 103 clinically stable subjects with PAH (WHO
FC II and III) who were on bosentan therapy for a minimum of three months. The
PAH patients included those with Primary PAH, and PAH associated with</span><span
lang=EN-GB> connective tissue disease</span><span lang=EN-GB>. Patients were
randomized to placebo or sildenafil (20 mg</span> three times a day<span
lang=EN-GB>) in combination with bosentan (62.5&#8209;125&nbsp;mg</span> twice
a day<span lang=EN-GB>). The primary efficacy endpoint was the change from
baseline at Week 12 in 6</span>MWD<span lang=EN-GB>. The results indicate that
there is no significant difference in mean change from baseline on 6MWD
observed between sildenafil (20 mg three times a day) and placebo (</span>13.62&nbsp;m
(95% CI: -3.89 to 31.12) and 14.08&nbsp;m (95% CI: -1.78 to 29.95),
respectively<span lang=EN-GB>).</span></p>

<p class=MsoNormal><span style='background:yellow'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Differences in 6MWD were observed between
patients with primary PAH and PAH associated with</span><span lang=EN-GB> connective
tissue disease</span><span lang=EN-GB>. For subjects with primary PAH (67
subjects), mean changes from baseline were 26.39 m (95% CI: 10.70 to 42.08) and
11.84 m (95% CI: -8.83 to 32.52) for the sildenafil and placebo groups,
respectively. However, for subjects with PAH associated with </span><span
lang=EN-GB>connective tissue disease</span><span lang=EN-GB> (36 subjects) mean
changes from baseline were -18.32 m (95% CI: -65.66 to 29.02) and 17.50&nbsp;m (95%
CI: -9.41 to 44.41) for the sildenafil and placebo groups, respectively.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Overall, the
adverse events were generally similar between the two treatment groups
(sildenafil plus bosentan vs. bosentan alone), and consistent with the known
safety profile of sildenafil when used as monotherapy (see sections 4.4 and
4.5).</span></p>

<p class=MsoNormal><strong><span lang=EN-GB style='font-weight:normal'>&nbsp;</span></strong></p>

<p class=MsoNormal style='text-align:justify'><u><span lang=EN-GB>Paediatric
population</span></u></p>

<p class=MsoNormal style='text-align:justify'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='text-align:justify'><i><span lang=EN-GB>Pulmonary
arterial hypertension</span></i></p>

<p class=MsoNormal style='text-align:justify'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>A total of 234&nbsp;subjects aged 1&nbsp;to
17&nbsp;years were treated in a randomized, double-blind, multi&#8209;centre,
placebo controlled parallel group, dose ranging study. Subjects (38&nbsp;% male
and 62&nbsp;% female) had a body weight </span><span lang=EN-GB
style='font-family:Symbol'>&sup3;</span><span lang=EN-GB>&nbsp;8&nbsp;kg, and
had primary pulmonary hypertension (PPH) [33&nbsp;%], or PAH secondary to
congenital heart disease [systemic&#8209;to&#8209;pulmonary shunt 37&nbsp;%,
surgical repair 30&nbsp;%]. In this trial, 63</span><span lang=EN-GB> of 234
(27&nbsp;%) patients were &lt;&nbsp;7&nbsp;years old (sildenafil low dose = 2;
medium dose = 17; high dose = 28; placebo = 16) and 171 of 234 (73&nbsp;%)
patients were 7&nbsp;years or older (sildenafil low dose = 40; medium dose =
38; and high dose = 49; placebo = 44). </span>Most<span lang=EN-GB> subjects
were WHO Functional Class I (</span>75/234, 32&nbsp;<span lang=EN-GB>%) or II
(120/234, 51&nbsp;%) at baseline; fewer patients were Class III (35/234, 15&nbsp;%)
or IV (1/234, 0.4&nbsp;%); for a few patients (3/234, 1.3&nbsp;%), the WHO
Functional Class was unknown.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Patients were na&iuml;ve for specific PAH
therapy and the use of prostacyclin, prostacyclin analogues and endothelin receptor
antagonists was not permitted in the study, and neither was arginine
supplementation, nitrates, alpha-blockers and potent CYP450 3A4 inhibitors.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The primary objective of the study was to
assess the efficacy of 16&nbsp;weeks of chronic treatment with oral sildenafil
in paediatric subjects to improve exercise capacity as measured by the
Cardiopulmonary Exercise Test (CPET) in subjects who were developmentally able
to perform the test, n&nbsp;=&nbsp;115). Secondary endpoints included
haemodynamic monitoring, symptom assessment, WHO functional class, change in
background treatment, and quality of life measurements.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Subjects were allocated to one of three
sildenafil treatment groups, </span><span lang=EN-GB>low (10&nbsp;mg), medium
(10&#8209;40&nbsp;mg) or high dose (20-80&nbsp;mg) regimens of Revatio given
three times a day, </span><span lang=EN-GB>or placebo. Actual doses
administered within a group were dependent on body weight (see Section 4.8). </span><span
lang=EN-GB style='color:black'>The proportion of subjects receiving supportive medicinal
products at baseline (</span><span lang=EN-GB>anticoagulants, digoxin, calcium
channel blockers, diuretics and/or oxygen) <span style='color:black'>was
similar in the combined sildenafil treatment group (47.7&nbsp;%) and the
placebo treatment group (41.7&nbsp;%).</span></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The primary endpoint was the
placebo-corrected percentage change in peak VO<sub>2</sub> from baseline to
week 16 assessed by CPET in the combined dose groups (Table 2). A total of 106
out of 234&nbsp;(45&nbsp;%) subjects were evaluable for CPET, which comprised
those children &#8805;&nbsp;7&nbsp;years old and developmentally able to
perform the test. Children &lt;&nbsp;7&nbsp;years (sildenafil combined dose =
47; placebo&nbsp;= 16) were evaluable only for the secondary endpoints. Mean
baseline peak volume of oxygen consumed (VO<sub>2</sub>) values were comparable
across the sildenafil treatment groups (17.37&nbsp;to 18.03&nbsp;ml/kg/min),
and slightly higher for the placebo treatment group (20.02&nbsp;ml/kg/min). The
results of the main analysis (combined dose groups versus placebo) were not
statistically significant (p&nbsp;=&nbsp;0.056) (see Table 2). The estimated
difference between the medium sildenafil dose and placebo was 11.33&nbsp;% (95&nbsp;%&nbsp;CI:&nbsp;1.72
to 20.94) (see Table 2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Table 2:
Placebo corrected % change from baseline in peak VO<sub>2</sub> by active treatment
group</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:8.5pt;border-collapse:collapse'>
 <tr>
  <td width=177 valign=top style='width:132.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Treatment group</span></b></p>
  </td>
  <td width=150 valign=top style='width:112.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><b><span lang=EN-GB>Estimated difference</span></b></p>
  </td>
  <td width=184 valign=top style='width:138.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><b><span lang=EN-GB>95&nbsp;% Confidence interval</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=177 valign=top style='width:132.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Low dose</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>(n=24)</span></b></p>
  </td>
  <td width=150 valign=top style='width:112.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>3.81</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=184 valign=top style='width:138.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>-6.11, 13.73</span></p>
  </td>
 </tr>
 <tr>
  <td width=177 valign=top style='width:132.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Medium dose</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>(n=26)</span></b></p>
  </td>
  <td width=150 valign=top style='width:112.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>11.33</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=184 valign=top style='width:138.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>1.72, 20.94</span></p>
  </td>
 </tr>
 <tr>
  <td width=177 valign=top style='width:132.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>High dose</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>(n=27)</span></b></p>
  </td>
  <td width=150 valign=top style='width:112.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>7.98</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=184 valign=top style='width:138.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>-1.64, 17.60</span></p>
  </td>
 </tr>
 <tr>
  <td width=177 valign=top style='width:132.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Combined dose
  groups (n=77)</span></b></p>
  </td>
  <td width=150 valign=top style='width:112.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>7.71</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>(p = 0.056)</span></p>
  </td>
  <td width=184 valign=top style='width:138.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>-0.19, 15.60</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><i><span lang=EN-GB>n=29 for placebo group</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>Estimates based on ANCOVA with
adjustments for the covariates baseline peak VO<sub>2</sub>, etiology and
weight group</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Dose related improvements were observed
with pulmonary vascular resistance index (PVRI) and mean pulmonary arterial
pressure (mPAP). </span><span lang=EN-GB>The sildenafil medium and high dose
groups both showed PVRI reductions compared to placebo, of 18&nbsp;% (95&nbsp;%CI:
2&nbsp;% to<span style='color:black;background:white'> 32&nbsp;%) and 27&nbsp;%
(95&nbsp;%CI: 14&nbsp;% to&nbsp;39&nbsp;%), respectively; whilst the low dose
group showed </span>no significant difference from placebo (difference of 2&nbsp;%).
The sildenafil medium and high dose groups displayed mPAP changes from baseline
compared to placebo, of &#8209;3.5&nbsp;mmHg (95&nbsp;%CI: &#8209;8.9, 1.9) and
&#8209;7.3&nbsp;mmHg (95&nbsp;%CI: &#8209;12.4, &#8209;2.1), respectively;
whilst the low dose group showed little difference from placebo (difference of
1.6&nbsp;mmHg). Improvements were observed with cardiac index with all three
sildenafil groups over placebo, 10&nbsp;%, 4&nbsp;% and 15&nbsp;% for the low,
medium and high dose groups respectively.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Significant
improvements in functional class were demonstrated only in subjects on
sildenafil high dose compared to placebo. Odds ratios for the sildenafil low,
medium and high dose groups compared to placebo were 0.6 (95&nbsp;% CI: 0.18,
2.01), 2.25 (95&nbsp;% CI: 0.75, 6.69) and 4.52 (95&nbsp;% CI: 1.56, 13.10),
respectively.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB>Long term extension data</span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>Of the 234 paediatric subjects treated in the short-term,
placebo-controlled study, 220 subjects entered the long-term extension study.
Subjects who had been in the placebo group in the short-term study were
randomly reassigned to sildenafil treatment; subjects weighing </span><span
lang=EN-GB>&#8804; 20&nbsp;kg entered the medium or high dose groups (1:1),
while subjects weighing &gt; 20&nbsp;kg entered the low, medium or high dose
groups (1:1:1). </span><span lang=EN-GB>Of the total 229 subjects who received
sildenafil, there were 55, 74, and 100 subjects in the low, medium and high
dose groups, respectively.</span><span lang=EN-GB> </span><span lang=EN-GB>Across
the short-term and long-term studies, the overall duration of treatment from
start of double-blind for individual subjects ranged from 3 to 3129 days. By
sildenafil treatment group, median duration of sildenafil treatment was 1696
days (excluding the 5 subjects who received placebo in double-blind and were
not treated in the long-term extension study).</span></p>

<p class=MsoPlainText><span lang=X-NONE>&nbsp;</span></p>

<p class=MsoPlainText><span lang=X-NONE style='font-size:11.0pt'>Kaplan-Meier estimates
of survival at 3&nbsp;years in patients &gt;&nbsp;20&nbsp;kg in weight at
baseline were 94&nbsp;%, 93&nbsp;% and 85&nbsp;% in the low, medium and high
dose groups, respectively; for patients &#8804;&nbsp;20&nbsp;kg in weight at
baseline, the survival estimates were 94&nbsp;% and 93&nbsp;% for subjects in the
medium and high dose groups respectively (see sections 4.4 and 4.8).</span></p>

<p class=MsoPlainText><span lang=X-NONE style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>During the
conduct of the study, there were a total of 42 deaths reported, whether on
treatment or reported as part of the survival follow-up. 37 deaths occurred
prior to a decision taken by the Data Monitoring Committee to down titrate
subjects to a lower dosage, based on an observed mortality imbalance with
increasing sildenafil doses.</span><span lang=EN-GB> Among these 37 deaths, </span><span
lang=EN-GB>the number (%) of deaths was 5/55 (9.1%), 10/74 (13.5%), and 22/100
(22%) in the sildenafil low, medium, and high dose groups, respectively. An
additional 5 deaths were reported subsequently. The causes of deaths were
related to PAH. </span><span lang=EN-GB>Higher than recommended doses should
not be used in paediatric patients with PAH (see sections 4.2 and 4.4).</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'>Peak VO<sub>2</sub> was assessed
1 year after the start of the placebo-controlled study. Of those sildenafil
treated subjects developmentally able to perform the CPET 59/114 subjects (52&nbsp;%)
had not shown any deterioration in Peak VO<sub>2</sub> from start of sildenafil.
Similarly 191 of 229&nbsp;subjects (83&nbsp;%) <span lang=EN-GB
style='color:black;background:white'>who had received</span><span lang=EN-GB> <span
style='color:black;background:white'>sildenafil </span></span>had either
maintained or improved their WHO Functional Class at 1&nbsp;year assessment.</p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Persistent pulmonary hypertension of the
newborn</span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>A randomized, double-blind, two-arm,
parallel-group, placebo-controlled study was conducted in 59&nbsp;neonates with
persistent pulmonary hypertension of the newborn (PPHN), or hypoxic respiratory
failure (HRF) and at risk for PPHN with oxygenation index (OI) &gt;15 and
&lt;60. The primary objective was to evaluate the efficacy and safety of IV
sildenafil when added to inhaled nitric oxide (iNO) compared with iNO alone.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The co-primary endpoints were treatment
failure rate, defined as need for additional treatment targeting PPHN, need for
</span><span lang=EN-GB>extracorporeal membrane oxygenation (</span><span
lang=EN-GB>ECMO), or death during the study; and time on iNO treatment after
initiation of IV study drug for patients without treatment failure. The
difference in </span><span lang=EN-GB>treatment failure rates was not
statistically significant between the two treatment groups (27.6% and 20.0% in
the iNO + IV sildenafil group and iNO + placebo group, respectively). For
patients without treatment failure, the mean time on iNO treatment </span><span
lang=EN-GB>after initiation of IV study drug </span><span lang=EN-GB>was the
same, approximately 4.1&nbsp;days, for the two&nbsp;treatment groups.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Treatment-emergent adverse events and
serious adverse events were reported in 22 (75.9%) and 7&nbsp;(24.1%) subjects
in the iNO + IV sildenafil treatment group, respectively, and in 19 (63.3%) and
2&nbsp;(6.7%) subjects in the iNO + placebo group, respectively. The most
commonly reported treatment&#8209;emergent adverse events were hypotension (8
[27.6%] subjects), hypokalaemia (7 [24.1%] subjects), anaemia and drug
withdrawal syndrome (4 [13.8%] subjects each) and bradycardia (3&nbsp;[10.3%]
subjects) in the iNO + IV sildenafil treatment group and pneumothorax (4
[13.3%] subjects), anaemia, oedema, hyperbilirubinaemia, C-reactive protein
increased, and hypotension (3&nbsp;[10.0%] subjects each) in the iNO + placebo
treatment group (see section 4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=NormalBold><span style='font-size:11.0pt'>5.2&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt'>Pharmacokinetic properties</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span class=SmPCsubheading><u><span
lang=EN-GB style='font-weight:normal'>Absorption</span></u></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sildenafil is
rapidly absorbed. Maximum observed plasma concentrations are reached within 30
to 120&nbsp;minutes (median 60&nbsp;minutes) of oral dosing in the fasted
state. The mean absolute oral bioavailability is 41&nbsp;% (range 25&#8209;63&nbsp;%).
After oral three times a day dosing of sildenafil, AUC and C<sub>max</sub>
increase in proportion with dose over the dose range of 20-40&nbsp;mg. After
oral doses of 80&nbsp;mg three times a day a more than dose proportional
increase in sildenafil plasma levels has been observed. In pulmonary arterial
hypertension patients, the oral bioavailability of sildenafil after 80&nbsp;mg
three times a day was on average 43&nbsp;% (90&nbsp;% CI: 27&nbsp;% &#8209;60&nbsp;%)
higher compared to the lower doses. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>When sildenafil
is taken with food, the rate of absorption is reduced with a mean delay in T<sub>max</sub>
of 60&nbsp;minutes and a mean reduction in C<sub>max </sub>of 29&nbsp;% however,
the extent of absorption was not significantly affected (AUC decreased by 11&nbsp;%).</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
class=SmPCsubheading><u><span lang=EN-GB style='font-weight:normal'>Distribution</span></u></span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>The mean steady state volume of distribution (Vss) for
sildenafil is 105&nbsp;l, indicating distribution into the tissues. After oral
doses of 20&nbsp;mg three times a day, the mean maximum total plasma
concentration of sildenafil at steady state is approximately 113&nbsp;ng/ml.
Sildenafil and its major circulating N-desmethyl metabolite are approximately
96&nbsp;% bound to plasma proteins. Protein binding is independent of total
drug concentrations.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
class=SmPCsubheading><u><span lang=EN-GB style='font-weight:normal'>Biotransformation</span></u></span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Sildenafil is cleared predominantly by the CYP3A4 (major route) and
CYP2C9 (minor route) hepatic microsomal isoenzymes. The major circulating
metabolite results from N-demethylation of sildenafil. This metabolite has a
phosphodiesterase selectivity profile similar to sildenafil and an <i>in vitro</i>
potency for PDE5 approximately 50&nbsp;% that of the parent drug. The
N-desmethyl metabolite is further metabolised, with a terminal half-life of
approximately 4&nbsp;h. </span>In patients with pulmonary arterial
hypertension, plasma concentrations of <span lang=EN-GB>N-desmethyl metabolite</span>
are approximately 72&nbsp;% those of sildenafil after 20&nbsp;mg three times a
day dosing (translating into a 36&nbsp;% contribution to sildenafil&#8217;s
pharmacological effects). The subsequent effect on efficacy is unknown.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
class=SmPCsubheading><u><span lang=EN-GB style='font-weight:normal'>Elimination</span></u></span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The total body clearance of sildenafil is 41&nbsp;l/h with a
resultant terminal phase half-life of 3&#8209;5&nbsp;h. After either oral or
intravenous administration, sildenafil is excreted as metabolites predominantly
in the faeces (approximately 80&nbsp;% of administered oral dose) and to a
lesser extent in the urine (approximately 13&nbsp;% of administered oral dose).</span></p>

<p class=MsoNormal style='line-height:normal'><span class=SmPCsubheading><span
lang=EN-GB>&nbsp;</span></span></p>

<p class=MsoNormal style='page-break-after:avoid'><span class=SmPCsubheading><u><span
lang=EN-GB style='font-weight:normal'>Pharmacokinetics in special patient groups</span></u></span></p>

<p class=MsoNormal style='page-break-after:avoid'><span class=SmPCsubheading><u><span
lang=EN-GB style='font-weight:normal'><span style='text-decoration:none'>&nbsp;</span></span></u></span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Elderly</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Healthy elderly
volunteers (65&nbsp;years or over) had a reduced clearance of sildenafil,
resulting in approximately 90&nbsp;% higher plasma concentrations of sildenafil
and the active N-desmethyl metabolite compared to those seen in healthy younger
volunteers (18-45&nbsp;years). Due to age-differences in plasma protein
binding, the corresponding increase in free sildenafil plasma concentration was
approximately 40&nbsp;%.</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Renal
insufficiency</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In volunteers
with mild to moderate renal impairment (creatinine clearance
=&nbsp;30-80&nbsp;ml/min), the pharmacokinetics of sildenafil were not altered
after receiving a 50&nbsp;mg single oral dose. In volunteers with severe renal
impairment (creatinine clearance &lt;&nbsp;30&nbsp;ml/min), sildenafil
clearance was reduced, resulting in mean increases in AUC and C<sub>max</sub>
of 100&nbsp;% and 88&nbsp;% respectively compared to age&#8209;matched
volunteers with no renal impairment. In addition, N-desmethyl metabolite AUC
and C<sub>max</sub> values were significantly increased by 200&nbsp;% and 79&nbsp;%
respectively in subjects with severe renal impairment compared to subjects with
normal renal function.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Hepatic
insufficiency</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In volunteers
with mild to moderate hepatic cirrhosis (Child-Pugh class A and B) sildenafil
clearance was reduced, resulting in increases in AUC (85&nbsp;%) and C<sub>max</sub>
(47&nbsp;%) compared to age-matched volunteers with no hepatic impairment. In
addition, N-desmethyl metabolite AUC and C<sub>max</sub> values were
significantly increased by 154&nbsp;% and 87&nbsp;%, respectively in cirrhotic
subjects compared to subjects with normal hepatic function. The pharmacokinetics
of sildenafil in patients with severely impaired hepatic function have not been
studied.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Population
pharmacokinetics</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In patients with
pulmonary arterial hypertension, the average steady state concentrations were
20&#8209;50&nbsp;% higher over the investigated dose range of
20&#8211;80&nbsp;mg three times a day compared to healthy volunteers. There was
a doubling of the C<sub>min</sub> compared to healthy volunteers. Both findings
suggest a lower clearance and/or a higher oral bioavailability of sildenafil in
patients with pulmonary arterial hypertension compared to healthy volunteers.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB>Paediatric
population</span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>From the analysis of the pharmacokinetic profile of sildenafil in
patients involved in the paediatric clinical trials, body weight was shown to
be a good predictor of drug exposure in children. Sildenafil plasma
concentration half-life values were estimated to range from 4.2 to
4.4&nbsp;hours for a range of 10&nbsp;to 70&nbsp;kg of body weight and did not
show any differences that would appear as clinically relevant. C<sub>max</sub>
after a single 20&nbsp;mg sildenafil dose administered PO was estimated at 49,
104 and 165&nbsp;ng/ml for 70, 20 and 10&nbsp;kg patients, respectively. C<sub>max</sub>
after a single 10&nbsp;mg sildenafil dose administered PO was estimated at 24,
53 and 85&nbsp;ng/ml for 70, 20 and 10&nbsp;kg patients, respectively. T<sub>max</sub>
was estimated at approximately 1&nbsp;hour and was almost independent from body
weight.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.3&nbsp;&nbsp;&nbsp;&nbsp; Preclinical safety data</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Non-clinical data revealed no special hazard for humans based on
conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity
and carcinogenic potential, toxicity to reproduction and development.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In pups of rats which were pre- and postnatally treated with
60&nbsp;mg/kg sildenafil, a decreased litter size, a lower pup weight on day 1
and a decreased 4-day survival were seen at exposures which were approximately
fifty times the expected human exposure at 20&nbsp;mg three times a day.
Effects in non&#8209;clinical studies were observed at exposures considered
sufficiently in excess of the maximum human exposure indicating little relevance
to clinical use.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-autospace:none'><span
lang=EN-GB>There were no adverse reactions, with possible relevance to clinical
use, seen in animals at clinically relevant exposure levels which were not also
observed in clinical studies.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.5pt;text-indent:-28.5pt;line-height:
normal'><b><span lang=EN-GB>6.1<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>List of excipients</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Powder for
oral suspension</span></u><span lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sorbitol</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Citric acid
anhydrous</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sucralose </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sodium citrate</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Xanthan gum</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Titanium dioxide
(E171)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sodium benzoate
(E211)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Silica,
colloidal anhydrous</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Grape flavour</span></u><span lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>Maltodextrin</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>Grape juice concentrate</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Gum acacia</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Pineapple juice concentrate</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Citric</span><span lang=EN-GB style='font-size:12.0pt;font-family:
TimesNewRoman'> </span><span lang=EN-GB>acid anhydrous</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Natural flavouring</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.2&nbsp;&nbsp;&nbsp;&nbsp; Incompatibilities</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not applicable.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.3&nbsp;&nbsp;&nbsp;&nbsp; Shelf life&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2&nbsp;years.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>After
reconstitution, the oral suspension is stable for 30 days.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>6.4&nbsp;&nbsp;&nbsp; Special precautions for storage</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><u>Powder</u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not store
above 30&deg;C.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in the
original package in order to protect from moisture.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Oral
suspension</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store below
30&deg;C or in refrigerator (2&deg;C to 8&deg;C). Do not freeze.</span></p>

<p class=MsoNormal style='line-height:normal'><span style='background:yellow'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For storage
conditions after reconstitution of the medicinal product, see section 6.3.</span></p>

<p class=MsoNormal style='line-height:normal'><span style='background:yellow'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.5&nbsp;&nbsp;&nbsp;&nbsp; Nature
and contents of container</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>One 125&nbsp;ml
amber glass bottle (with a polypropylene screw cap) contains 32.27&nbsp;g of
powder for oral suspension.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Once reconstituted the bottle contains 112&nbsp;ml
of oral suspension, of which 90&nbsp;ml is intended for dosing and
administration.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Pack size: 1 bottle</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each pack also contains a polypropylene
measuring cup (graduated to indicate 30&nbsp;ml), polypropylene oral dosing syringe
(3&nbsp;ml) with HDPE plunger and a LDPE press-in bottle adaptor.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.6&nbsp;&nbsp;&nbsp;&nbsp; Special precautions for
disposal and other handling</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Any unused medicinal product or waste
material should be disposed of in accordance with local requirements.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>It is recommended
that a pharmacist reconstitutes Revatio oral suspension prior to its dispensing
to the patient. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><u><span lang=EN-GB>Reconstitution instructions</span></u></p>

<p class=Default style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>Note:</span></b><span lang=EN-GB style='font-size:
11.0pt'> A total volume of 90&nbsp;ml (3 x 30&nbsp;ml) of water irrespective of
the dose to be taken should be used to reconstitute the contents of the bottle</span></p>

<p class=Default style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default style='margin-left:.5in;text-indent:-.25in;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Tap the bottle to
release the powder.</span></p>

<p class=Default style='margin-left:.5in;text-indent:-.25in;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Remove the cap.</span></p>

<p class=Default style='margin-left:.5in;text-indent:-.25in;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Measure 30&nbsp;ml of
water by filling the measuring cup (included in the carton) to the marked line
then pour the water into the bottle. Using the cup measure another 30&nbsp;ml
of water and add this to the bottle (figure 1).</span></p>

<p class=Default style='margin-left:.5in;text-align:justify'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="117%"
 style='width:117.14%;margin-left:-44.75pt;border-collapse:collapse'>
 <tr>
  <td width="100%" valign=top style='width:100.0%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB><img
  border=0 width=473 height=202
  src="Revatio%20II-86-PI-en-clea_files/image001.jpg"></span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign=top style='width:100.0%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='margin-left:.5in;text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>figure 1</span></p>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default style='margin-left:.5in;text-indent:-.25in;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt'>4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Replace the cap and
shake the bottle vigorously for a minimum of 30&nbsp;seconds (figure 2).</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="126%"
 style='width:126.34%;margin-left:-66.15pt;border-collapse:collapse'>
 <tr>
  <td width="100%" valign=top style='width:100.0%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='text-align:center;page-break-after:avoid'><span
  lang=EN-GB><img border=0 width=523 height=213
  src="Revatio%20II-86-PI-en-clea_files/image002.jpg"></span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign=top style='width:100.0%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='margin-left:.5in;text-align:center'><span
  lang=EN-GB>figure 2</span></p>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default style='margin-left:.5in;text-indent:-.25in'><span lang=EN-GB
style='font-size:11.0pt'>5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Remove the cap.</span></p>

<p class=Default style='margin-left:.5in;text-indent:-.25in;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt'>6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Using the cup measure
another 30&nbsp;ml of water and add this to the bottle. You should always add a
total of 90&nbsp;ml (3 x 30&nbsp;ml) of water irrespective of the dose you are
taking (figure 3). </span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse'>
 <tr>
  <td width="100%" valign=top style='width:100.0%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='text-align:center;page-break-after:avoid'><span
  lang=EN-GB><img border=0 width=207 height=202
  src="Revatio%20II-86-PI-en-clea_files/image003.jpg"></span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign=top style='width:100.0%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='text-align:center;page-break-after:avoid'><span
  lang=EN-GB>figure 3</span></p>
  <p class=Default align=center style='text-align:center;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=Default style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default style='margin-left:.5in;text-indent:-.25in'><span lang=EN-GB
style='font-size:11.0pt'>7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Replace the cap and shake
the bottle vigorously for a minimum of 30&nbsp;seconds (figure 4).</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="126%"
 style='width:126.14%;margin-left:-65.75pt;border-collapse:collapse'>
 <tr>
  <td width="100%" valign=top style='width:100.0%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB><img
  border=0 width=524 height=212
  src="Revatio%20II-86-PI-en-clea_files/image004.jpg"></span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign=top style='width:100.0%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>figure 4</span></p>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default style='margin-left:.5in;text-indent:-.25in'><span lang=EN-GB
style='font-size:11.0pt'>8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Remove the cap.</span></p>

<p class=Default style='margin-left:.5in;text-indent:-.25in'><span lang=EN-GB
style='font-size:11.0pt'>9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Press the bottle
adaptor into the neck of the bottle (as shown on figure 5 below). The adaptor
is provided so that you can fill the oral dosing syringe with medicine from the
bottle. Replace the cap on the bottle. </span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse'>
 <tr>
  <td width="100%" valign=top style='width:100.0%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB><img
  border=0 width=363 height=228
  src="Revatio%20II-86-PI-en-clea_files/image005.jpg"></span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign=top style='width:100.0%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB>figure
  5</span></p>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default style='margin-left:.5in;text-indent:-.25in'><span lang=EN-GB
style='font-size:11.0pt'>10.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>When reconstituted the
powder provides a white grape flavoured oral suspension. Write the date of
expiry of the reconstituted oral suspension on the bottle label (the date of
expiry of the reconstituted oral suspension is 30&nbsp;days from the date of reconstitution).
Any unused oral suspension should be discarded or returned to your pharmacist
after this date.</span></p>

<p class=Default style='margin-left:.5in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=Default style='margin-left:.25in;text-indent:-.25in'><span lang=EN-GB
style='font-size:11.0pt;background:yellow'>&nbsp;</span></p>

<p class=Default><u><span lang=EN-GB style='font-size:11.0pt'>Instructions for
use</span></u></p>

<p class=Default style='margin-left:.5in;text-indent:-.25in'><span lang=EN-GB
style='font-size:11.0pt'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Shake the closed bottle
of reconstituted oral suspension vigorously for a minimum of 10&nbsp;seconds
before use. Remove the cap (figure 6).</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=712
 style='width:534.2pt;margin-left:-39.9pt;border-collapse:collapse'>
 <tr>
  <td width=712 valign=top style='width:534.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB><img
  border=0 width=463 height=270
  src="Revatio%20II-86-PI-en-clea_files/image006.jpg"></span></p>
  </td>
 </tr>
 <tr>
  <td width=712 valign=top style='width:534.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>figure 6</span></p>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default style='margin-left:.5in;text-indent:-.25in;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>While the bottle is
upright, on a flat surface, insert the tip of the oral dosing syringe into the
adaptor (figure 7).</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='text-align:center;page-break-after:avoid'><span
  lang=EN-GB><img border=0 width=115 height=252
  src="Revatio%20II-86-PI-en-clea_files/image007.jpg"></span></p>
  </td>
 </tr>
 <tr>
  <td width=619 valign=top style='width:464.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB>figure
  7</span></p>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default style='margin-left:.5in;text-indent:-.25in'><span lang=EN-GB
style='font-size:11.0pt'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Turn the bottle upside
down while holding the oral dosing syringe in place. Slowly pull back the
plunger of the oral dosing syringe to the graduation mark that marks the dose
for you (withdrawing 1&nbsp;ml provides a 10&nbsp;mg dose, withdrawing
2&nbsp;ml provides a 20&nbsp;mg dose). To measure the dose accurately, the top
edge of the plunger should be lined up with the appropriate graduated mark on
the oral dosing syringe (figure 8).</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB><img
  border=0 width=115 height=277
  src="Revatio%20II-86-PI-en-clea_files/image008.jpg"></span></p>
  </td>
 </tr>
 <tr>
  <td width=619 valign=top style='width:464.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB>figure
  8</span></p>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default style='margin-left:.5in;text-indent:-.25in'><span lang=EN-GB
style='font-size:11.0pt'>4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>If large bubbles can be
seen, slowly push the plunger back into the syringe. This will force the
medicine back into the bottle. Repeat step 3 again.</span></p>

<p class=Default style='margin-left:.5in;text-indent:-.25in'><span lang=EN-GB
style='font-size:11.0pt'>5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Turn the bottle back
upright with the oral dosing syringe still in place. Remove the oral dosing syringe
from the bottle.</span></p>

<p class=Default style='margin-left:.5in;text-indent:-.25in'><span lang=EN-GB
style='font-size:11.0pt'>6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Put the tip of the oral
dosing syringe into the mouth. Point the tip of the oral dosing syringe towards
the inside of the cheek. SLOWLY push down the plunger of the oral dosing syringe.
Do not squirt the medicine out quickly. If the medicine is to be given to a
child, make sure the child is sitting, or is held, upright before giving the
medicine (figure 9).</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB><img
  border=0 width=126 height=147
  src="Revatio%20II-86-PI-en-clea_files/image009.jpg"></span></p>
  </td>
 </tr>
 <tr>
  <td width=619 valign=top style='width:464.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB>figure
  9</span></p>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default style='margin-left:.5in;text-indent:-.25in'><span lang=EN-GB
style='font-size:11.0pt'>7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Replace the cap on the
bottle, leaving the bottle adaptor in place. Wash the oral dosing syringe as
instructed below.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Cleaning
and storing the syringe:</span></p>

<p class=Default style='margin-left:39.0pt;text-indent:-21.0pt'><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>1. The syringe should be
washed after each dose. Pull the plunger out of the syringe and wash both parts
in water.</span></p>

<p class=Default style='margin-left:.5in;text-indent:-.25in'><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>2. Dry the two parts. Push the
plunger back in to the syringe. Keep it in a clean safe place with the
medicine.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;background:yellow'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Once reconstituted, the
oral suspension should only be administered using the oral dosing syringe
supplied with each pack. Refer to the patient leaflet for more detailed
instructions for use.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;background:yellow'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;background:yellow'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Pfizer Europe MA EEIG</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Boulevard de la Plaine 17</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>1050 Bruxelles</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Belgium</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S) </span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>EU/1/05/318/003</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DATE OF
FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of first
authorisation: 28 October 2005</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of latest
renewal: 23 September 2010</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; DATE OF REVISION OF THE
TEXT</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Detailed information on this medicinal
product is available on the website of the European Medicines Agency <a
href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a> </span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>ANNEX
II</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-align:justify;text-indent:
-28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:70.8pt;
margin-bottom:0in;margin-left:56.7pt;margin-bottom:.0001pt;text-align:center'><b><span
lang=EN-GB>A.&nbsp;&nbsp;&nbsp;&nbsp; MANUFACTURER RESPONSIBLE FOR BATCH
RELEASE</span></b></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:70.8pt;
margin-bottom:0in;margin-left:56.7pt;margin-bottom:.0001pt;text-align:center'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.55pt;margin-bottom:
0in;margin-left:85.0pt;margin-bottom:.0001pt;text-indent:-28.1pt'><b><span
lang=EN-GB>B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS OR RESTRICTIONS
REGARDING SUPPLY AND USE</span></b></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:70.8pt;
margin-bottom:0in;margin-left:56.7pt;margin-bottom:.0001pt;text-align:center'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.55pt;margin-bottom:
0in;margin-left:85.0pt;margin-bottom:.0001pt;text-indent:-28.1pt'><b><span
lang=EN-GB>C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER CONDITIONS AND REQUIREMENTS
OF THE MARKETING AUTHORISATION</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.55pt;margin-bottom:
0in;margin-left:85.0pt;margin-bottom:.0001pt;text-indent:-28.1pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.55pt;margin-bottom:
0in;margin-left:85.0pt;margin-bottom:.0001pt;text-indent:-28.1pt'><b><span
lang=EN-GB>D. &nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS OR RESTRICTIONS WITH REGARD
TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></b></p>

<b><span style='font-size:13.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<h1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:28.35pt;
text-align:justify;text-indent:-28.35pt;line-height:normal'><span
style='font-size:11.0pt'>A.</span><span style='font-size:11.0pt;font-weight:
normal'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style='font-size:11.0pt'>MANUFACTURER
RESPONSIBLE FOR BATCH RELEASE</span><span style='font-size:11.0pt'> </span></h1>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB>Name and address of the manufacturer(s)
responsible for batch release</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>Fareva Amboise</span></p>

<p class=MsoNormal><span lang=FR>Zone Industrielle</span></p>

<p class=MsoNormal><span lang=FR>29 route des Industries</span></p>

<p class=MsoNormal><span lang=FR>37530 Poc</span><span lang=FR-BE>&eacute;</span><span
lang=FR>-sur-Cisse</span></p>

<p class=MsoNormal><span lang=FR>France</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=FR>&nbsp;</span></p>

<h1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:28.35pt;
text-align:justify;text-indent:-28.35pt;line-height:normal'><span
style='font-size:11.0pt'>B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS OR
RESTRICTIONS REGARDING SUPPLY AND USE</span></h1>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Medicinal product subject to restricted
medical prescription (See Annex I: Summary of Product Characteristics, section
4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt'><b>C. &nbsp;&nbsp;&nbsp;&nbsp; OTHER
CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</b></p>

<p class=MsoNormal style='margin-right:-.05pt;text-align:justify;line-height:
normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><u><span lang=EN-GB>Periodic Safety Update Reports </span></u></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The requirements for submission of periodic
safety update reports for this medicinal product are set out in the list of
Union reference dates (EURD list) provided for under Article 107c(7) of
Directive 2001/83/EC and any subsequent updates published on the European
medicines web-portal. </span></p>

<p class=MsoNormal style='margin-right:-.05pt;text-autospace:none'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='margin-right:-.05pt;text-autospace:none'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;page-break-after:
avoid;text-autospace:none'><b><span lang=EN-GB>D.</span></b><b>&nbsp;&nbsp;&nbsp;&nbsp; </b><b><span
lang=EN-GB>CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE
OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;page-break-after:
avoid;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Risk Management Plan (RMP)</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The MAH shall
perform the required pharmacovigilance activities and interventions detailed in
the agreed RMP presented in Module 1.8.2. of the Marketing Authorisation and
any agreed subsequent updates of the RMP.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>An updated RMP should be submitted:</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>At the request of the European Medicine Agency;</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-9.0pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
lang=EN-GB>Whenever the risk management system is modified, especially as the result
of new information being received that may lead to a significant change to the
benefit/risk profile or as the result </span></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>of an important (pharmacovigilance or risk minimisation)
milestone being reached.</span></p>

<p class=Default><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Additional risk minimisation measures</span></b><span
lang=EN-GB> </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'>The Marketing Authorisation
Holder (MAH) shall agree the details of a controlled distribution system for
the 20&nbsp;ml vial of Revatio <span lang=EN-GB>0.8&nbsp;mg/ml solution for
injection </span>with the National Competent Authorities and must implement
such programme nationally to ensure that prior to prescribing all healthcare
professionals who intend to prescribe and/or dispense Revatio <span lang=EN-GB>0.8&nbsp;mg/ml
solution for injection </span>are provided with the following:</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in;line-height:normal;
text-autospace:none'><span style='font-family:"TimesNewRomanPSMT",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Information for healthcare professionals</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in;line-height:normal;
text-autospace:none'><span style='font-family:"TimesNewRomanPSMT",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Copy of the Summary of Product Characteristics (SPC)</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in;line-height:normal;
text-autospace:none'><span style='font-family:"TimesNewRomanPSMT",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Data Capture Form (DCF) designed to facilitate reporting of
events of hypotension and associated problems</p>

<p class=MsoNormal style='text-autospace:none'>The Information for healthcare
professionals should contain the following key elements:</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in;line-height:normal;
text-autospace:none'><span style='font-family:"TimesNewRomanPSMT",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Information about the Pharmacovigilance Monitoring Programme
regarding the potential risk of clinically relevant hypotension and related
problems to be put into place with the use of the DCF.</p>

<p class=MsoNormal style='text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='text-autospace:none'>The Marketing Authorisation
Holder shall agree the Information for healthcare professionals, and the
healthcare professionals to be targeted, with the national competent authority
of each Member State prior to the launch of the 20&nbsp;ml vial of Revatio <span
lang=EN-GB>0.8&nbsp;mg/ml solution for injection in that country</span>.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>ANNEX
III</span></b></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>LABELLING
AND PACKAGE LEAFLET</span></b></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&nbsp;</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
lang=SV>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
lang=SV>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
lang=SV>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
lang=SV>&nbsp;</span></b></p>

<h1 align=center style='margin:0in;text-align:center;text-indent:0in;
line-height:normal'><span lang=SV style='font-size:11.0pt'>A. LABELLING<br
clear=all style='page-break-before:always'>
</span></h1>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='height:40.45pt'>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:40.45pt'>
  <p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>PARTICULARS
  TO APPEAR ON THE OUTER PACKAGING </span></b></p>
  <p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>OUTER
  PACKAGING/CARTON</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF
  THE MEDICINAL PRODUCT</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=SV>Revatio 20&nbsp;mg
film-coated tablets</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=SV>Sildenafil </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=SV>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=SV>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
  OF ACTIVE SUBSTANCE(S)</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'>&nbsp;</p>

<p class=MsoNormal style='text-align:justify'>Each tablet contains 20&nbsp;mg
of sildenafil (as citrate).</p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST OF
  EXCIPIENTS</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'>&nbsp;</p>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'><span lang=EN-GB>Contains lactose monohydrate.</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'><span lang=EN-GB>See leaflet for further information.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
  FORM AND CONTENTS</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>90 film-coated
tablets</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>90 x 1
film-coated tablets</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>300 film-coated
tablets</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
  AND ROUTE(S) OF ADMINISTRATION</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>Oral use.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
  WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH
  OF CHILDREN</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>Keep out of the sight
and reach of children.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
  SPECIAL WARNING(S), IF NECESSARY</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
  DATE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='text-align:justify'>EXP</p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt;page-break-after:avoid'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
  STORAGE CONDITIONS</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
lang=EN-GB>Do not store above 30&deg;C. Store in the original package in order
to protect from moisture.</span></p>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL PRECAUTIONS
  FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM
  SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME AND ADDRESS OF
  THE MARKETING AUTHORISATION HOLDER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pfizer Europe MA
EEIG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Boulevard de la
Plaine 17</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1050 Bruxelles</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Belgium</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
  AUTHORISATION NUMBER(S)</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>EU/1/05/318/001</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>EU/1/05/318/004</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>EU/1/05/318/005</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>Batch</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
  CLASSIFICATION FOR SUPPLY</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS ON USE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><b><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='text-align:justify'><b><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='text-align:justify'><b><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION IN
  BRAILLE&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><b><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal><span lang=EN-GB>Revatio 20&nbsp;mg</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span style='background:silver'>2D
barcode carrying the unique identifier included.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER &#8211; HUMAN READABLE
DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>PC:</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>SN:</p>

<p class=MsoNormal>NN:<span lang=EN-GB> </span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=SV>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING </span></b></p>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=EN-GB>OUTER CARTON </span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF
  THE MEDICINAL PRODUCT</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>Revatio 0.8&nbsp;mg/ml solution for
injection</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span
lang=EN-GB style='color:black'>Sildenafil</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=SV>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=SV>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
  OF ACTIVE SUBSTANCE(S)</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'>&nbsp;</p>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>Each ml of solution contains
0.8&nbsp;mg of sildenafil (as citrate). Each 20&nbsp;ml vial contains 12.5&nbsp;ml
(10&nbsp;mg sildenafil, as citrate).</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST OF
  EXCIPIENTS</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'>&nbsp;</p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span
lang=EN-GB style='color:black'>Contains glucose and water for injections.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
  FORM AND CONTENTS</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB
style='color:black'>Solution for injection</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>1 vial 10&nbsp;mg/12.5&nbsp;ml</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
  AND ROUTE(S) OF ADMINISTRATION</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span
lang=EN-GB style='color:black'>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>Intravenous use.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
  WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH
  OF CHILDREN</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>Keep out of the sight
and reach of children.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
  SPECIAL WARNING(S), IF NECESSARY</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
  DATE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='text-align:justify'>EXP</p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
  STORAGE CONDITIONS</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt;page-break-after:avoid'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
  PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
  DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME AND ADDRESS OF
  THE MARKETING AUTHORISATION HOLDER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pfizer Europe MA
EEIG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Boulevard de la
Plaine 17</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1050 Bruxelles</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Belgium</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
  AUTHORISATION NUMBER(S)</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span
lang=EN-GB>EU/1/05/318/002</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>Batch </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
  CLASSIFICATION FOR SUPPLY</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS ON USE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><b><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='text-align:justify'><b><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='text-align:justify'><b><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION IN
  BRAILLE&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><b><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB
style='color:black'>Revatio 0.8&nbsp;mg/ml</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span style='background:silver'>2D
barcode carrying the unique identifier included.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER &#8211; HUMAN READABLE
DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>PC:</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>SN:</p>

<p class=MsoNormal>NN:<span lang=EN-GB> </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>PARTICULARS
  TO APPEAR ON THE IMMEDIATE PACKAGING </span></b></p>
  <p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>VIAL LABEL </span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF
  THE MEDICINAL PRODUCT</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>Revatio 0.8&nbsp;mg/ml solution for
injection</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span
lang=EN-GB style='color:black'>Sildenafil</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=SV>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=SV>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
  OF ACTIVE SUBSTANCE(S)</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'>&nbsp;</p>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>Each ml of solution contains
0.8&nbsp;mg of sildenafil (as citrate). Each 20&nbsp;ml vial contains
12.5&nbsp;ml (10&nbsp;mg sildenafil, as citrate).</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST OF
  EXCIPIENTS</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'>&nbsp;</p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span
lang=EN-GB style='color:black'>Contains glucose and water for injections.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
  FORM AND CONTENTS</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB
style='color:black'>Solution for injection</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>1 vial
10&nbsp;mg/12.5&nbsp;ml</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
  AND ROUTE(S) OF ADMINISTRATION</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span
lang=EN-GB style='color:black'>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>Intravenous use.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
  WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH
  OF CHILDREN</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>Keep out of the sight
and reach of children.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
  SPECIAL WARNING(S), IF NECESSARY</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
  DATE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='text-align:justify'>EXP</p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
  STORAGE CONDITIONS</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt;page-break-after:avoid'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
  PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED
  FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME AND ADDRESS OF
  THE MARKETING AUTHORISATION HOLDER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pfizer Europe MA
EEIG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Boulevard de la
Plaine 17</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1050 Bruxelles</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Belgium</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
  AUTHORISATION NUMBER(S)</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span
lang=EN-GB>EU/1/05/318/002</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp;  BATCH NUMBER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>Batch </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
  CLASSIFICATION FOR SUPPLY</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS ON USE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><b><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='text-align:justify'><b><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='text-align:justify'><b><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION IN
  BRAILLE&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><b><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER &#8211; HUMAN READABLE
DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>MINIMUM
  PARTICULARS TO APPEAR ON BLISTERS</span></b></p>
  <p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>IMMEDIATE
  PACKAGING/BLISTER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF
  THE MEDICINAL PRODUCT</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
-28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>Revatio 20&nbsp;mg
tablets</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
-28.35pt'><span lang=EN-GB>Sildenafil </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF
  THE MARKETING AUTHORISATION HOLDER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>Pfizer</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
  DATE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='text-align:justify'>EXP</p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
  NUMBER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span
lang=EN-GB>LOT</span></p>

<p class=MsoEndnoteText style='text-align:justify'><span lang=X-NONE>&nbsp;</span></p>

<p class=MsoEndnoteText style='text-align:justify'><span lang=X-NONE>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='height:40.45pt'>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:40.45pt'>
  <p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>PARTICULARS
  TO APPEAR ON THE OUTER PACKAGING </span></b></p>
  <p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>OUTER
  CARTON</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF
  THE MEDICINAL PRODUCT</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=SV>Revatio 10&nbsp;mg/ml
powder for oral suspension</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=SV>Sildenafil </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=SV>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=SV>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
  OF ACTIVE SUBSTANCE(S)</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'>&nbsp;</p>

<p class=MsoNormal style='text-align:justify'>Once reconstituted one bottle contains
1.12&nbsp;g of sildenafil (as citrate) with a final volume of 112 ml.</p>

<p class=MsoNormal style='text-align:justify'>Each ml of the reconstituted suspension
contains 10&nbsp;mg of sildenafil (as citrate).</p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST OF
  EXCIPIENTS</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'>&nbsp;</p>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'><span lang=EN-GB>Contains sorbitol.</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'><span lang=EN-GB>See leaflet for further information.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
  FORM AND CONTENTS</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB
style='background:silver'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB
style='background:silver'>Powder for oral suspension</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>1 bottle </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>1 press-in bottle
adapter, 1 measuring cup and 1 oral dosing syringe</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
  AND ROUTE(S) OF ADMINISTRATION</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>Shake bottle
well before use.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>Oral use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Reconstitution instructions:</span></p>

<p class=MsoNormal><span lang=EN-GB>Tap the bottle to release the powder and
remove the cap.</span></p>

<p class=MsoNormal><span lang=EN-GB>Add a <b>total</b> of 90&nbsp;ml of </span><span
lang=EN-GB>water (3 x 30 ml) <b>strictly following the package leaflet</b>, ensuring
the bottle is shaken vigorously after adding 60 ml and the remaining 30 ml</span><span
lang=EN-GB>. Remove the cap again, press the bottle adaptor into the neck of
the bottle. Note: Expires 30 days after reconstitution.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
  WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH
  OF CHILDREN</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>Keep out of the sight
and reach of children.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
  SPECIAL WARNING(S), IF NECESSARY</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt;page-break-after:avoid'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
  DATE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'>EXP</p>

<p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB
style='background:yellow'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.1pt;text-align:justify;text-indent:
  -28.1pt;page-break-after:avoid'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
  STORAGE CONDITIONS</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
lang=EN-GB>Powder: Do not store above 30&deg;C. Store in the original package
in order to protect from moisture.</span></p>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>After reconstitution: Store below 30&deg;C or in refrigerator
at 2&deg;C to 8&deg;C. Do not freeze. Discard any remaining oral suspension 30
days after reconstitution.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL PRECAUTIONS
  FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM
  SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME AND ADDRESS OF
  THE MARKETING AUTHORISATION HOLDER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pfizer Europe MA
EEIG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Boulevard de la
Plaine 17</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1050 Bruxelles</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Belgium</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
  AUTHORISATION NUMBER(S)</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>EU/1/05/318/003</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp;  BATCH NUMBER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>Batch </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
  CLASSIFICATION FOR SUPPLY</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS ON USE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><b><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='text-align:justify'><b><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='text-align:justify'><b><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION IN
  BRAILLE&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Revatio 10 mg/ml</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span style='background:silver'>2D
barcode carrying the unique identifier included.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER &#8211; HUMAN READABLE
DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>PC:</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>SN:</p>

<p class=MsoNormal>NN:<span lang=EN-GB> </span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='height:40.45pt'>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:40.45pt'>
  <p class=MsoNormal><b><span lang=EN-GB>PARTICULARS TO APPEAR ON THE IMMEDIATE
  PACKAGING</span></b></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>BOTTLE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF
  THE MEDICINAL PRODUCT</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=SV>Revatio 10&nbsp;mg/ml
powder for oral suspension</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=SV>Sildenafil </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=SV>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=SV>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
  OF ACTIVE SUBSTANCE(S)</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Once
reconstituted one bottle contains 1.12&nbsp;g of sildenafil (as citrate) with a
f</span>inal volume of 112 ml.</p>

<p class=MsoNormal style='text-align:justify'>Each&nbsp;ml of reconstituted suspension
contains 10&nbsp;mg of sildenafil (as citrate).</p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST OF
  EXCIPIENTS</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'>&nbsp;</p>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'><span lang=EN-GB>Contains sorbitol.</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'><span lang=EN-GB style='background:silver'>See leaflet for further
information.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
  FORM AND CONTENTS</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB
style='background:silver'>Powder for oral suspension</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
  AND ROUTE(S) OF ADMINISTRATION</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>Shake bottle
well before use.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>Oral use.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Reconstitution instructions:</span></p>

<p class=MsoNormal><span lang=EN-GB>Tap the bottle to release the powder and
remove the cap.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>Add a <b>total</b>
of 90&nbsp;ml of </span><span lang=EN-GB>water (3 x 30 ml) <b>strictly
following the package leaflet</b>, ensuring the bottle is shaken vigorously
after adding 60 ml and the remaining 30 ml.</span><span lang=EN-GB> Remove the
cap again, press the bottle adaptor into the neck of the bottle. Note: Expires
30 days after reconstitution.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
  WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH
  OF CHILDREN</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>Keep out of the sight
and reach of children.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
  SPECIAL WARNING(S), IF NECESSARY</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'>&nbsp;</p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt;page-break-after:avoid'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
  DATE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'>EXP</p>

<p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
lang=EN-GB style='background:yellow'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt;page-break-after:avoid'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
  STORAGE CONDITIONS</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
lang=EN-GB style='background:yellow'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
lang=EN-GB>Powder: Do not store above 30&deg;C. Store in the original package
in order to protect from moisture.</span></p>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>After reconstitution: Store below 30&deg;C or in refrigerator
at 2&deg;C to 8&deg;C. Do not freeze. Discard any remaining suspension 30 days
after reconstitution.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL PRECAUTIONS
  FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM
  SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME OF THE
  MARKETING AUTHORISATION HOLDER OR MARKETING AUTHORISATION HOLDER LOGO</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pfizer</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
  AUTHORISATION NUMBER(S)</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>EU/1/05/318/003</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp;  BATCH NUMBER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>Batch </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
  CLASSIFICATION FOR SUPPLY</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS ON USE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><b><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='text-align:justify'><b><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='text-align:justify'><b><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
  -28.35pt'><b><span lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION IN
  BRAILLE&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8211; HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h1 align=center style='margin:0in;text-align:center;text-indent:0in;
line-height:normal'><span style='font-size:11.0pt'>&nbsp;</span></h1>

<h1 align=center style='margin:0in;text-align:center;text-indent:0in;
line-height:normal'><span style='font-size:11.0pt'>&nbsp;</span></h1>

<h1 align=center style='margin:0in;text-align:center;text-indent:0in;
line-height:normal'><span style='font-size:11.0pt'>&nbsp;</span></h1>

<h1 align=center style='margin:0in;text-align:center;text-indent:0in;
line-height:normal'><span style='font-size:11.0pt'>&nbsp;</span></h1>

<h1 align=center style='margin:0in;text-align:center;text-indent:0in;
line-height:normal'><span style='font-size:11.0pt'>&nbsp;</span></h1>

<h1 align=center style='margin:0in;text-align:center;text-indent:0in;
line-height:normal'><span style='font-size:11.0pt'>&nbsp;</span></h1>

<h1 align=center style='margin:0in;text-align:center;text-indent:0in;
line-height:normal'><span style='font-size:11.0pt'>&nbsp;</span></h1>

<h1 align=center style='margin:0in;text-align:center;text-indent:0in;
line-height:normal'><span style='font-size:11.0pt'>&nbsp;</span></h1>

<h1 align=center style='margin:0in;text-align:center;text-indent:0in;
line-height:normal'><span style='font-size:11.0pt'>&nbsp;</span></h1>

<h1 align=center style='margin:0in;text-align:center;text-indent:0in;
line-height:normal'><span style='font-size:11.0pt'>&nbsp;</span></h1>

<h1 align=center style='margin:0in;text-align:center;text-indent:0in;
line-height:normal'><span style='font-size:11.0pt'>&nbsp;</span></h1>

<h1 align=center style='margin:0in;text-align:center;text-indent:0in;
line-height:normal'><span style='font-size:11.0pt'>&nbsp;</span></h1>

<h1 align=center style='margin:0in;text-align:center;text-indent:0in;
line-height:normal'><span style='font-size:11.0pt'>&nbsp;</span></h1>

<h1 align=center style='margin:0in;text-align:center;text-indent:0in;
line-height:normal'><span style='font-size:11.0pt'>&nbsp;</span></h1>

<h1 align=center style='margin:0in;text-align:center;text-indent:0in;
line-height:normal'><span style='font-size:11.0pt'>&nbsp;</span></h1>

<h1 align=center style='margin:0in;text-align:center;text-indent:0in;
line-height:normal'><span style='font-size:11.0pt'>&nbsp;</span></h1>

<h1 align=center style='margin:0in;text-align:center;text-indent:0in;
line-height:normal'><span style='font-size:11.0pt'>&nbsp;</span></h1>

<h1 align=center style='margin:0in;text-align:center;text-indent:0in;
line-height:normal'><span style='font-size:11.0pt'>&nbsp;</span></h1>

<h1 align=center style='margin:0in;text-align:center;text-indent:0in;
line-height:normal'><span style='font-size:11.0pt'>&nbsp;</span></h1>

<h1 align=center style='margin:0in;text-align:center;text-indent:0in;
line-height:normal'><span style='font-size:11.0pt'>&nbsp;</span></h1>

<h1 align=center style='margin:0in;text-align:center;text-indent:0in;
line-height:normal'><span style='font-size:11.0pt'>&nbsp;</span></h1>

<h1 align=center style='margin:0in;text-align:center;text-indent:0in;
line-height:normal'><span style='font-size:11.0pt'>B. PACKAGE LEAFLET</span></h1>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Package leaflet: Information for the patient</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Revatio 20&nbsp;mg film-coated tablets</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>Sildenafil</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:7.1pt;text-indent:-7.1pt;line-height:
normal'><b><span lang=EN-GB>Read all of this leaflet carefully before you start
taking this medicine</span><span lang=EN-GB> because it contains</span></b></p>

<p class=MsoNormal style='margin-left:7.1pt;text-indent:-7.1pt;line-height:
normal'><b><span lang=EN-GB>important information for you</span></b><b><span
lang=EN-GB>.</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>This medicine has been prescribed for you only.
Do not pass it on to others. It may harm them, even if their signs of illness
are the same as yours.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects, talk to your doctor
or pharmacist. This includes any possible side effects not listed in this
leaflet. See section 4.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What is in this leaflet</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What Revatio is
and what it is used for</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What you need
to know before you take Revatio</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to take
Revatio</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible side
effects </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to
store Revatio</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents of the
pack and other information</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What Revatio
is and what it is used for</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Revatio contains the active substance sildenafil which belongs to a
group of medicines called phosphodiesterase type 5 (PDE5) inhibitors. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Revatio brings down blood pressure in the lungs by widening the
blood vessels in the lungs. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Revatio is used to treat adults and children and adolescents from 1
to 17&nbsp;years old with high blood pressure in the blood vessels in the lungs
(pulmonary arterial hypertension). </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What you need to know before you take
Revatio</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Do not take
Revatio: </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-12.8pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are allergic to sildenafil or any of the
other ingredients of this medicine (listed in section 6).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-13.5pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are taking medicines containing nitrates,
or nitric oxide donors such as amyl nitrate (&#8220;poppers&#8221;). These
medicines are often given for relief of chest pain (or &#8220;angina pectoris&#8221;).
Revatio can cause a serious increase in the effects of these medicines. Tell
your doctor if you are taking any of these medicines. If you are not certain,
ask your doctor or pharmacist. </span></p>

<p class=MsoEndnoteText><span lang=X-NONE>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-13.5pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if </span><span lang=EN-GB>you are taking
riociguat. This drug is used to treat pulmonary arterial hypertension (i.e.,
high blood pressure in the lungs) and chronic thromboembolic pulmonary
hypertension (i.e., high blood pressure in the lungs secondary to blood clots).
PDE5 inhibitors, such as Revatio have been shown to increase the hypotensive
effects of this medicine. If you are taking riociguat or are unsure tell your
doctor.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-13.5pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have recently had a stroke, a heart
attack or if you have severe liver disease or very low blood pressure
(&lt;90/50&nbsp;mmHg).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-13.5pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are taking a medicine to treat fungal
infections such as ketoconazole or itraconazole or medicines containing
ritonavir (for HIV).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-14.2pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have ever had loss of vision because of a
problem with blood flow to the nerve in the eye called n</span><span
lang=EN-GB>on-arteritic anterior ischaemic optic neuropathy (NAION).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Warnings and precautions</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Talk to your doctor before taking Revatio if you:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:31.5pt;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB> have a disease due to a blocked or narrow vein
in the lungs rather than a blocked or narrow artery.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-14.85pt;line-height:
normal'><span lang=EN-GB style='font-family:"TimesNewRomanPSMT",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>have a severe heart problem.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-14.85pt;line-height:
normal'><span lang=EN-GB style='font-family:"TimesNewRomanPSMT",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>have a problem with the pumping chambers of your
heart </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-14.85pt;line-height:
normal'><span lang=EN-GB style='font-family:"TimesNewRomanPSMT",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>have high blood pressure in the blood vessels in
the lungs.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-14.85pt;line-height:
normal'><span lang=EN-GB style='font-family:"TimesNewRomanPSMT",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>have low blood pressure at rest.</span></p>

<p class=MsoNormal style='margin-left:31.5pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:"TimesNewRomanPSMT",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>l</span>ose a large amount of body fluids
(dehydration) which can occur when you sweat a lot or do not drink enough
liquids. This can happen if you are sick with a fever, vomiting, or diarrhoea<span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-left:31.5pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:"TimesNewRomanPSMT",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>have a rare inherited eye disease<i> </i>(<i>retinitis
pigmentosa</i>).</span></p>

<p class=MsoNormal style='margin-left:31.5pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:"TimesNewRomanPSMT",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>have an abnormality of red blood cells (sickle
cell anaemia), cancer of blood cells (leukaemia), cancer of bone marrow (multiple
myeloma), or any disease or deformity of the penis. </span></p>

<p class=MsoNormal style='margin-left:31.5pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:"TimesNewRomanPSMT",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>currently have a stomach ulcer, a bleeding
disorder (such as haemophilia) or problems with nose bleeds.</span></p>

<p class=MsoNormal style='margin-left:31.5pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:"TimesNewRomanPSMT",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>take medicines for erectile dysfunction.</span></p>

<p class=MsoNormal style='margin-left:7.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>When used to
treat male erectile dysfunction (ED), the following visual side effects have
been reported with PDE5 inhibitors, including sildenafil at an unknown
frequency; partial, sudden, temporary, or permanent decrease or loss of vision
in one or both eyes.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you </span><span lang=EN-GB>experience sudden decrease or loss of
vision, <b>stop taking&nbsp;Revatio and contact your doctor immediately</b>
(see also section 4).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Prolonged and sometimes painful erections have been reported in men
after taking sildenafil. If you have an erection, which lasts continuously for
more than 4 hours, </span><b><span lang=EN-GB>stop taking&nbsp;Revatio and
contact your doctor immediately</span></b><span lang=EN-GB> (see also section
4).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i>Special
considerations for patients with kidney or liver problems</i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'>You should
tell your doctor if you have kidney or liver problems, as your dose may need to
be adjusted.</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Children</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Revatio should not be given to children below 1&nbsp;year of age.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Other medicines and Revatio</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Tell your doctor or pharmacist if you are taking, have recently
taken or might take any other medicines.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
     lang=EN-GB>&nbsp;&nbsp; Medicines containing nitrates, or nitric oxide
     donors such as amyl nitrate (&#8220;poppers&#8221;). These medicines are
     often given for relief of angina pectoris or &#8220;chest pain&#8221; (see
     section 2. Before you take Revatio)</span></li>
 <li class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
     lang=EN-GB>&nbsp;&nbsp; Tell your doctor or pharmacist if you are already
     taking riociguat.</span></li>
 <li class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
     lang=EN-GB>&nbsp;&nbsp; Therapies for pulmonary hypertension (e.g.
     bosentan, iloprost) </span></li>
 <li class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
     lang=EN-GB>&nbsp;&nbsp; Medicines containing St. John&#8217;s Wort (herbal
     medicinal product), rifampicin (used to treat bacterial infections),
     carbamazepine, phenytoin and phenobarbital (used, among others, to treat
     epilepsy) </span></li>
 <li class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
     lang=EN-GB>&nbsp;&nbsp; Blood thinning medicines (for example warfarin)
     although these did not result in any side effect.</span></li>
 <li class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
     lang=EN-GB>&nbsp;&nbsp; Medicines containing erythromycin, clarithromycin,
     telithromycin (these are antibiotics used to treat certain bacterial
     infections), saquinavir (for HIV) or nefazodone (for mental depression),
     as your dose may need to be adjusted.</span></li>
 <li class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
     lang=EN-GB>&nbsp;&nbsp; Alpha-blocker therapy (e.g. doxazosin) for the
     treatment of high blood pressure or prostate problems, as the combination
     of the two medicines may cause symptoms resulting in the lowering of your
     blood pressure (e.g. dizziness, light headedness).</span></li>
</ul>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Revatio with food and drink</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>You should not drink grapefruit juice while you are being treated
with Revatio.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Pregnancy and breast-feeding</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you are
pregnant, or breast-feeding, think you may be pregnant or are planning to have
a baby, ask your doctor or pharmacist for advice before taking this medicine.
Revatio should not be used during pregnancy unless strictly necessary.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Revatio should
not be given to women of child bearing potential unless using appropriate
contraceptive methods.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Revatio passes
into your breast milk at very low levels and would not be expected to harm your
baby. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>Driving and using machines</span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>Revatio can cause dizziness and can affect vision. You should be
aware of how you react to the medicine before you drive or use machines.&nbsp; </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Revatio contains lactose</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you have been told by your doctor that you have an intolerance to
some sugars, contact your doctor before taking this -medicinal product.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to take
Revatio</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Always take this medicine exactly as your doctor has told you. Check
with your doctor or pharmacist if you are not sure. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For adults, the
recommended dose is 20&nbsp;mg three times a day (taken 6 to 8 hours apart)
taken with or without food. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Use in children and adolescents</span></b></p>

<p class=MsoNormal><span lang=EN-GB>For children and adolescents aged 1 year to
17&nbsp;years old, the recommended dose is either 10&nbsp;mg three times a day
for children and adolescents</span><span lang=EN-GB> &#8804;&nbsp;20 kg or
20&nbsp;mg three times a day for children and adolescents &gt;&nbsp;20 kg, taken
with or without food. Higher <span style='color:black;background:white'>doses should
not be used in children</span>.</span><span lang=EN-GB> </span><span
lang=EN-GB>This medicine should be used only in case of administration of 20&nbsp;mg
three times a day. Other pharmaceutical forms may be more appropriate</span><span
lang=EN-GB> for administration to patients </span><span lang=EN-GB>&#8804;&nbsp;20&nbsp;kg
and other younger patients </span><span lang=EN-GB>who are not able to swallow
tablets.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>If you take more Revatio than you should</span></b></p>

<p class=MsoNormal><span lang=EN-GB>You should not take more medicine than your
doctor tells you to. </span></p>

<p class=MsoNormal><span lang=EN-GB>If you take more medicine than you have
been told to take contact your doctor immediately. Taking more Revatio than you
should may increase the risk of known side effects. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>If you forget to take Revatio</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you forget to take Revatio, take a dose as soon as you remember,
then continue to take your medicine at the usual times. Do not take a double
dose to make up for a forgotten dose.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>If you stop taking Revatio</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Suddenly stopping your treatment with Revatio may lead to your
symptoms getting worse. Do not stop taking Revatio unless your doctor tells you
to. Your doctor may tell you to reduce the dose over a few days before stopping
completely.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you have any further questions on the use of this medicine, ask
your doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects </span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Like all medicines, Revatio can cause side effects,
although not everybody gets them.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you experience any of the following side effects you should stop
taking Revatio and contact a doctor immediately (see also section 2): </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>- if you experience sudden decrease or loss of vision (frequency not
known)</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>- if you have an erection, which lasts continuously for more than 4
hours. Prolonged and sometimes &nbsp; painful erections have been reported in
men after taking sildenafil (frequency not known).</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal;page-break-after:
avoid'><u><span lang=EN-GB>Adults</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Side effects reported very commonly (may affect more than 1 in 10 people)
were </span><span lang=EN-GB>headache, facial flushing, indigestion, diarrhoea
and pain in the arms or legs.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Side effects reported commonly (may affect up to 1 in 10 people)
included: </span><span lang=EN>infection under the skin</span><span lang=EN-GB>,
flu-like symptoms, inflammation of the sinuses, reduced number of red blood
cells (anaemia), fluid retention, difficulty sleeping, anxiety, migraine, shaking,
&#8220;pins and needles&#8221;-like sensation, burning sensation, </span><span
lang=EN>reduced sense of touch</span><span lang=EN-GB>, </span><span lang=EN>bleeding
at the back of the eye, </span><span lang=EN-GB>effects on vision, </span>blurred
vision<span lang=EN> and</span><span lang=EN-GB> light sensitivity, effects on
colour vision, eye irritation, </span>bloodshot eyes /red eyes, <span
lang=EN-GB>vertigo, bronchitis, nosebleed, runny nose, cough, stuffy nose,
stomach inflammation, gastroenteritis, heartburn, piles, abdominal distension,
dry mouth, hair loss, redness of the skin, night sweats, muscle aches, back
pain and increased body temperature.</span></p>

<p class=MsoEndnoteText style='text-autospace:none'><span lang=X-NONE>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Side effects reported uncommonly (may affect </span><span
lang=EN-GB>1 in 100 people</span><span lang=EN-GB>) included: </span>r<span
lang=EN-GB>educed sharpness of vision, </span><span lang=EN>double vision,
abnormal sensation in the eye, penile bleeding, presence of blood in semen and/or
urine, and </span><span lang=EN-GB>breast enlargement in men</span><span
lang=EN>.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN>Skin rash and sudden decrease or loss of hearing </span><span
lang=EN-GB>and decreased blood pressure</span><span lang=EN> have also been
reported at an unknown frequency </span><span lang=EN-GB>(frequency cannot be
estimated from the available data).</span></p>

<p class=MsoBodyText2 style='text-align:justify;text-autospace:none'><span
lang=EN-GB style='color:windowtext'>&nbsp;</span></p>

<p class=MsoBodyText2 style='text-autospace:none'><u><span lang=EN-GB>Children
and adolescents</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The following serious adverse events have
been reported commonly (may affect up to 1 in 10 people); pneumonia, heart
failure, right heart failure,&nbsp;heart related shock, high blood pressure in
the lungs, chest pain, fainting, respiratory infection, bronchitis, viral infection
in the stomach and intestines, urinary tract infections and tooth cavities.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The following serious adverse events were
considered to be treatment related and were reported uncommonly (may affect up
to 1 in 100 people), allergic reaction (such as skin rash, swelling of the
face, lips and tongue, wheezing, difficulty breathing or swallowing)</span><span
lang=EN-GB>, convulsion, irregular heart-beat, hearing impairment, shortness of
breath, inflammation of the digestive tract, wheezing due to disrupted airflow.</span></p>

<p class=MsoBodyText2 style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText2 style='text-autospace:none'><span lang=EN-GB>Side effects
reported very commonly (may affect more than</span><span lang=EN-GB> 1 in 10 people</span><span
lang=EN-GB>) were headache, vomiting, infection of the throat, fever,
diarrhoea, flu and nosebleed.</span></p>

<p class=MsoBodyText2 style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText2 style='text-autospace:none'><span lang=EN-GB>Side effects
reported commonly (may affect up to 1 in 10 people) were nausea, increased
erections, pneumonia and runny nose.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Reporting of side effects</span></b></p>

<p class=BodytextAgency style='margin-bottom:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>If you get any
side effects, talk to your doctor or pharmacist.</span><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:red'> </span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>This
includes any possible side effects not listed in this leaflet.</span><span
lang=EN-GB> </span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>You
can also report side effects directly via <span style='background:silver'>the
national reporting system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix
V</a></span></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>.
By reporting side effects you can help provide more information on the safety
of this medicine.</span></p>

<p class=BodytextAgency style='margin-bottom:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to store Revatio</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Keep this medicine out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not use this medicine after the expiry date which is stated on
the carton after EXP. The expiry date refers to the last day of that month.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not store above 30<sup>O</sup>C. Store in the original package in
order to protect from moisture.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not throw away any medicines via wastewater or household waste.
Ask your pharmacist how to throw away medicines you no longer use. These
measures will help to protect the environment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents
of the pack and other information</span></b></p>

<p class=MsoBodyText style='page-break-after:avoid'><b><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></b></p>

<p class=MsoBodyText style='page-break-after:avoid'><b><span lang=EN-GB
style='text-decoration:none'>What Revatio contains</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The active substance is sildenafil. Each tablet
contains 20&nbsp;mg of sildenafil (as the citrate).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The other ingredients are:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Tablet core: microcrystalline cellulose, calcium
hydrogen phosphate (anhydrous), croscarmellose sodium, magnesium stearate.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Film coat: hypromellose, titanium dioxide (E171),
lactose monohydrate, glycerol triacetate</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What Revatio looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Revatio film-coated tablets are white and round in shape. The
tablets are marked with &#8220;PFIZER&#8221; on one side and &#8220;RVT
20&#8221; on the other. The tablets are provided in blister packs containing 90
tablets, </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>90 x 1 tablets as perforated unit dose blisters</span><span
lang=EN-GB> and in blister packs containing 300 tablets.</span><span
lang=EN-GB> Not all pack sizes may be marketed.</span><span lang=EN-GB> </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Marketing Authorisation Holder and Manufacturer</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Marketing Authorisation Holder: </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Pfizer Europe MA EEIG, Boulevard de la Plaine 17, 1050 Bruxelles,
Belgium</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span lang=FR>Manufacturer:</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span lang=FR>Fareva
Amboise, Zone Industrielle, 29 route des Industries, 37530 Poc</span><span
lang=FR-BE>&eacute;</span><span lang=FR>-sur-Cisse, France.</span></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For any information about this medicinal
product, please contact the local representative of the Marketing Authorisation
Holder.</span></p>

<p class=MsoBodyText style='text-align:justify'><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=622
 style='border-collapse:collapse'>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=FR>Belgi&euml; /Belgique / Belgien</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=NormalBold><span style='font-size:11.0pt'>Lietuva</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoHeader style='text-align:justify'><span lang=PT style='font-size:
  11.0pt;font-family:"Times New Roman",serif'>Pfizer S.A./N.V. </span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=NormalBold><span style='font-size:11.0pt;font-weight:normal'>Pfizer
  Luxembourg SARL filialas Lietuvoje</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoEndnoteText style='text-align:justify'><span lang=DE>T&eacute;l/Tel:
  +32 (0)2 </span>554 62 11</p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=NormalBold><span lang=LT style='font-size:11.0pt;font-weight:normal'>Tel.
  +</span><span style='font-size:11.0pt;font-weight:normal'>3705 2514000</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><s><span
  lang=DE><span style='text-decoration:none'>&nbsp;</span></span></s></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><s><span
  lang=FR><span style='text-decoration:none'>&nbsp;</span></span></s></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;text-autospace:none'><b><span
  lang=BG>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=NormalBold style='text-align:justify'><span style='font-size:11.0pt'>Luxembourg/Luxemburg</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=BG>&#1055;&#1092;&#1072;&#1081;&#1079;&#1077;&#1088;
  &#1051;&#1102;&#1082;&#1089;&#1077;&#1084;&#1073;&#1091;&#1088;&#1075;
  &#1057;&#1040;&#1056;&#1051;, &#1050;&#1083;&#1086;&#1085;
  &#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoHeader style='text-align:justify'><span lang=PT style='font-size:
  11.0pt;font-family:"Times New Roman",serif'>Pfizer S.A.</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&#1058;&#1077;&#1083;.:
  +359 2 970 4333</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=DE>T&eacute;l/Tel: +32 (0)2 </span><span lang=FR>554 62 11</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><s><span
  lang=DE><span style='text-decoration:none'>&nbsp;</span></span></s></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><s><span
  lang=FR><span style='text-decoration:none'>&nbsp;</span></span></s></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><b><span lang=IT>&#268;esk&aacute; republika</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><b><span lang=HU>Magyarorsz&aacute;g</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><span lang=IT>Pfizer s.r.o.</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><span lang=IT>Pfizer Kft.</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><span lang=IT>Tel: +420-283-004-111</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><span lang=HU>Tel.:</span><span lang=EN-GB> + 36 1 488 37 00</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=DE>&nbsp;</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=DE>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='height:.2in'>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt;
  height:.2in'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=DE>Danmark</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:.2in'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=SV>Malta</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT>Pfizer ApS</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=IT>Vivian Corporation Ltd.</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT>Tlf: +45 44 20 11 00</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=EN-GB>Tel: +356 21344610</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=DE>&nbsp;</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=DE>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><b><span lang=DE>Deutschland</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=NormalBold style='text-align:justify;page-break-after:avoid'><span
  lang=DE style='font-size:11.0pt'>Nederland</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><span lang=DE>Pfizer OFG Germany GmbH</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><span lang=PT>Pfizer bv</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><span lang=PT>Tel: +49 (0)800 5500634</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><span lang=PT>Tel: +31 (0)10 406 43 01</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT>&nbsp;</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=PT>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=ET>Eesti</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=DE style='layout-grid-mode:line'>Norge</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=EN-GB>Pfizer Luxembourg SARL Eesti filiaal</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT style='layout-grid-mode:line'>Pfizer AS</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=ET>Tel: +</span><span lang=EN-GB>372 666 7500</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT style='layout-grid-mode:line'>Tlf: +47 67 52 61 00</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT>&nbsp;</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=DE>&Ouml;sterreich</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=DE>UPJOHN HELLAS
  &#917;&#928;&#917;</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=DE>Pfizer Corporation Austria Ges.m.b.H.</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&#932;&#951;&#955;</span><span
  lang=DE>: +30 2100 100 002</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=DE>Tel: +43 (0)1 521 15-0</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoHeader style='text-align:justify'><span lang=DE style='font-size:
  11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:line'>&nbsp;</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=DE>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=PT>Espa&ntilde;a</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=PL>Polska</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT>Pfizer GEP, S.L.</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PL>Pfizer Polska Sp. z o.o.,</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT>Tel: +34 91 490 99 00</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PL>Tel.: </span><span lang=FR>+48 22 335 61 00</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><s><span
  lang=FR><span style='text-decoration:none'>&nbsp;</span></span></s></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=PT>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><b><span lang=PT>France</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=NormalBold style='text-align:justify'><span lang=PT
  style='font-size:11.0pt'>Portugal</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><span lang=PT>Pfizer PFE France</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT>Laborat&oacute;rios Pfizer, Lda.</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><span lang=EN-GB>T&eacute;l: +33 (0)1 58 07 34 40</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT>Tel: +351 21 </span><span lang=FR>423 5500</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><b><span lang=PT>&nbsp;</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><b><span lang=PT>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><b><span lang=PT>Hrvatska</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><b><span
  lang=FR>Rom&acirc;nia</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><span lang=EN-GB>Pfizer Croatia d.o.o.</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  lang=PT>Pfizer Rom&acirc;nia S.R.L.</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><span lang=EN-GB>Tel: +385 1 3908 777</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  lang=RO>Tel: +40 21 207 28 00</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><b><span lang=PT>&nbsp;</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><b><span lang=PT>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=EN-GB>Ireland</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=SL>Slovenija</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=EN-GB>Pfizer </span><span lang=FR>Healthcare Ireland</span></p>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=NL>Tel: 1800 633 363 (toll free)</span></p>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=NL>+44 (0)1304 616161</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=EN-GB>Pfizer Luxembourg SARL</span></p>
  <p class=MsoNormal style='line-height:normal'>Pfizer, podru&#382;nica za
  svetovanje s podro&#269;ja farmacevtske dejavnosti, Ljubljana </p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=NL>&nbsp;</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=SL>Tel: + </span><span lang=EN-GB>386 (0) 1 52 11 400</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=NL>&nbsp;</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoEndnoteText style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><b><span lang=NL>&Iacute;s</span></b><b><span
  lang=IS style='layout-grid-mode:line'>land</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=SK>Slovensk&aacute; republika</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoEndnoteText style='text-align:justify'><span lang=IS
  style='layout-grid-mode:line'>Icepharma hf.</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
  none'><span lang=IS>Pfizer Luxembourg SARL</span><span lang=IS>,
  organiza&#269;n&aacute; zlo&#382;ka </span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=IT>S</span><span lang=CS>&iacute;</span><span lang=IT>mi</span><span
  lang=IS style='layout-grid-mode:line'>: + 354 540 8000</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=SK>Tel: </span><strong><span lang=EN-GB style='font-weight:normal'>+421-2-3355
  5500</span></strong></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoHeader style='text-align:justify'><span lang=IS style='font-size:
  11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:line'>&nbsp;</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=PT>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=PT>Italia</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=PT>Suomi/Finland</span></b></p>
  </td>
 </tr>
 <tr style='height:.1in'>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt;
  height:.1in'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT style='layout-grid-mode:line'>Pfizer Established Medicine Italy
  S.r.l.</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:.1in'>
  <p class=MsoEndnoteText style='text-align:justify'><span lang=FR>Pfizer Oy</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=EN-GB>Tel: +39 06 33 18 21</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=EN-GB>Puh/Tel: +358 (0)9 43 00 40</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=EL>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=SV>Sverige </span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.1in;text-align:justify;line-height:
  normal'><span lang=EN-GB>PFIZER </span><span lang=EL>&#917;&#923;&#923;&#913;&#931;
  &#913;</span><span lang=EN-GB>.&#917;. (CYPRUS BRANCH)</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=EN-GB>Pfizer AB</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=EL>&#932;&#951;&#955;: +357</span><span lang=EL> </span><span lang=EL>22</span><span
  lang=EL> </span><span lang=EL>81</span><span lang=EN-GB>7690</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=NL>Tel: + 46 (0)8 550 520 00</span></p>
  </td>
 </tr>
 <tr style='height:15.3pt'>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt;
  height:15.3pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=LV>&nbsp;</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:15.3pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='height:15.3pt'>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt;
  height:15.3pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=LV>Latvija</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:15.3pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=EN-GB>United Kingdom</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=LV>Pfizer </span><span
  lang=EN-GB>Luxembourg SARL fili&#257;le Latvij&#257;</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=EN-GB>Pfizer Limited</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=LV>Tel: </span><span lang=EN-GB>+371 670 35 775</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT>Tel: +44 (0)1304 616161</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>This leaflet
was last revised in </span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;text-align:justify;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-22.45pt;text-align:justify;line-height:
normal'><b><span lang=EN-GB>Other sources of information</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Detailed
information on this medicine is available on the European Medicines Agency
website: <a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a>. There
are also links to other website about rare diseases and treatments.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Package leaflet: Information for the user</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Revatio 0.8&nbsp;mg/ml solution for injection</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>Sildenafil</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Read all of this leaflet carefully before you are given this
medicine because it contains important information for you.</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it again.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your doctor,
pharmacist or nurse.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>This medicine has been prescribed for you only.
Do not pass it on to others. It may harm them, even if their signs of illness are
the same as yours.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects, talk to your
doctor, pharmacist or nurse. This includes any possible side effects not listed
in this leaflet. See section 4.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What is in this leaflet</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What Revatio is
and what it is used for</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What you need
to know before you are given Revatio</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How Revatio is
given</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible side
effects </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to
store Revatio</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents of the
pack and other information</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What Revatio
is and what it is used for</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Revatio contains the active substance sildenafil which belongs to a
group of medicines called phosphodiesterase type 5 (PDE5) inhibitors.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Revatio brings down blood pressure in the lungs by widening the
blood vessels in the lungs.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Revatio is used to treat adults with high blood pressure in the
blood vessels in the lungs (pulmonary arterial hypertension).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>Revatio solution for injection is an alternative
formulation of Revatio for patients who temporarily cannot take their Revatio
tablets.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What you need to know before you
are given Revatio</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>You should
not be given Revatio:</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are allergic to sildenafil or any of the
other ingredients of this medicine (listed in section 6).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-17.3pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>&nbsp; if you are taking medicines containing
nitrates, or nitric oxide donors such as amyl nitrate (&#8220;poppers&#8221;).
These medicines are often given for relief of chest pain (or &#8220;angina pectoris&#8221;).
Revatio can cause a serious increase in the effects of these medicines. Tell
your doctor if you are taking any of these medicines. If you are not certain,
ask your doctor or pharmacist.</span></p>

<p class=MsoEndnoteText><span lang=X-NONE>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>if <span lang=EN-GB>you are taking riociguat. This drug is used
to treat pulmonary arterial hypertension (i.e., high blood pressure in the
lungs) and chronic thromboembolic pulmonary hypertension (i.e., high blood
pressure in the lungs secondary to blood clots). PDE5 inhibitors, such as Revatio
have been shown to increase the hypotensive effects of this medicine. If you
are taking riociguat or are unsure tell your doctor.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have recently had a stroke, a heart
attack or if you have severe liver disease or very low blood pressure
(&lt;&nbsp;90/50&nbsp;mmHg).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are taking a medicine to treat fungal
infections such as ketoconazole or itraconazole or medicines containing
ritonavir (for HIV).</span></p>

<p class=MsoNormal style='margin-left:13.5pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-19.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have ever had loss of vision because of a
</span><span lang=EN-GB>problem with blood flow to the nerve in the eye called
n</span><span lang=EN-GB>on-arteritic anterior ischaemic optic neuropathy
(NAION).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Warnings and Precautions</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Talk to your doctor before using Revatio if you:</span></p>

<p class=MsoNormal style='margin-left:31.5pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:"TimesNewRomanPSMT",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>have a disease due to a blocked or narrow vein
in the lungs rather than a blocked or narrow artery.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-14.85pt;line-height:
normal'><span lang=EN-GB style='font-family:"TimesNewRomanPSMT",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>have a severe heart problem.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-14.85pt;line-height:
normal'><span lang=EN-GB style='font-family:"TimesNewRomanPSMT",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>have a problem with the pumping chambers of your
heart</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-14.85pt;line-height:
normal'><span lang=EN-GB style='font-family:"TimesNewRomanPSMT",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>have high blood pressure in the blood vessels in
the lungs.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-14.85pt;line-height:
normal'><span lang=EN-GB style='font-family:"TimesNewRomanPSMT",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>have low blood pressure at rest.</span></p>

<p class=MsoNormal style='margin-left:31.5pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:"TimesNewRomanPSMT",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>l</span>ose a large amount of body fluids
(dehydration) which can occur when you sweat a lot or do not drink enough
liquids. This can happen if you are sick with a fever, vomiting, or diarrhoea<span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-left:31.5pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:"TimesNewRomanPSMT",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>have a rare inherited eye disease (<i>retinitis
pigmentosa</i>).</span></p>

<p class=MsoNormal style='margin-left:31.5pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:"TimesNewRomanPSMT",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>have an abnormality of red blood cells (sickle
cell anaemia), cancer of blood cells (leukaemia), cancer of bone marrow (multiple
myeloma), or any disease or deformity of the penis.</span></p>

<p class=MsoNormal style='margin-left:31.5pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:"TimesNewRomanPSMT",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>currently have a stomach ulcer, a bleeding
disorder (such as haemophilia) or problems with nose bleeds.</span></p>

<p class=MsoNormal style='margin-left:31.5pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:"TimesNewRomanPSMT",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>take medicines for erectile dysfunction.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>When used to
treat male erectile dysfunction (ED), the following visual side effects have
been reported with PDE5 inhibitors, including sildenafil at an unknown
frequency; partial, sudden, temporary, or permanent decrease or loss of vision
in one or both eyes.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you </span><span
lang=EN-GB>experience sudden decrease or loss of vision, <b>stop taking Revatio
and contact your doctor immediately</b> (see also section 4).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Prolonged and
sometimes painful erections have been reported in men after taking sildenafil.
If you have an erection, which lasts continuously for more than 4 hours, </span><b><span
lang=EN-GB>stop taking&nbsp;Revatio and contact your doctor immediately</span></b><span
lang=EN-GB> (see also section 4).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i>&nbsp;</i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i>Special
considerations for patients with kidney or liver problems</i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'>You should
tell your doctor if you have kidney or liver problems, as your dose may need to
be adjusted.</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Children and adolescents</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Revatio should not be given to children and adolescents under the
age of 18.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Other medicines and Revatio</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Tell your doctor or pharmacist if you are taking, have recently
taken or might take any other medicines. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoEndnoteText style='margin-left:.5in;text-indent:-22.5pt'><span
lang=X-NONE style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=X-NONE>&nbsp;&nbsp; Medicines containing nitrates, or
nitric oxide donors such as amyl nitrate (&#8220;poppers&#8221;). These
medicines are often given for relief of angina pectoris or &#8220;chest
pain&#8221; (see section 2. Before you take Revatio).</span></p>

<p class=MsoEndnoteText style='margin-left:.5in;text-indent:-22.5pt'><span
lang=X-NONE style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=X-NONE>&nbsp;&nbsp; Tell your doctor or pharmacist if
you are already taking riociguat.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-indent:-22.5pt;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>&nbsp;&nbsp; Therapies for pulmonary
hypertension (e.g. bosentan, iloprost).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-indent:-22.5pt;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>&nbsp;&nbsp; Medicines containing St.
John&#8217;s Wort (herbal medicinal product), rifampicin (used to treat
bacterial infections), carbamazepine, phenytoin and phenobarbital (used, among
others, to treat epilepsy). </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-indent:-22.5pt;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>&nbsp;&nbsp; Blood thinning medicines (for
example warfarin) although these did not result in any side effects.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-indent:-22.5pt;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>&nbsp;&nbsp; Medicines containing erythromycin,
clarithromycin, telithromycin (these are antibiotics used to treat certain
bacterial infections), saquinavir (for HIV) or nefazodone (for mental depression),
as your dose may need to be adjusted.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-indent:-22.5pt;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>&nbsp;&nbsp; Alpha-blocker therapy (e.g.
doxazosin) for the treatment of high blood pressure or prostate problems, as
the combination of the two medicines may cause symptoms of low blood pressure
(e.g. dizziness, lightheadedness).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Revatio with food and drink</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>You should not drink grapefruit juice while you are being treated
with Revatio.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>Pregnancy and breast-feeding</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>If you are pregnant or breast-feeding, think you may be pregnant or
are planning to have a baby, ask your doctor or pharmacist for advice before taking
this medicine. Revatio should not be used during pregnancy unless strictly
necessary.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Revatio should
not be given to women of child bearing potential unless using appropriate
contraceptive methods.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Revatio passes
into your breast milk at very low levels and would not be expected to harm your
baby.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Driving and using machines</span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>Revatio can cause dizziness and can affect vision. You should be
aware of how you react to the medicine before you drive or use machines.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How Revatio is
given</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>Revatio is given as an intravenous injection and
will always </span><span lang=EN-GB style='color:black'>be given to you by a
doctor or a nurse. Your doctor will determine the duration of your treatment
and how much </span><span lang=EN-GB style='color:black'>Revatio</span><span
lang=EN-GB style='color:black'> intravenous injection you will receive each day
and will monitor your response and condition. The usual dose is 10&nbsp;mg
(corresponding to 12.5&nbsp;ml) three times a day.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>A Revatio</span><span lang=EN-GB
style='color:black'> intravenous injection will be given to you instead of your
</span><span lang=EN-GB style='color:black'>Revatio tablets.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>If you receive more Revatio than you should</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>If you are concerned
that you may have been given too much </span><span lang=EN-GB style='color:
black'>Revatio</span><span lang=EN-GB style='color:black'>, tell your doctor or
nurse immediately. </span><span lang=EN-GB>Taking more Revatio than you should
may increase the risk of known side effects.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>If you miss a dose of Revatio</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>As you will be given this medicine under close
medical supervision, it is unlikely that a dose would be missed. However tell
your doctor or pharmacist if you think that a dose has been forgotten. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB style='color:black'>A double dose</span><span lang=EN-GB
style='color:black'> should not be given</span><span lang=EN-GB
style='color:black'> to make up for a forgotten dose.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>If you stop use of Revatio</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Suddenly stopping your treatment with Revatio may lead to your
symptoms getting worse. Your doctor may reduce the dose over a few days before
stopping completely.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you have any further questions on the use of this medicine, ask
your doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible side
effects </span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>Like all medicines, Revatio can cause side effects, although not
everybody gets them.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you experience any of the following side effects you should stop
taking Revatio and contact a doctor immediately (see also section 2):</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>- if you experience sudden decrease or loss of vision (frequency not
known)</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>- if you have an erection, which lasts continuously for more than 4
hours. Prolonged and sometimes &nbsp; painful erections have been reported in
men after taking sildenafil (frequency not known).</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal;page-break-after:
avoid'><u><span lang=EN-GB>Adults</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='color:black'>Side effects reported in a clinical
trial with intravenous Revatio were similar to those reported in clinical
trials with Revatio tablets. In clinical trials the side effects reported
commonly </span><span lang=EN-GB style='color:black'>(may affect up to 1 in 10 people)</span><span
lang=EN-GB style='color:black'> were </span><span lang=EN-GB style='color:black'>facial
flushing</span><span lang=EN-GB style='color:black'>, headache, low blood
pressure and nausea.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>In clinical trials side effects reported
commonly </span><span lang=EN-GB style='color:black'>(may affect up to 1 in 10 people)
</span><span lang=EN-GB style='color:black'>by </span><span lang=EN-GB
style='color:black'>p</span><span lang=EN-GB style='color:black'>atients with
pulmonary arterial hypertension were facial flushing and nausea.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In clinical trials with Revatio tablets side effects reported very
commonly (may affect more than 1 in 10 people) were </span><span lang=EN-GB>headache,
facial flushing, indigestion, diarrhoea and pain in the arms or legs.</span></p>

<p class=MsoEndnoteText style='text-autospace:none'><span lang=X-NONE>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Side effects reported commonly (may affect up to 1 in 10 people)
included: </span><span lang=EN>infection under the skin</span><span lang=EN-GB>,
flu-like symptoms, inflammationof the sinuses, reduced number of red blood
cells (anaemia), fluid retention, difficulty sleeping, anxiety, migraine, shaking,
&#8220;pins and needles&#8221;-like sensation, burning sensation, </span><span
lang=EN>reduced sense of touch,</span><span lang=EN> </span><span lang=EN>bleeding
at the back of the eye, </span><span lang=EN-GB>effects on vision, </span>blurred
vision<span lang=EN> and</span><span lang=EN-GB> light sensitivity, effects on
colour vision, eye irritation, </span>bloodshot eyes /red eyes, <span
lang=EN-GB>vertigo, bronchitis, nosebleed, runny nose, cough, stuffy nose,
stomach inflammation, gastroenteritis, heartburn, piles, abdominal distension,
dry mouth, hair loss, redness of the skin, night sweats, muscle aches, back
pain and increased body temperature.</span></p>

<p class=MsoEndnoteText style='text-autospace:none'><span lang=X-NONE>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Side effects reported uncommonly (may affect upto </span><span
lang=EN-GB>1 in 100 people</span><span lang=EN-GB>) included: </span>r<span
lang=EN-GB>educed sharpness of vision, </span><span lang=EN>double vision,
abnormal sensation in the eye, penile bleeding, presence of blood in semen and/or
urine, and </span><span lang=EN-GB>breast enlargement in men</span><span
lang=EN>.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN>Skin rash and sudden decrease or loss of hearing </span><span
lang=EN-GB>and decreased blood pressure</span><span lang=EN> have also been
reported at an unknown frequency </span><span lang=EN-GB>(frequency cannot be
estimated from the available data).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Reporting of side effects</span></b></p>

<p class=BodytextAgency style='margin-bottom:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>If you get any
side effects, talk to your doctor or pharmacist.</span><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:red'> </span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>This
includes any possible side effects not listed in this leaflet.</span><span
lang=EN-GB> </span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>You
can also report side effects directly via <span style='background:silver'>the
national reporting system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix
V</a></span></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>.
By reporting side effects you can help provide more information on the safety
of this medicine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to store Revatio</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Keep this medicine out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not use this medicine after the expiry date which is stated on
the vial label and carton after EXP. The expiry date refers to the last day of
that month.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Revatio does not require any special storage conditions.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not throw away any medicines via wastewater or household waste.
Ask your pharmacist how tothrow away medicines you no longer use. These
measures will help to protect the environment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents of
the pack and other information</span></b></p>

<p class=MsoBodyText><b><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></b></p>

<p class=MsoBodyText><b><span lang=EN-GB style='text-decoration:none'>What
Revatio contains</span></b></p>

<p class=MsoBodyText style='margin-left:27.0pt;text-indent:-.25in'><span
lang=EN-GB style='text-decoration:none'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='text-decoration:none'>The active
substance is sildenafil. Each ml of solution contains 0.8&nbsp;mg of sildenafil
(as citrate).  Each 20&nbsp;ml vial contains 10&nbsp;mg sildenafil (as
citrate). </span></p>

<p class=MsoBodyText style='margin-left:27.0pt;text-indent:-.25in'><span
lang=EN-GB style='text-decoration:none'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='text-decoration:none'>The other
ingredients are glucose and water for injections.&nbsp; </span></p>

<p class=MsoBodyText><span lang=EN-GB style='text-decoration:none'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>What Revatio looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='color:black'>Each pack of Revatio </span><span
lang=EN-GB style='color:black'>solution for injection </span><span lang=EN-GB
style='color:black'>contains one </span><span lang=EN-GB style='color:black'>20&nbsp;ml
clear glass vial, which is closed with a chlorobutyl rubber stopper and an
aluminium seal.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Marketing Authorisation Holder and Manufacturer</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Marketing Authorisation Holder: </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Pfizer Europe MA EEIG, Boulevard de la Plaine 17, 1050 Bruxelles,
Belgium</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=FR>Manufacturer:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=FR>Fareva Amboise, Zone Industrielle, 29 route des Industries, 37530 Poc</span><span
lang=FR-BE>&eacute;</span><span lang=FR>-sur-Cisse, France.</span></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For any information about this medicinal
product, please contact the local representative of the Marketing Authorisation
Holder.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText style='text-align:justify'><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=622
 style='border-collapse:collapse'>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=FR>Belgi&euml; /Belgique / Belgien</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=NormalBold style='text-align:justify'><span style='font-size:11.0pt'>Lietuva</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoHeader style='text-align:justify'><span lang=PT style='font-size:
  11.0pt;font-family:"Times New Roman",serif'>Pfizer S.A./N.V. </span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoHeader style='text-align:justify'><span lang=PT style='font-size:
  11.0pt;font-family:"Times New Roman",serif'>Pfizer Luxembourg SARL filialas
  Lietuvoje</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoEndnoteText style='text-align:justify'><span lang=DE>T&eacute;l/Tel:
  +32 (0)2 </span>554 62 11</p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT>Tel. +3705 2514000</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><s><span
  lang=DE><span style='text-decoration:none'>&nbsp;</span></span></s></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><s><span
  lang=FR><span style='text-decoration:none'>&nbsp;</span></span></s></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;text-autospace:none'><b><span
  lang=BG>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=EN-GB>Luxembourg/Luxemburg</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=BG>&#1055;&#1092;&#1072;&#1081;&#1079;&#1077;&#1088;
  &#1051;&#1102;&#1082;&#1089;&#1077;&#1084;&#1073;&#1091;&#1088;&#1075;
  &#1057;&#1040;&#1056;&#1051;, &#1050;&#1083;&#1086;&#1085;
  &#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT>Pfizer S.A.</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&#1058;&#1077;&#1083;.:
  +359 2 970 4333</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=DE>T&eacute;l/Tel: +32 (0)2 </span><span lang=FR>554 62 11</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><s><span
  lang=DE><span style='text-decoration:none'>&nbsp;</span></span></s></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><s><span
  lang=FR><span style='text-decoration:none'>&nbsp;</span></span></s></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=IT>&#268;esk&aacute; republika</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=HU>Magyarorsz&aacute;g</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=IT>Pfizer s.r.o.</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=IT>Pfizer Kft.</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=IT>Tel: +420-283-004-111</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=HU>Tel.:</span><span lang=EN-GB> + 36 1 488 37 00</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=DE>&nbsp;</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=DE>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=DE>Danmark</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=SV>Malta</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT>Pfizer ApS</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=IT>Vivian Corporation Ltd.</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT>Tlf: +45 44 20 11 00</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=EN-GB>Tel: +356 21344610</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=DE>&nbsp;</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=DE>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='height:9.0pt'>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt;
  height:9.0pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=DE>Deutschland</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:9.0pt'>
  <p class=NormalBold style='text-align:justify'><span lang=DE
  style='font-size:11.0pt'>Nederland</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=DE>Pfizer OFG Germany GmbH</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT>Pfizer bv</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT>Tel: +49 (0)800 5500634</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT>Tel: +31 (0)10 406 43 01</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT>&nbsp;</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=PT>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><b><span lang=ET>Eesti</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><b><span lang=DE style='layout-grid-mode:line'>Norge</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=EN-GB>Pfizer Luxembourg SARL Eesti filiaal</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT style='layout-grid-mode:line'>Pfizer AS</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=ET>Tel: +</span><span lang=EN-GB>372 666 7500</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT style='layout-grid-mode:line'>Tlf: +47 67 52 61 00</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT>&nbsp;</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=DE>&Ouml;sterreich</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=DE>UPJOHN HELLAS
  &#917;&#928;&#917;</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=DE>Pfizer Corporation Austria Ges.m.b.H.</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&#932;&#951;&#955;</span><span
  lang=DE>: +30 2100 100 002</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=DE>Tel: +43 (0)1 521 15-0</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoHeader style='text-align:justify'><span lang=DE style='font-size:
  11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:line'>&nbsp;</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=DE>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=PT>Espa&ntilde;a</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=PL>Polska</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT>Pfizer GEP, S.L.</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PL>Pfizer Polska Sp. z o.o.,</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT>Tel: +34 91 490 99 00</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PL>Tel.: </span><span lang=FR>+48 22 335 61 00</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><s><span
  lang=FR><span style='text-decoration:none'>&nbsp;</span></span></s></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=PT>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=PT>France</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=NormalBold style='text-align:justify'><span lang=PT
  style='font-size:11.0pt'>Portugal</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT>Pfizer PFE France</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT>Laborat&oacute;rios Pfizer, Lda.</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=EN-GB>T&eacute;l: +33 (0)1 58 07 34 40</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT>Tel: +351 21 </span><span lang=FR>423 5500</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=PT>&nbsp;</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=PT>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><b><span lang=PT>Hrvatska</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><b><span
  lang=FR>Rom&acirc;nia</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><span lang=EN-GB>Pfizer Croatia d.o.o.</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  lang=PT>Pfizer Rom&acirc;nia S.R.L.</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><span lang=EN-GB>Tel: +385 1 3908 777</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  lang=RO>Tel: +40 21 207 28 00</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=PT>&nbsp;</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=PT>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><b><span lang=EN-GB>Ireland</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><b><span lang=SL>Slovenija</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><span lang=EN-GB>Pfizer </span><span lang=FR>Healthcare Ireland</span></p>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><span lang=NL>Tel: 1800 633 363 (toll free)</span></p>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><span lang=NL>+44 (0)1304 616161</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><span lang=EN-GB>Pfizer Luxembourg SARL</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>Pfizer,
  podru&#382;nica za svetovanje s podro&#269;ja farmacevtske dejavnosti,
  Ljubljana </p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=NL>&nbsp;</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><span lang=SL>Tel: + </span><span lang=EN-GB>386 (0) 1 52 11 400</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=NL>&nbsp;</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoEndnoteText style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><b><span lang=NL>&Iacute;s</span></b><b><span
  lang=IS style='layout-grid-mode:line'>land</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=SK>Slovensk&aacute; republika</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoEndnoteText style='text-align:justify'><span lang=IS
  style='layout-grid-mode:line'>Icepharma hf.</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
  none'><span lang=IS>Pfizer Luxembourg SARL</span><span lang=IS>,
  organiza&#269;n&aacute; zlo&#382;ka </span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=IT>S</span><span lang=CS>&iacute;</span><span lang=IT>mi</span><span
  lang=IS style='layout-grid-mode:line'>: + 354 540 8000</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=SK>Tel: </span><strong><span lang=EN-GB style='font-weight:normal'>+421-2-3355
  5500</span></strong></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoHeader style='text-align:justify'><span lang=IS style='font-size:
  11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:line'>&nbsp;</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=PT>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=PT>Italia</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=PT>Suomi/Finland</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT style='layout-grid-mode:line'>Pfizer Established Medicine Italy
  S.r.l.</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoEndnoteText style='text-align:justify'><span lang=FR>Pfizer Oy</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=EN-GB>Tel: +39 06 33 18 21</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=EN-GB>Puh/Tel: +358 (0)9 43 00 40</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=EL>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=SV>Sverige </span></b></p>
  </td>
 </tr>
 <tr style='height:.1in'>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt;
  height:.1in'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><strong><span
  lang=EN-GB style='font-weight:normal'>&nbsp;</span></strong><span lang=EN-GB>PFIZER
  </span><span lang=EL>&#917;&#923;&#923;&#913;&#931; &#913;</span><span
  lang=EN-GB>.&#917;. (CYPRUS BRANCH)</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:.1in'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=EN-GB>Pfizer AB</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=EL>&#932;&#951;&#955;: +357</span><span lang=EL> </span><span lang=EL>22</span><span
  lang=EL> </span><span lang=EL>81</span><span lang=EN-GB>7690</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=NL>Tel: + 46 (0)8 550 520 00</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=LV>&nbsp;</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=LV>Latvija</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=EN-GB>United Kingdom</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=LV>Pfizer </span><span
  lang=EN-GB>Luxembourg SARL fili&#257;le Latvij&#257;</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=EN-GB>Pfizer Limited</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=LV>Tel: </span><span lang=EN-GB>+371 670 35 775</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT>Tel: +44 (0)1304 616161</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>This leaflet was last revised in </span></b></p>

<p class=MsoNormal style='margin-right:-22.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-22.45pt;line-height:normal'><b><span
lang=EN-GB>Other sources of information</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Detailed
information on this medicine is available on the European Medicines Agency
website: <a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a>. There
are also links to other website about rare diseases and treatments.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Package leaflet: Information for the patient</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Revatio 10&nbsp;mg/ml powder for oral suspension</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>Sildenafil</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Read all of this leaflet carefully before you start taking this
medicine because it contains important information for you.</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>This medicine has been prescribed for you only. Do
not pass it on to others. It may harm them, even if their signs of illness are
the same as yours.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:27.0pt;margin-bottom:.0001pt;text-indent:-27.0pt;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects, talk to your doctor
or pharmacist. This includes any possible side effects not listed in this
leaflet. See section 4.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What is in this leaflet</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What Revatio is
and what it is used for</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What you need
to know before you take Revatio</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to take
Revatio</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible side
effects </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to
store Revatio</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents of the
pack and other information</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What Revatio
is and what it is used for</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Revatio contains the active substance sildenafil which belongs to a
group of medicines called phosphodiesterase type 5 (PDE5) inhibitors.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Revatio brings down blood pressure in the lungs by widening the
blood vessels in the lungs.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Revatio is used to treat adults and children and adolescents from 1
to 17 years old with high blood pressure in the blood vessels in the lungs (pulmonary
arterial hypertension).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What you need to know before you
take Revatio</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Do not take
Revatio:</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:22.5pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are allergic to sildenafil or any of the
other ingredients of this medicine (listed in section 6)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:22.5pt;text-indent:-17.3pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are taking medicines containing nitrates,
or nitric oxide donors such as amyl nitrate (&#8220;poppers&#8221;). These
medicines are often given for relief of chest pain (or &#8220;angina
pectoris&#8221;). Revatio can cause a serious increase in the effects of these
medicines. Tell your doctor if you are taking any of these medicines. If you
are not certain, ask your doctor or pharmacist.</span></p>

<p class=MsoEndnoteText><span lang=X-NONE>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:22.5pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>if <span lang=EN-GB>you are taking riociguat. This drug is used
to treat pulmonary arterial hypertension (i.e., high blood pressure in the
lungs) and chronic thromboembolic pulmonary hypertension (i.e., high blood
pressure in the lungs secondary to blood clots). PDE5 inhibitors, such as
Revatio have been shown to increase the hypotensive effects of this medicine.
If you are taking riociguat or are unsure tell your doctor.</span></p>

<p class=MsoNormal style='margin-left:22.5pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:22.5pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have recently had a stroke, a heart
attack or if you have severe liver disease or very low blood pressure
(&lt;90/50&nbsp;mmHg).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:22.5pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are taking a medicine to treat fungal
infections such as ketoconazole or itraconazole or medicines containing
ritonavir (for HIV).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoDate style='margin-left:22.5pt;text-indent:-.25in'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have ever had loss of vision because of a
problem with blood flow to the nerve in the eye called n</span><span
lang=EN-GB>on-arteritic anterior ischaemic optic neuropathy (NAION).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>Warnings and Precautions</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Talk to your doctor before taking Revatio if you:</span></p>

<p class=MsoNormal style='margin-left:35.45pt;text-indent:-21.95pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:"TimesNewRomanPSMT",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>have a disease due to a blocked or narrow vein
in the lungs rather than a blocked or narrow artery.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-14.85pt;line-height:
normal'><span lang=EN-GB style='font-family:"TimesNewRomanPSMT",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>have a severe heart problem.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-14.85pt;line-height:
normal'><span lang=EN-GB style='font-family:"TimesNewRomanPSMT",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>have a problem with the pumping chambers of your
heart</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-14.85pt;line-height:
normal'><span lang=EN-GB style='font-family:"TimesNewRomanPSMT",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>have high blood pressure in the blood vessels in
the lungs.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-14.85pt;line-height:
normal'><span lang=EN-GB style='font-family:"TimesNewRomanPSMT",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>have low blood pressure at rest.</span></p>

<p class=MsoNormal style='margin-left:31.5pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:"TimesNewRomanPSMT",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>l</span>ose a large amount of body fluids
(dehydration) which can occur when you sweat a lot or do not drink enough
liquids. This can happen if you are sick with a fever, vomiting, or diarrhoea</p>

<p class=MsoNormal style='margin-left:31.5pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:"TimesNewRomanPSMT",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>have a rare inherited eye disease<i> (retinitis
pigmentosa)</i></span></p>

<p class=MsoNormal style='margin-left:31.5pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:"TimesNewRomanPSMT",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>have an abnormality of red blood cells (sickle
cell anaemia), (cancer of blood cells (leukaemia), cancer of bone marrow) (multiple
myeloma), or any disease or deformity of the penis.</span></p>

<p class=MsoNormal style='margin-left:35.45pt;text-indent:-21.95pt;line-height:
normal'><span lang=EN-GB style='font-family:"TimesNewRomanPSMT",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>currently have a stomach ulcer, a bleeding
disorder (such as haemophilia) or problems with nose bleeds.</span></p>

<p class=MsoNormal style='margin-left:35.45pt;text-indent:-21.95pt;line-height:
normal'><span lang=EN-GB style='font-family:"TimesNewRomanPSMT",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>take medicines for erectile dysfunction.</span></p>

<p class=MsoNormal style='margin-left:35.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>When used to
treat male erectile dysfunction (ED), the following visual side effects have
been reported with PDE5 inhibitors, including sildenafil at an unknown
frequency; partial, sudden, temporary, or permanent decrease or loss of vision
in one or both eyes.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you </span><span
lang=EN-GB>experience sudden decrease or loss of vision, <b>stop taking Revatio
and contact your doctor immediately</b> (see also section 4).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Prolonged and
sometimes painful erections have been reported in men after taking sildenafil.
If you have an erection, which lasts continuously for more than 4 hours, </span><b><span
lang=EN-GB>stop taking&nbsp;Revatio and contact your doctor immediately</span></b><span
lang=EN-GB> (see also section 4).</span></p>

<p class=MsoNormal style='margin-left:7.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i>Special
considerations for patients with kidney or liver problems</i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'>You should
tell your doctor if you have kidney or liver problems, as your dose may need to
be adjusted. </p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Children</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Revatio should not be given to children below 1 year of age. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Other medicines and Revatio</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Tell your doctor or pharmacist if you are taking, have recently
taken or might take any other medicines.</span></p>

<p class=MsoEndnoteText style='margin-left:35.7pt'><span lang=X-NONE>&nbsp;</span></p>

<p class=MsoEndnoteText style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=X-NONE style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=X-NONE>Medicines containing nitrates, or nitric oxide
donors such as amyl nitrate (&#8220;poppers&#8221;). These medicines are often
given for relief of angina pectoris or &#8220;chest pain&#8221; (see section 2.
Before you take Revatio)</span></p>

<p class=MsoEndnoteText style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=X-NONE style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=X-NONE>Tell your doctor or pharmacist if you are
already taking riociguat.</span></p>

<p class=MsoEndnoteText style='margin-top:0in;margin-right:-.1pt;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt;text-indent:-17.85pt'><span
lang=X-NONE style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=X-NONE>Therapies for pulmonary hypertension (e.g.
bosentan, iloprost)</span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
     lang=EN-GB>Medicines containing St. John&#8217;s Wort (herbal medicinal
     product), rifampicin (used to treat bacterial infections), carbamazepine,
     phenytoin and phenobarbital (used, among others, to treat epilepsy)</span></li>
 <li class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
     lang=EN-GB>blood thinning medicines (for example warfarin) although these did
     not result in any side effect</span></li>
 <li class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
     lang=EN-GB>Medicines containing erythromycin, clarithromycin,
     telithromycin (these are antibiotics used to treat certain bacterial
     infections), saquinavir (for HIV) or nefazodone (for mental depression), as
     your dose may need to be adjusted.</span></li>
 <li class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
     lang=EN-GB>Alpha-blocker therapy (e.g. doxazosin) for the treatment of
     high blood pressure or prostate problems, as the combination of the two
     medicines may cause symptoms of low blood pressure (e.g. dizziness, light headedness).</span></li>
</ul>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Revatio with food and drink</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>You should not drink grapefruit juice while you are being treated
with Revatio.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>Pregnancy and breast-feeding</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>If you are pregnant or breast-feeding, think you may be pregnant or
are planning to have a baby, ask your doctor or pharmacist for advice before
taking this medicine. Revatio should not be used during pregnancy unless
strictly necessary.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Revatio should not be given to women of child bearing potential
unless using appropriate contraceptive methods.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Revatio passes
into your breast milk at very low levels and would not be expected to harm your
baby.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>Driving and using machines</span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>Revatio can cause dizziness and can affect vision. You should be
aware of how you react to the medicine before you drive or use machines.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Revatio contains sorbitol</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you have been told by your doctor that you have an intolerance to
some sugars, contact your doctor before taking this medicinal product.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to take
Revatio</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Always take this medicine exactly as your doctor has told you. Check
with your doctor or pharmacist if you are not sure.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For adults, the
recommended dose is 20&nbsp;mg three times a day (taken 6 to 8&nbsp;hours
apart) taken with or without food. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Use in children and adolescents</span></b></p>

<p class=MsoNormal><span lang=EN-GB>For children and adolescents aged 1 year to
17&nbsp;years old, the recommended dose is either 10&nbsp;mg (1&nbsp;ml of oral
suspension) three times a day for children and adolescents</span><span
lang=EN-GB> weighing<span style='color:#FF6600'> </span>20&nbsp;kg or under, or
20&nbsp;mg (2&nbsp;ml of oral suspension) three times a day for children and
adolescents weighing over 20&nbsp;kg,<span style='color:#FF6600'> </span>taken
with or without food. Higher <span style='color:black;background:white'>doses should
not be used in children</span>.</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The oral suspension
must be shaken vigorously for a minimum of 10&nbsp;seconds before use.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Instructions to reconstitute the oral suspension</span></b></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>It is recommended
that your pharmacist reconstitutes (makes up) the oral suspension before giving
it to you.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>If reconstituted, the
oral suspension is in a liquid form. If the powder is not reconstituted, you
should reconstitute the oral suspension by following the instructions below.</span></p>

<p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>Note:</span></b><span
lang=EN-GB style='font-size:11.0pt'> A total volume of 90&nbsp;ml (3 x 30&nbsp;ml)
of water irrespective of the dose you are taking should be used to reconstitute
the contents of the bottle.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default style='margin-left:.5in;text-indent:-.25in'><span lang=EN-GB
style='font-size:11.0pt'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Tap the bottle to
release the powder.</span></p>

<p class=Default style='margin-left:.5in;text-indent:-.25in'><span lang=EN-GB
style='font-size:11.0pt'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Remove the cap.</span></p>

<p class=Default style='margin-left:.5in;text-indent:-.25in'><span lang=EN-GB
style='font-size:11.0pt'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Measure 30&nbsp;ml of
water by filling the measuring cup (included in the carton) to the marked line
then pour the water into the bottle. Using the cup measure another 30&nbsp;ml
of water and add this to the bottle (figure 1).</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="117%"
 style='width:117.14%;margin-left:-44.75pt;border-collapse:collapse'>
 <tr>
  <td width="100%" valign=top style='width:100.0%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB><img
  border=0 width=473 height=202
  src="Revatio%20II-86-PI-en-clea_files/image010.jpg"></span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign=top style='width:100.0%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='margin-left:.5in;text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>figure 1</span></p>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default style='margin-left:.5in;text-indent:-.25in;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt'>4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Replace the cap and
shake the bottle vigorously for a minimum of 30&nbsp;seconds (figure 2).</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="126%"
 style='width:126.34%;margin-left:-66.15pt;border-collapse:collapse'>
 <tr>
  <td width="100%" valign=top style='width:100.0%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='text-align:center;page-break-after:avoid'><span
  lang=EN-GB><img border=0 width=523 height=213
  src="Revatio%20II-86-PI-en-clea_files/image011.jpg"></span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign=top style='width:100.0%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='margin-left:.5in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB>figure 2</span></p>
  <p class=Default align=center style='text-align:center;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default style='margin-left:.5in;text-indent:-.25in'><span lang=EN-GB
style='font-size:11.0pt'>5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Remove the cap.</span></p>

<p class=Default style='margin-left:.5in;text-indent:-.25in;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt'>6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Using the cup measure
another 30&nbsp;ml of water and add this to the bottle. You should always add a
total of 90&nbsp;ml (3 x 30&nbsp;ml) of water irrespective of the dose you are
taking (figure 3).</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse'>
 <tr>
  <td width="100%" valign=top style='width:100.0%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='text-align:center;page-break-after:avoid'><span
  lang=EN-GB><img border=0 width=207 height=202
  src="Revatio%20II-86-PI-en-clea_files/image012.jpg"></span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign=top style='width:100.0%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='text-align:center;page-break-after:avoid'><span
  lang=EN-GB>figure 3</span></p>
  <p class=Default align=center style='text-align:center;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default style='margin-left:.5in;text-indent:-.25in'><span lang=EN-GB
style='font-size:11.0pt'>7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Replace the cap and
shake the bottle vigorously for a minimum of 30&nbsp;seconds (figure 4).</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=781
 style='width:585.75pt;margin-left:-65.75pt;border-collapse:collapse'>
 <tr>
  <td width=781 valign=top style='width:585.75pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB><img
  border=0 width=524 height=212
  src="Revatio%20II-86-PI-en-clea_files/image013.jpg"></span></p>
  </td>
 </tr>
 <tr>
  <td width=781 valign=top style='width:585.75pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>figure 4</span></p>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default style='margin-left:.5in;text-indent:-.25in'><span lang=EN-GB
style='font-size:11.0pt'>8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Remove the cap.</span></p>

<p class=Default style='margin-left:.5in;text-indent:-.25in'><span lang=EN-GB
style='font-size:11.0pt'>9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Press the bottle
adaptor into the neck of the bottle (as shown on figure 5 below). The adaptor
is provided so that you can fill the oral dosing syringe with medicine from the
bottle. Replace the cap on the bottle.</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse'>
 <tr>
  <td width="100%" valign=top style='width:100.0%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB><img
  border=0 width=363 height=228
  src="Revatio%20II-86-PI-en-clea_files/image014.jpg"></span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign=top style='width:100.0%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB>figure
  5</span></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default style='margin-left:.5in;text-indent:-.25in'><span lang=EN-GB
style='font-size:11.0pt'>10.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Write the date of
expiry of the reconstituted oral suspension on the bottle label (the date of
expiry of the reconstituted oral suspension is 30 days from the date of reconstitution).
Any unused oral suspension should be discarded or returned to your pharmacist
after this date. </span></p>

<p class=Default style='margin-left:.25in;text-indent:-.25in'><span lang=EN-GB
style='font-size:11.0pt;background:yellow'>&nbsp;</span></p>

<p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>Instructions for
use </span></b></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Your pharmacist
should advise you how to measure the medicine using the oral dosing syringe
provided in the pack. Once reconstituted, the oral suspension should only be
administered using the oral dosing syringe supplied with each pack. Please see
instructions below before using the oral suspension.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default style='margin-left:.5in;text-indent:-.25in'><span lang=EN-GB
style='font-size:11.0pt'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Shake the closed bottle
of reconstituted oral suspension vigorously for a minimum of 10&nbsp;seconds
before use. Remove the cap (figure 6).</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="115%"
 style='width:115.04%;margin-left:-39.9pt;border-collapse:collapse'>
 <tr>
  <td width="100%" valign=top style='width:100.0%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB><img
  border=0 width=463 height=270
  src="Revatio%20II-86-PI-en-clea_files/image015.jpg"></span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign=top style='width:100.0%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>figure 6</span></p>
  <p class=Default style='text-align:justify'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default style='margin-left:.5in;text-indent:-.25in'><span lang=EN-GB
style='font-size:11.0pt'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>While the bottle is
upright, on a flat surface, insert the tip of the oral dosing syringe into the
adaptor (figure 7).</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse'>
 <tr style='height:94.15pt'>
  <td width="100%" valign=top style='width:100.0%;padding:0in 5.4pt 0in 5.4pt;
  height:94.15pt'>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB><img
  border=0 width=115 height=252
  src="Revatio%20II-86-PI-en-clea_files/image016.jpg"></span></p>
  </td>
 </tr>
 <tr style='height:29.55pt'>
  <td width="100%" valign=top style='width:100.0%;padding:0in 5.4pt 0in 5.4pt;
  height:29.55pt'>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB>figure
  7</span></p>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default style='margin-left:.5in;text-indent:-.25in;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Turn the bottle upside
down while holding the oral dosing syringe in place. Slowly pull back the
plunger of the oral dosing syringe to the graduation mark that marks the dose
for you (withdrawing 1 ml provides a 10&nbsp;mg dose, withdrawing 2&nbsp;ml provides
a 20&nbsp;mg dose). To measure the dose accurately, the top edge of the plunger
should be lined up with the appropriate graduated mark on the oral dosing syringe
(figure 8).</span></p>

<p class=Default style='margin-left:.5in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse'>
 <tr>
  <td width="100%" valign=top style='width:100.0%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='text-align:center;page-break-after:avoid'><span
  lang=EN-GB><img border=0 width=115 height=277
  src="Revatio%20II-86-PI-en-clea_files/image017.jpg"></span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign=top style='width:100.0%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB>figure
  8</span></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default style='margin-left:.5in;text-indent:-.25in'><span lang=EN-GB
style='font-size:11.0pt'>4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>If large bubbles can be
seen, slowly push the plunger back into the syringe. This will force the
medicine back into the bottle. Repeat step 3 again.</span></p>

<p class=Default style='margin-left:.5in;text-indent:-.25in'><span lang=EN-GB
style='font-size:11.0pt'>5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Turn the bottle back
upright with the oral dosing syringe still in place. Remove the oral dosing syringe
from the bottle.</span></p>

<p class=Default style='margin-left:.5in;text-indent:-.25in'><span lang=EN-GB
style='font-size:11.0pt'>6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Put the tip of the oral
dosing syringe into the mouth. Point the tip of the oral dosing syringe towards
the inside of the cheek. SLOWLY push down the plunger of the oral dosing syringe.
Do not squirt the medicine out quickly. If the medicine is to be given to a
child, make sure the child is sitting, or is held, upright before giving the
medicine (figure 9).</span></p>

<p class=Default style='margin-left:.5in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse'>
 <tr>
  <td width="100%" valign=top style='width:100.0%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB><img
  border=0 width=126 height=147
  src="Revatio%20II-86-PI-en-clea_files/image018.jpg"></span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign=top style='width:100.0%;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB>figure
  9</span></p>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default style='margin-left:.5in;text-indent:-.25in'><span lang=EN-GB
style='font-size:11.0pt'>7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Replace the cap on the
bottle, leaving the bottle adaptor in place. Wash the oral dosing syringe as
instructed below.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;background:yellow'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Cleaning
and storing the syringe:</span></p>

<p class=Default style='margin-left:21.0pt;text-indent:-21.0pt'><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>1. The syringe should be
washed after each dose. Pull the plunger out of the syringe and wash both parts
in water.</span></p>

<p class=Default style='margin-left:.25in;text-indent:-.25in'><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>2. Dry the two parts. Push the
plunger back in to the syringe. Keep it in a clean safe place with the
medicine.</span></p>

<p class=Default style='margin-left:.25in;text-indent:-.25in'><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>If you take more Revatio than you should</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>You should
not take more medicine than your doctor tells you to.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>If you take
more medicine than you have been told to take contact your doctor immediately.
Taking more Revatio than you should may increase the risk of known side
effects.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>If you forget to take Revatio</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you forget to take Revatio, take a dose as soon as you remember,
then continue to take your medicine at the usual times. Do not take a double
dose to make up for a forgotten dose.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>If you stop taking Revatio</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Suddenly stopping your treatment with Revatio may lead to your
symptoms getting worse. Do not stop taking Revatio unless your doctor tells you
to. Your doctor may tell you to reduce the dose over a few days before stopping
completely.</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span
lang=EN-GB>If you have any further questions on the use of this medicine, ask
your doctor or pharmacist.</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible side
effects</span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>Like all medicines, this medicine can cause side effects, although
not everybody gets them.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you experience any of the following side effects you should stop
taking Revatio and contact a doctor immediately (see also section 2):</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>- if you experience sudden decrease or loss of vision (frequency not
known)</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>- if you have an erection, which lasts continuously for more than 4
hours. Prolonged and sometimes &nbsp; painful erections have been reported in
men after taking sildenafil (frequency not known).</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal;page-break-after:
avoid'><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal;page-break-after:
avoid'><u><span lang=EN-GB>Adults</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Side effects reported very commonly (may affect more than 1 in 10 people)
were </span><span lang=EN-GB>headache, facial flushing, indigestion, diarrhoea
and pain in the arms or legs.</span></p>

<p class=MsoEndnoteText style='text-autospace:none'><span lang=X-NONE>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Side effects reported commonly (may affect up to 1 in 10 people)
included: </span><span lang=EN>infection under the skin</span><span lang=EN-GB>,
flu-like symptoms, inflammation of the sinuses, reduced number of red blood
cells (anaemia), fluid retention, difficulty sleeping, anxiety, migraine,
shaking, &#8220;pins and needles&#8221;-like sensation, burning sensation, </span><span
lang=EN>reduced sense of touch</span><span lang=EN-GB>, </span><span lang=EN>bleeding
at the back of the eye, </span><span lang=EN-GB>effects on vision, </span>blurred
vision<span lang=EN> and</span><span lang=EN-GB> light sensitivity, effects on
colour vision, eye irritation, </span>bloodshot eyes /red eyes, <span
lang=EN-GB>vertigo, bronchitis, nosebleed, runny nose, cough, stuffy nose, stomach
inflammation, gastroenteritis, heartburn, piles, abdominal distension, dry
mouth, hair loss, redness of the skin, night sweats, muscle aches, back pain
and increased body temperature.</span></p>

<p class=MsoEndnoteText style='text-autospace:none'><span lang=X-NONE>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Side effects reported uncommonly (may affect up to 1 in 100 people)
included: </span>r<span lang=EN-GB>educed sharpness of vision, </span><span
lang=EN>double vision, abnormal sensation in the eye, penile bleeding, presence
of blood in semen and/or urine, and </span><span lang=EN-GB>breast enlargement
in men</span><span lang=EN>. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN>Skin rash and sudden decrease or loss of hearing </span><span
lang=EN-GB>and decreased blood pressure</span><span lang=EN> have also been
reported at an unknown frequency </span><span lang=EN-GB>(frequency cannot be
estimated from the available data).</span></p>

<p class=MsoBodyText2 style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText2 style='text-align:justify;text-autospace:none'><u><span
lang=EN-GB>Children and adolescents</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The following serious adverse events have
been reported commonly (may affect up to 1 in 10 people); pneumonia,&nbsp;heart
failure, right heart failure,&nbsp;heart related shock, high blood pressure in
the lungs, chest pain, fainting, respiratory infection, bronchitis, viral infection
in the stomach and intestines, urinary tract infections and tooth cavities.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The following serious adverse events were
considered to be treatment related and were reported uncommonly (may affect up
to 1 in 100 people), allergic reaction (such as skin rash, swelling of the
face, lips and tongue, wheezing, difficulty breathing or swallowing)</span><span
lang=EN-GB>, convulsion, irregular heart-beat, hearing impairment, shortness of
breath, inflammation of the digestive tract, wheezing due to disrupted airflow.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Side effects
reported very commonly (may affect more than </span><span lang=EN-GB>1 in 10
people</span><span lang=EN-GB>) were headache, vomiting, infection of the
throat, fever, diarrhoea, flu and nosebleed.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Side effects
reported commonly (may affect up to 1 in 10 people) were nausea, increased
erections, pneumonia and runny nose.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Reporting
of side effects</span></b></p>

<p class=BodytextAgency style='margin-bottom:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>If you
get any side effects, talk to your doctor or pharmacist.</span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:red'> </span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>This
includes any possible side effects not listed in this leaflet.</span><span
lang=EN-GB> </span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>You
can also report side effects directly via <span style='background:silver'>the
national reporting system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix
V</a></span></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>.
By reporting side effects you can help provide more information on the safety
of this medicine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to store Revatio</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Keep this medicine out of the sight and reach of
children.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not use this medicine after the expiry date which is stated on
the bottle after &#8216;EXP&#8217;. The expiry date refers to the last day of
that month.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB>Powder</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not store above 30&deg;C.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Store in the original package in order to protect from moisture.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB>Reconstituted oral suspension</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store below
30&deg;C or in refrigerator at 2</span><span lang=EN-GB>&ordm;C to 8&deg;C. Do
not freeze. Any remaining oral suspension should be discarded 30 days after reconstitution.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not throw away any medicines via wastewater or household waste.
Ask your pharmacist how to throw away medicines you no longer use. These
measures will help protect the environment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents of
the pack and other information</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoBodyText><b><span lang=EN-GB style='text-decoration:none'>What
Revatio contains</span></b></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The active substance is sildenafil (as
sildenafil citrate).</span></p>

<p class=MsoNormal style='margin-left:.25in;line-height:normal'><span
lang=EN-GB>After reconstitution, each ml of the oral suspension contains 10&nbsp;mg
of sildenafil (as citrate)</span></p>

<p class=MsoNormal style='margin-left:.25in;line-height:normal'><span
lang=EN-GB>One bottle of reconstituted oral suspension (112&nbsp;ml) contains
1.12&nbsp;g of sildenafil (as citrate)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The other ingredients are: <u>Powder for oral suspension</u>:
sorbitol, citric acid anhydrous, sucralose, sodium citrate, xanthan gum, titanium
dioxide (E171), sodium benzoate (E211), silica, colloidal anhydrous; <u>Grape flavour</u>:
</span><span lang=EN-GB>maltodextrin, grape juice concentrate, gum acacia, pineapple
juice concentrate, citric</span><span lang=EN-GB style='font-size:12.0pt;
font-family:TimesNewRoman'> </span><span lang=EN-GB>acid anhydrous, natural
flavouring</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What Revatio looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Revatio is supplied as a white to off-white powder for oral
suspension providing a white, grape flavoured oral suspension when reconstituted
with water.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>One 125&nbsp;ml
amber glass bottle (with a polypropylene screw cap) contains 32.27&nbsp;g of
powder for oral suspension.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Once reconstituted the bottle contains 112&nbsp;ml
of oral suspension, of which 90&nbsp;ml is intended for dosing and
administration.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Pack size: 1 bottle</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each pack also contains a polypropylene
measuring cup (graduated to indicate 30&nbsp;ml), polypropylene oral dosing syringe
(3&nbsp;ml) with HDPE plunger and a LDPE press-in bottle adaptor.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Marketing
Authorisation Holder and Manufacturer</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Marketing
Authorisation Holder </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pfizer Europe MA
EEIG, Boulevard de la Plaine 17, 1050 Bruxelles, Belgium</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>Manufacturer</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>Fareva Amboise,
Zone Industrielle, 29 route des Industries, 37530 Poc</span><span lang=FR-BE>&eacute;</span><span
lang=FR>-sur-Cisse, France.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>For any
information about this medicinal product, please contact the local
representative of the Marketing Authorisation Holder.</span></p>

<p class=MsoBodyText style='text-align:justify'><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=622
 style='border-collapse:collapse'>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><b><span lang=FR>Belgi&euml; /Belgique / Belgien</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=NormalBold style='text-align:justify;page-break-after:avoid'><span
  style='font-size:11.0pt'>Lietuva</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoHeader style='text-align:justify;page-break-after:avoid'><span
  lang=PT style='font-size:11.0pt;font-family:"Times New Roman",serif'>Pfizer
  S.A./N.V. </span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoHeader style='text-align:justify;page-break-after:avoid'><span
  lang=DE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Pfizer
  Luxembourg SARL filialas Lietuvoje</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoEndnoteText style='text-align:justify;page-break-after:avoid'><span
  lang=DE>T&eacute;l/Tel: +32 (0)2 </span>554 62 11</p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=DE>Tel. +3705 2514000</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><s><span
  lang=DE><span style='text-decoration:none'>&nbsp;</span></span></s></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><s><span
  lang=FR><span style='text-decoration:none'>&nbsp;</span></span></s></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;text-autospace:none'><b><span
  lang=BG>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=EN-GB>Luxembourg/Luxemburg</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=BG>&#1055;&#1092;&#1072;&#1081;&#1079;&#1077;&#1088;
  &#1051;&#1102;&#1082;&#1089;&#1077;&#1084;&#1073;&#1091;&#1088;&#1075;
  &#1057;&#1040;&#1056;&#1051;, &#1050;&#1083;&#1086;&#1085;
  &#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT>Pfizer S.A.</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&#1058;&#1077;&#1083;.:
  +359 2 970 4333</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=DE>T&eacute;l/Tel: +32 (0)2 </span><span lang=FR>554 62 11</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><s><span
  lang=DE><span style='text-decoration:none'>&nbsp;</span></span></s></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><s><span
  lang=FR><span style='text-decoration:none'>&nbsp;</span></span></s></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=IT>&#268;esk&aacute; republika</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=HU>Magyarorsz&aacute;g</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=IT>Pfizer s.r.o.</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=IT>Pfizer Kft.</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=IT>Tel: +420-283-004-111</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=HU>Tel.:</span><span lang=EN-GB> + 36 1 488 37 00</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=DE>&nbsp;</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=DE>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='height:16.95pt'>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt;
  height:16.95pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=DE>Danmark</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:16.95pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=SV>Malta</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT>Pfizer ApS</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=IT>Vivian Corporation Ltd.</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT>Tlf: +45 44 20 11 00</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=EN-GB>Tel: +356 21344610</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=DE>&nbsp;</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=DE>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=DE>Deutschland</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=NormalBold style='text-align:justify'><span lang=DE
  style='font-size:11.0pt'>Nederland</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=DE>Pfizer OFG Germany GmbH</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT>Pfizer bv</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT>Tel: +49 (0)800 5500634</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT>Tel: +31 (0)10 406 43 01</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT>&nbsp;</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=PT>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=ET>Eesti</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=DE style='layout-grid-mode:line'>Norge</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT>Pfizer Luxembourg SARL Eesti filiaal</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT style='layout-grid-mode:line'>Pfizer AS</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=ET>Tel: +</span><span lang=EN-GB>372 666 7500</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT style='layout-grid-mode:line'>Tlf: +47 67 52 61 00</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT>&nbsp;</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=DE>&Ouml;sterreich</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=DE>UPJOHN HELLAS
  &#917;&#928;&#917;</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=DE>Pfizer Corporation Austria Ges.m.b.H.</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&#932;&#951;&#955;</span><span
  lang=DE>: +30 2100 100 002</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=DE>Tel: +43 (0)1 521 15-0</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoHeader style='text-align:justify'><span lang=DE style='font-size:
  11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:line'>&nbsp;</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=DE>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=PT>Espa&ntilde;a</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=PL>Polska</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT>Pfizer GEP, S.L.</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PL>Pfizer Polska Sp. z o.o.,</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT>Tel: +34 91 490 99 00</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PL>Tel.: </span><span lang=FR>+48 22 335 61 00</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><s><span
  lang=FR><span style='text-decoration:none'>&nbsp;</span></span></s></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=PT>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=PT>France</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=NormalBold style='text-align:justify'><span lang=PT
  style='font-size:11.0pt'>Portugal</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT>Pfizer PFE France</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT>Laborat&oacute;rios Pfizer, Lda.</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=EN-GB>T&eacute;l: +33 (0)1 58 07 34 40</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT>Tel: +351 21 </span><span lang=FR>423 5500</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=PT>&nbsp;</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=PT>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><b><span lang=PT>Hrvatska</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><b><span
  lang=FR>Rom&acirc;nia</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><span lang=PT>Pfizer Croatia d.o.o.</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  lang=PT>Pfizer Rom&acirc;nia S.R.L.</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><span lang=EN-GB>Tel: +385 1 3908 777</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  lang=RO>Tel: +40 21 207 28 00</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=PT>&nbsp;</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=PT>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=EN-GB>Ireland</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=SL>Slovenija</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=EN-GB>Pfizer </span><span lang=FR>Healthcare Ireland</span></p>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=NL>Tel: 1800 633 363 (toll free)</span></p>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=NL>+44 (0)1304 616161</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=PT>Pfizer Luxembourg SARL</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PT>Pfizer,
  podru&#382;nica za svetovanje s podro&#269;ja farmacevtske dejavnosti,
  Ljubljana</span><span lang=PT> </span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=NL>&nbsp;</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=SL>Tel: + </span><span lang=EN-GB>386 (0) 1 52 11 400</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=NL>&nbsp;</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoEndnoteText style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><b><span lang=NL>&Iacute;s</span></b><b><span
  lang=IS style='layout-grid-mode:line'>land</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=SK>Slovensk&aacute; republika</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoEndnoteText style='text-align:justify'><span lang=IS
  style='layout-grid-mode:line'>Icepharma hf.</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
  none'><span lang=IS>Pfizer Luxembourg SARL</span><span lang=IS>,
  organiza&#269;n&aacute; zlo&#382;ka </span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=IT>S</span><span lang=CS>&iacute;</span><span lang=IT>mi</span><span
  lang=IS style='layout-grid-mode:line'>: + 354 540 8000</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=SK>Tel: </span><strong><span lang=EN-GB style='font-weight:normal'>+421-2-3355
  5500</span></strong></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoHeader style='text-align:justify'><span lang=IS style='font-size:
  11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:line'>&nbsp;</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=PT>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=PT>Italia</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=PT>Suomi/Finland</span></b></p>
  </td>
 </tr>
 <tr style='height:.1in'>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt;
  height:.1in'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=EN-GB style='layout-grid-mode:line'>Pfizer Established Medicine Italy
  S.r.l.</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:.1in'>
  <p class=MsoEndnoteText style='text-align:justify'><span lang=FR>Pfizer Oy</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=EN-GB>Tel: +39 06 33 18 21</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=EN-GB>Puh/Tel: +358 (0)9 43 00 40</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=EL>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=SV>Sverige </span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><strong><span
  lang=EN-GB style='font-weight:normal'>&nbsp;</span></strong><span lang=PT>PFIZER
  </span><span lang=EL>&#917;&#923;&#923;&#913;&#931; &#913;</span><span
  lang=PT>.</span><span lang=EN-GB>&#917;</span><span lang=PT>. (CYPRUS BRANCH)</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=EN-GB>Pfizer AB</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=EL>&#932;&#951;&#955;: +357</span><span lang=EL> </span><span lang=EL>22</span><span
  lang=EL> </span><span lang=EL>81</span><span lang=EN-GB>7690</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><span
  lang=NL>Tel: + 46 (0)8 550 520 00</span></p>
  </td>
 </tr>
 <tr style='height:15.3pt'>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt;
  height:15.3pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=LV>&nbsp;</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:15.3pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='height:15.3pt'>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt;
  height:15.3pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><b><span lang=LV>Latvija</span></b></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:15.3pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><b><span lang=EN-GB>United Kingdom</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  lang=LV>Pfizer </span><span lang=PT>Luxembourg SARL fili&#257;le Latvij&#257;</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><span lang=EN-GB>Pfizer Limited</span></p>
  </td>
 </tr>
 <tr>
  <td width=300 valign=top style='width:225.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><span lang=LV>Tel: </span><span lang=EN-GB>+371 670 35 775</span></p>
  </td>
  <td width=321 valign=top style='width:241.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><span lang=PT>Tel: +44 (0)1304 616161</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB>This leaflet
was last revised in </span></b></p>

<p class=MsoNormal style='margin-right:-22.45pt;text-align:justify;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-22.45pt;text-align:justify;line-height:
normal'><b><span lang=EN-GB>Other sources of information</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Detailed
information on this medicine is available on the European Medicines Agency
website: <a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a>. There
are also links to other website about rare diseases and treatments.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

</div>

</body>

</html>
